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Abstract 
The vascular endothelium contributes to the maintenance of vascular health by regulating 
vascular tone and leukocyte adhesion, amongst others. The vasoregulatory actions of the 
endothelium are mediated through coordinated release of vasodilators such as nitric oxide 
(NO) and prostacyclin, and vasoconstrictors such as endothelin-1 and thromboxane A2. 
Endothelial NO is the principal vasodilator in the vasculature and is produced by 
endothelial nitric oxide synthase (eNOS). Insulin is a vasoactive hormone that exerts its 
vasodilatory effects through eNOS-mediated NO production. Endothelial function is 
impaired in a number of disorders, including insulin resistance, diabetes and 
atherosclerosis, leading to dysregulated vasodilation as well as increased monocyte 
adhesion and plaque formation (atherosclerosis). The underlying molecular mechanisms 
leading to endothelial dysfunction are still in question. 
The work presented in this thesis addressed this question by investigating how insulin 
signalling and eNOS-mediated NO and superoxide production in human vascular 
endothelial cells are affected under experimental hyperinsulinaemia (chapter 3) and 
experimental hyperglycaemia (chapter 4). Atherogenic processes in human aortic 
endothelial cells (HAEC) were investigated by assessing monocyte adhesion under 
experimental hyperinsulinaemia (chapter 3), and by determining the contribution of NO 
and AMP-dependent kinase (AMPK) activity to the regulation of endothelial chemokine 
production (chapter 6). The potential of insulin to modify the subcellular distribution of 
eNOS was investigated in chapter 5. 
Clinical hyperinsulinaemia correlates with attenuated NO-mediated vasodilation, but it is 
not cl ear how hyperinsulinaemia impairs eNOS-mediated NO production. The present 
study modelled hyperinsulinaemia in HAEC and demonstrated a blunted response of 
hyperinsulinaemic cells to Ca
2+-stimulated, but not insulin-stimulated eNOS-mediated NO 
synthesis. To address the underlying mechanisms responsible, the protein expression levels 
of components of the metabolic and mitogenic insulin signalling pathways, and of the 
metabolic energy sensor, AMPK, were quantified. Experimental hyperinsulinaemia 
slightly and non-significantly increased basal and insulin-stimulated eNOS
S1177 
phosphorylation in a time-dependent manner, and the levels of eNOS
T495 increased 
following acute insulin stimulation under these conditions. No marked dysregulation of 
individual insulin signalling pathway components was identified as a potential cause, but 
increased activating AMPK
T172 phosphorylation was found to be a potential cause of 3 
 
increased unstimulated eNOSS1177 phosphorylation under experimental hyperinsulinaemia. 
Monocyte adhesion to hyperinsulinaemic HAEC did not differ from control HAEC, 
indicating that experimental hyperinsulinaemia did not act as a proatherogenic factor in the 
present study. 
Overt diabetes was simulated by experimental hyperglycaemia in human umbilical vein 
endothelial cells (HUVEC) and its effect on insulin-stimulated eNOS phosphorylation and 
endothelial superoxide production assessed. Insulin tended to stimulate phosphorylation of 
eNOS
S615 and eNOS
S1177, and decrease phosphorylation of eNOS
S114, eNOS
T495 and 
eNOSS633 under control conditions. Experimental hyperglycaemia slightly reduced basal 
phosphorylation of Ser633 and significantly reduced insulin-stimulated phosphorylation of 
Ser114, but mildly increased basal Ser615 phosphorylation, indicating some dysregulation 
of eNOS phosphorylation. The upstream components of the metabolic insulin signalling 
pathway were not impaired in hyperglycaemic conditions. 
The subcellular localisation of eNOS is thought to have implications for its function. This 
study showed tha t eNOS localises to the plasma membrane, the nucleus, the cytoplasm 
and, primarily, the perinuclear area of HAEC. Insulin stimulation did not affect this 
distribution. Phospho-eNOS species were found primarily at the plasma membrane, and 
insulin may modulate the abundance of an intracellular eNOST495 species.  
Previous work in our laboratory on AMPK-mediated reduction of adhesion molecule 
expression has lead to the investigation of AMPK- and NO-mediated regulation of 
chemokine production in the present study. Inhibition of NO synthesis increased the 
production of monocyte chemoattractant protein (MCP) -1 in HAEC. AMPK activity 
downregulated TNFa-stimulated MCP-1 expression, and this was NO-dependent in the 
short-term, but may be NO-independent during prolonged AMPK activation. These data 
implicate NO and AMPK as antiatherogenic mediators in vascular endothelial cells in 
vitro. 
Taken together, the data in this thesis provide further insight into some of the molecular 
mechanisms involved in endothelial function and their response to hyperinsulinaemia, 
hyperglycaemia and proatherogenic stimulation. 4 
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1.1  The vascular endothelium 
The vascular endothelium is a single cell layer lining the lumen of blood vessels, providing 
a physical barrier between the blood vessel wall and the lumen. It is a key player in the 
maintenance of cardiovascular health. It regulates a number of processes, including the 
maintenance of vascular tone, passage of substances into and out of the bloodstream, 
platelet aggregation, coagulation, fibrinolysis and monocyte adhesion (Wheatcroft et al., 
2003).  
Vascular tone is regulated by a number of endothelium-derived substances with vasodilator 
or vasoconstrictor function, which act on vascular smooth muscle cells in the underlying 
vascular wall. The principal vasodilators include nitric oxide (NO), prostacyclin and 
endothelium-derived hyperpolarising factor (EDHF), whereas the vasoconstrictors include 
endothelin-1 and thromboxane A2. NO is the main endothelium-derived vasodilator in 
large blood vessels, while EDHF is more important in smaller vessels (Wheatcroft et al., 
2003). The maintenance of a correct balance between these vasoactive molecules is crucial, 
so that vascular tone can be adjusted appropriately to stimuli such as shear stress (passage 
of blood through the blood vessel), exercise, feeding, temperature changes and changes in 
blood volume. 
Endothelial dysfunction can be defined as defective endothelium-dependent vasodilation 
and dysregulated expression of endothelial adhesion molecules and chemokines. 
Endothelial dysfunction is a component of metabolic disorders such as insulin resistance, 
Type II diabetes and the metabolic syndrome, as well as atherosclerosis. The relationship 
with each of these diseases is still under debate, and is discussed in sections 1.4 - 1.6. 
 Christine F. Kohlhaas     Chapter 1, 20 
 
1.2  Nitric oxide production in the vascular endothelium 
1.2.1  Nitric oxide synthases 
Nitric oxide synthases are enzymes that catalyse the conversion of L-arginine to NO and L-
citrulline, and were first discovered in 1989 (see review by (Alderton et al., 2001)). 
Mammalian nitric oxide synthases (NOS) exist in three isoforms: endothelial (eNOS, or 
NOS III), neuronal (nNOS, or NOS I) and inducible NOS (iNOS, or NOS II) (Andrew & 
Mayer, 1999, Stuehr, 1999). The NOS enzymes are homodimers consisting of an N-
terminal oxygenase domain and a C-terminal reductase domain (see Figure 1-1). The latter 
shares at least 50% homology with the cytochrome P-450 reductase (Stuehr, 1999). These 
NOS dimers form heterotetramers with two molecules of calmodulin (CaM). NOS require 
the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), haem and tetrahydrobiopterin 
(BH4) for enzymatic activity (Knowles & Moncada, 1994, Andrew & Mayer, 1999, Stuehr, 
1999).  
The haem group plays a crucial role in the dimerisation of all three NOS isoforms (Baek  et 
al., 1993, Klatt et al., 1996, List et al., 1997). BH4 is postulated to modulate oxy-haem 
reactivity (Stuehr, 1999) , and it stabilises the conformation and affects the activity of NOS 
(Mayer & Hemmens, 1997, Andrew & Mayer, 1999). Figure 1-2 illustrates the synthesis of 
NO by NOS. Some of the characteristics of each NOS isoform are outlined below. 
 
   
 
Figure 1-1 The domain structures of NOS 
The myristoylation (Myr) and palmitoylation (Palm) sites on eNOS are shown. Diagram adapted 
from (Alderton et al., 2001) Christine F. Kohlhaas     Chapter 1, 21 
 
1.2.1.1  eNOS 
As the principal source of endothelial NO, eNOS is of major importance to the normal 
functioning of the cardiovascular system. eNOS is activated by hormonal  factors, including 
insulin  (Sobrevia et al., 1996, Zeng & Quon, 1996) and vasopressin (Resta et al., 1997), as 
well as by mechanical forces such as shear stress generated by blood flow through blood 
vessels (Corson et al., 1996). Shear stress-mediated eNOS activation in vitro has been 
proposed to be dependent on the phosphatidylinositol-3 kinase (PI3K)-PKB pathway 
(Dimmeler et al., 1999). Shear stress, exercise and hypoxia not only activate eNOS, but 
also upregulate eNOS transcription (reviewed in (Nathan & Xie, 1994)).  
 
Figure 1-2 Nitric oxide synthesis by NOS 
Electrons (e
-) are donated to the reductase domain of eNOS by NADPH and pass through the FAD 
and FMN domains to the haem iron in the oxygenase domain. Here, the electrons interact with BH4 
at the active site to catalyse the conversion of L-arginine and oxygen to L-citrulline and nitric 
oxide. This process depends on the binding of Ca
2+/CaM to eNOS. Diagram adapted from 
(Alderton et al., 2001) 
 
1.2.1.2  nNOS 
Neuronal NOS (nNOS) (monomer size ~155 kDa) is widely expressed in central and 
peripheral neurones. Compared to eNOS, nNOS possesses an N-terminal extension of 
about 300 amino acid residues that encode a PDZ domain. The PDZ domain permits 
association of nNOS with cytoskeletal/structural proteins such as dystrophin and PSD-95 
that serve to localise nNOS within the cell (reviewed in (Andrew & Mayer, 1999, Stuehr, 
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At low concentrations of L-arginine, nNOS catalyses the production of O2
.-, H2O2 and 
peroxinitrite (ONOO
.-) in a so-called uncoupled reaction (Mayer et al., 1991, Heinzel et 
al., 1992, Andrew & Mayer, 1999). These highly reactive oxygen species have damaging 
effects on cellular function that can lead to pathogenic outcomes.  
 
1.2.1.3  iNOS 
The inducible form of NOS, iNOS, is expressed at high levels in macrophages, endothelial 
cells, cardiac myocytes and smooth muscle cells in response to proinflammatory stimuli 
such as cytokines. A few other tissues, such as the lung epithelium, constitutively express 
iNOS (monomeric form: ~130 kDa). The enzyme is thought to play a role in host defence, 
but has also been implicated in inflammatory diseases and may have a negative effect on 
atherosclerotic lesions (Andrew & Mayer, 1999, Stuehr, 1999). By contrast, iNOS activity 
may also be beneficial in that it suppresses allograft athero sclerosis (Shears et al., 1997, 
Andrew & Mayer, 1999). 
 
 
1.2.2  Nitric oxide production 
Early work showed that aortic rings explanted from rabbits and preconstricted with 
noradrenaline dilated in response to acetylcholine, but this response failed when the rings 
were denuded of the endothelial layer (Furchgott & Zawadzki, 1980). This was the first 
indication that an endothelium-derived factor was responsible for vasodilation (also termed 
vasodilatation or vasorelaxation). This factor was later termed endothelium-derived 
relaxation factor (EDRF). Griffith and co -workers then demonstrated that EDRF is a 
humoral agent whose production can be stimulated by acetylcholine (Griffith et al., 1984), 
and this humoral agent was later proposed to be nitric oxide (NO) (Ignarro et al., 1987, 
Palmer et al., 1987). Some controversy remains to this day as to the true identity of EDRF. 
Other candidates for EDRF have been suggested, including the nitroxyl ion, which could 
then be oxidised to NO in a reaction with superoxide dismutase (SOD) (Murphy & Sies, 
1991). It is, however, accepted that eNOS is the source of endothelial NO.  
Ca2+-stimulated activation of eNOS and nNOS occurs in response to an intracellular surge 
in calcium levels and involves binding of Ca
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calcium-independent, as it binds CaM with high affinity (Andrew & Mayer, 1999, Stuehr, 
1999). Shear-stress- and insulin-stimulated eNOS activation is independent of the 
intracellular Ca
2+ concentration (Corson et al., 1996, Fisslthaler et al., 2000, Montagnani et 
al., 2001, Boo et al., 2002). 
Upon binding of CaM to constitutive NOS, the co-factors FMN and FAD, which are bound 
to the NOS reductase domain, accept electrons from NADPH and transfer these to the 
haem iron in the oxygenase domain. This leads to O2 binding, and activation of NOS 
(Stuehr, 1999, Alderton et al., 2001). In the oxygenase domain, the electrons interact with 
the haem iron and BH4 at the active site to catalyse the reaction of O2 with L-arginine to 
produce NO and L-citrulline (see Figure 1-2). This reaction proceeds via the reaction 
intermediate N
G-hydroxy-L-arginine (Alderton et al., 2001).  
In the absence of Ca2+/CaM, electron transfer between FAD and FMN is slow, indicating 
that Ca
2+ ions are required for efficient eNOS activation (Matsuda & Iyanagi, 1999). In the 
catalytically active eNOS dimer, electrons pass from the flavin domain of one monomer to 
the haem residue of the other monomer (Siddhanta et al., 1996). This explains the 
necessity for NOS dimerisation for catalytical activity.  
 
 
1.2.3  Other possible products of eNOS 
Under some conditions, eNOS can directly or indirectly  catalyse the formation of other 
reactive oxygen species, including nitroxyl (NO
-) ions, peroxynitrite (ONOO
-), superoxide 
(O2
-) and nitrosothiols. Superoxide is generated when eNOS is uncoupled from NADPH 
oxidation (Vasquez-Vivar et al., 1998, Xia et al., 1998). This process decreases NO 
synthesis. Superoxide can react with NO, leading to formation of both peroxynitrite and 
nitrate (Reiter et al., 2000). Peroxynitrite, in turn, can reduce NO bioavailability further 
through oxidation and uncoupling of eNOS, leading to enhanced O2
- production and 
decreased NO synthesis (Zou et al., 2002). Nitrosothiol can be generated by  stimulation of 
eNOS with bradykinin or Ca
2+ ionophore in the presence of homocysteine (Upchurch  et 
al., 1997). 
It has also been proposed that the nitroxyl ion is the initial reaction product of eNOS, 
which is then oxidised to NO in a reaction with superoxide dismutase (SOD) (Murphy & Christine F. Kohlhaas     Chapter 1, 24 
 
Sies, 1991). It is, however, generally accepted that NO is the principal  reaction product of 
eNOS.  
 
1.2.4  Nitric oxide-mediated vasodilation 
NO is a free radical (Mayer & Hemmens, 1997) and has an extremely short half-life of 
only 3-6 seconds (Griffith et al., 1984, Ignarro et al., 1987, Moncada & Higgs, 1991, 
Boger et al., 1996). Once produced, NO has several targets, including the enzyme soluble 
guanylate cyclase (sGC), which catalyses the formation of cyclic guanosine 
monophosphate (cGMP), a secondary messenger that relays information to cGMP-
responsive molecules. In the case of NO-mediated vasodilation, the cGMP-targeted 
molecules include two cGMP-dependent protein kinases, PKG I and PKG II (also known 
as cGK-I and -II) (Gewaltig & Kojda, 2002).  
PKG I mediates vasodilation by phosphorylating various molecules involved in smooth 
muscle relaxation, including inositol 1,4,5-triphosphate receptor-associated G kinase
 
(IRAG), myosin light chain (MLC) phosphatase, and phospholamban (Gewaltig & Kojda, 
2002). In these cases, phosphorylation ultimately results in decreased intracellular Ca
2+ 
levels: IRAG phosphorylation reduces the release of Ca
2+ from the sarcoplasmic reticulum 
(Ammendola et al., 2001), phosphorylation-activated MLC phosphatase prevents MLC 
phosphorylation and contraction (Surks et al., 1999), and phospholamban phosphorylation 
mediates sarcoendoplasmic reticulum ATPase (SERCA) activation, resulting in the rapid 
sequestration of intracellular Ca
2+ (Gewaltig & Kojda, 2002, Rivero-Vilches et al., 2003).  
A further NO-mediated vasodilatory mechanism is the activation of Ca
2+-activated K
+ 
(BKCa) channels by NO through the cGMP-PKG I pathway. Activation of the BKCa 
channels can occur either through direct activation of the BKCa  channels by NO (Bolotina 
et al., 1994) or by PKG I-dependent phosphorylation of the channel protein  (Alioua et al., 
1998) or of a protein phosphatase (Hall & Armstrong, 2000, Sausbier et al., 2000). BKCa 
channel activation increases the K
+ efflux, thus causing membrane hyperpolarisation and 
vasodilation (Gewaltig & Kojda, 2002). 
eNOS-derived NO is vitally important as a vasodilator: Disruption of the eNOS gene in 
mice results in mild hypertension (Huang et al., 1995, Gewaltig & Kojda, 2002); an 
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pharmacologically (Stamler et al., 1994, Gewaltig & Kojda, 2002). Currently, it is thought 
that at physiological concentrations of NO, vasodilation is mediated via cGMP-PKG I-
dependent mechanisms, while at high levels of NO (either pharmacologically induced or as 
encountered during endotoxic shock) (Thiemermann & Vane, 1990, Rosenberg et al., 
1994), this mechanism is bypassed and the alternative protein kinase A (PKA) pathway is 
activated by cGMP (Pfeifer et al., 1998, Sausbier et al., 2000). 
 
1.2.5  Other roles of nitric oxide 
Besides vasodilation, NO has antiatherogenic roles in the regulation of platelet function, 
monocyte adhesion (Kubes et al., 1991) and smooth muscle cell proliferation (Mayer & 
Hemmens, 1997, Gewaltig & Kojda, 2002). Platelet aggregation is prevented by lowering 
intracellular Ca
2+ concentration through activation of phospholamban and SERCA via the 
cGMP-PKG I pathway (reviewed in  (Gewaltig & Kojda, 2002)).  
Monocyte adhesion is dependent on the expression of chemokines and adhesion molecules, 
including vascular cell adhesion molecule (VCAM-1), monocyte chemoattractant protein-1 
(MCP-1) and cytokines, on the surface of vascular endothelial cells. Unregulated monocyte 
adhesion contributes to atherogenesis. NO inhibits NF?B expression and activation. NF?B-
dependent VCAM-1 expression is thus inhibited and monocyte adhesion decreased 
(reviewed in (Gewaltig & Kojda, 2002)). 
Smooth muscle cell proliferation is inhibited in vitro by NO (Garg & Hassid, 1989) 
through inhibition of O2
--producing enzymes (e.g. NADPH oxidase) (Clancy et al., 1992). 
Proliferation may also be blocked by cGMP-dependent activation of PKA and cGMP-
inhibition of cAMP phosphodiesterase (PDE III). Activated PKA is thought to inhibit the 
mitogenic molecule Raf-1, thus preventing smooth muscle cell proliferation (reviewed in 
(Gewaltig & Kojda, 2002)). Unregulated vascular smooth muscle cell proliferation is 
proatherogenic in that it can lead to artery thickening, thus increasing the risk of 
hypertension, stroke and infarction. 
The immune system utilises macrophage-produced NO as a cytotoxic attack factor (Mayer 
& Hemmens, 1997) and tumour cytostatic agent (MacMicking et al., 1997, Stuehr, 1999). 
In severe inflammatory conditions like septic shock, iNOS-catalysed NO synthesis can 
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been implicated in learning and memory (long-term potentiation, LTP), since LTP was 
markedly decreased in eNOS knockout mice (Son et al., 1996, Mayer & Hemmens, 1997, 
Wilson et al., 1997). The function of NO in long-term potentiation, together with other 
evidence for NO-controlled gene expression (Zeiher et al., 1995), point to a role for NO in 
transcriptional regulation.  
 
1.2.6  Regulation of eNOS activity 
Given the vital role of nitric oxide in the vasculature, it is imperative that its production be 
tightly controlled. A number of distinct mechanisms regulate eNOS activity, including 
transcriptional control, acylation, phosphorylation, subcellular localisation and association 
with other cellular molecules.  
 
1.2.6.1  Transcriptional control 
The promoter of the eNOS gene contains two positive regulatory domains, PRD I and 
PRDII. The former contains a high-affinity Sp1 transcription factor recognition site, to 
which Sp1 and Sp3 transcription factors bind, while the latter binds Ets-1, Elf-1, YY1, 
Sp1, and MYC-associated
 zinc finger protein (Karantzoulis-Fegaras et al., 1999). Trans-
acting factors have also been implicated in the regulation of eNOS transcription (Searles, 
2006). An upstream enhancer sequence needs to interact with the promoter sequence for 
full promoter activity. Erg, AP-2 and Sp1-related factor have been shown to interact with 
the enhancer sequence (Laumonnier et al., 2000, Searles, 2006). Shear stress, exercise and 
hypoxia not only activate eNOS, but also mediate upregulation of eNOS transcription 
(reviewed in (Nathan & Xie, 1994)).  
 
1.2.6.2  Acylation and subcellular localisation 
The eNOS monomer is post-translationally modified by myristoylation and palmitoylation. 
These modifications serve partly to target eNOS to various subcellular locations. eNOS is 
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myristoylation on glycine 2 of the bovine eNOS sequence. Myristoylation targets eNOS to 
the plasma membrane and the Golgi complex, while palmitoylation targets it to caveolae 
(Lamas et al., 1992, Busconi & Michel, 1993, Liu & Sessa, 1994, Garcia-Cardena et al., 
1996b, Liu et al., 1996, Shaul et al., 1996). Palmitoylation-deficient eNOS mutants were 
deficient in NO synthesis, suggesting that palmitoylation positively regulates NO release 
(Liu et al., 1996). 
Palmitoylation specifically targets eNOS to caveolae at the plasma membrane (Liu et al., 
1996). Caveolae are a form of so-called lipid rafts, microdomains devoid of phospholipids 
but rich in cholesterol and glycosphingolipids, as well as the coat protein caveolin-1 
(Brown & London, 1998). It has been suggested that caveolae act as signal transducing 
domains because they are thought to  bring transmembrane receptors such as the insulin 
receptor, in close proximity to their downstream targets by virtue of direct interaction of 
these signalling molecules with caveolin-1 (Kimura et al., 2002, Saltiel & Pessin, 2003). 
Likewise, eNOS is known to bind caveolin-1 through its oxygenase and reductase 
domains, thereby being held at plasma membrane caveolae in an inactivating complex 
(Feron et al., 1996, Garcia-Cardena et al., 1996a, Garcia-Cardena et al., 1997, Michel et 
al., 1997, Feron et al., 1998, Ghosh et al., 1998). The presence of eNOS at the plasma 
membrane is thought to optimise eNOS activation and nitric oxide release to the 
extracellular environment (Garcia-Cardena et al., 1996b, Shaul  et al., 1996). 
Intracellularly, eNOS is found in the particulate subcellular fraction of bovine aortic 
endothelial cells (Forstermann et al., 1991, Pollock  et al., 1991) and eNOS-transfecetd 
COS-7 cells (Busconi & Michel, 1993). Later studies showed that eNOS is targeted to the 
Golgi body of eNOS-transfected HEK cells (Sessa et al., 1995). It has been suggested that 
the plasma membrane- and Golgi-pools of eNOS respond differently to agonist-mediated 
activation (Zhang et al., 2006). In the cell line ECV304, exogenous eNOS also localised to 
the plasma membrane and the perinuclear/Golgi area (Sowa et al., 1999). However, the 
endothelial nature of ECV304 cells is controversial, as a recent genetic analysis found 
these cells to be identical to the bladder cancer-derived epithelial cell line T24/83 (Brown 
et al., 2000). Therefore, their use as an endothelial cell model is questionable.  
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1.2.6.3  Phosphorylation 
Human eNOS has several known phosphorylation sites: Ser114, Thr495, Ser615, Ser633 
and Ser1177. Regulation of eNOS activity is thought to involve concerted phosphorylation 
and dephosphorylation of these sites (Michell et al., 2001, Bauer et al., 2003, Mount et al., 
2007). In addition, eNOS can be tyrosine-phosphorylated, which may regulate its 
interaction with caveolin-1 (Garcia-Cardena et al., 1996a). Tyrosine phosphorylation is 
also postulated to decrease endothelium-dependent vasorelaxation in response to 
acetylcholine (Huang et al., 2002), suggesting that it inhibits NO synthesis. 
Ser1177 is the best-characterised eNOS phosphorylation site. It is located in the reductase 
domain and is phosphorylated by a number of kinases, including PKA (Michell et al., 
2001), PKB (Dimmeler et al., 1999, Fulton et al., 1999), AMPK (Fleming & Busse, 2003, 
Morrow et al., 2003), PKG and CaM-dependent kinase II (CaMKII) (Fleming et al., 2001) 
(reviewed in (Mount et al., 2007)). Phosphorylation of eNOS
S1177 increases eNOS activity 
and is required for agonist-mediated NO synthesis (Dimmeler et al., 1999, Fulton et al., 
1999, Michell et al., 2001). Phosphorylation of eNOSS1177 can be triggered by a number of 
factors, including shear stress, insulin, IGF-1, oestrogen, vascular endothelial growth factor 
(VEGF), bradykinin and ATP (Fleming et al., 1998, Michell et al., 2001, Bauer et al., 
2003, Mount et al., 2007). Insulin-stimulation of eNOS increases NO production in HAEC 
~4-fold (Salt et al., 2003). Ser1177 is located in the CT domain of eNOS, which is situated 
between the two eNOS monomers, thereby blocking the transfer of electrons in an 
autoinhibitory fashion. Phosphorylation of eNOS
S1177 has been suggested to  induce a 
conformational change that removes this CT domain block and increases eNOS activity 
(Lane & Gross, 2002). 
Several lines of evidence suggest that eNOST495 phosphorylation negatively regulates nitric 
oxide synthesis, because its dephosphorylation enhances NO production (Chen  et al., 1999, 
Fleming et al., 2001, Michell et al., 2001, Greif et al., 2002, Fleming & Busse, 2003, 
Matsubara et al., 2003). eNOST495 was constitutively phosphorylated in porcine aortic 
endothelial cells (PAEC) in the basal state and was rapidly dephosphorylated upon 
bradykinin stimulation, leading to eNOS activation (Fleming et al., 2001). In addition, 
PKA has been demonstrated to increase eNOS activation with associated Thr495 
phosphorylation (Michell et al., 2001). Furthermore, insulin stimulated a decrease in 
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mimicking Thr495 phosphorylation by site-directed mutagenesis decreased eNOS activity 
(Michell et al., 2002). 
The phosphorylation site Thr495 is situated in the CaM-binding domain of eNOS. PKC 
was identified as a candidate for eNOS
T495 phosphorylation, causing a decrease in eNOS 
activity through altering the binding of CaM (Fleming et al., 2001, Matsubara et al., 2003). 
Dephosphorylation of eNOSS1177 and eNOST495 is proposed to be mediated by phosphatase 
PP2A and phosphatase PP1, respectively (Michell et al., 2001, Greif et al., 2002). PKC 
activation has been proposed to mediate dephosphorylation of eNOS at Ser1177 and 
simultaneous phosphorylation at Thr495, thus having an inhibitory effect (Fleming et al., 
2001). It has been suggested that the coordinated phosphorylation of Ser1177 and Thr495 
is critical in determining agonist-stimulated eNOS activity (Fleming et al., 2001, Fleming 
& Busse, 2003). 
Although the other eNOS phosphorylation sites are less well-characterised, experimental 
evidence has demonstrated that the phosphorylation state of these sites also influences the 
stimulation and kinetics of eNOS activity, and may also modulate its interactions with 
other proteins. These findings highlight the complexity of eNOS regulation and the 
physiological importance of this enzyme. 
Ser114 is located in the oxygenase domain of eNOS. The effect of eNOS
S114 
phosphorylation on eNOS activity is controversial. Some groups demonstrated  an 
upregulation of eNOS activity with increased eNOSS114 phosphorylation. Shear stress and 
high dens ity lipoprotein were both reported to increase eNOSS114 phosphorylation and 
eNOS activity (Gallis et al., 1999, Drew et al., 2004). Site-directed mutagenesis of bovine 
eNOS and subsequent transfection into COS-7 cells suggested that mimicking 
phosphorylation at Ser114 increased eNOS activity. Controversially, in the same study, 
both the phosphorylation and dephosphorylation-mimetic eNOS
S114 mutants increased 
stimulated NO release (Bauer et al., 2003). By contrast, another group found that 
mimicking dephosphorylation of eNOSS114 by mutating the serine residue to alanine, 
increased eNOS activity, and that stimulation of eNOS with VEGF dephosphorylated  
Ser114 (Kou et al., 2002). It has been proposed that eNOS
S114 phosphorylation modulates 
Ser1177  phosphorylation and increases the interaction of eNOS with hsp90 and PKB 
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The role of the phosphorylation site Ser615  in the FMN binding domain of eNOS is not 
fully understood. eNOS
S615 phosphorylation has been reported to increase eNOS activity 
and in our own laboratory, eNOS
S615 phosphorylation is associated with insulin-stimulated 
NO release (Michell et al., 2002, Ritchie et al., 2007). The eNOS agonists VEGF, 
bradykinin and ATP have been shown to stimulate eNOS
S615 phosphorylation, suggesting 
that Ser615 is an activating site (Michell et al., 2002). Ser615 phosphorylation increased 
the activity of eNOS at lower concentrations of CaM without affecting maximal activity 
(Michell et al., 2002). PKB has been implicated in the phosphorylation of the bovine site 
equivalent to Ser615 in BAEC (Michell et al., 2002). In agreement with this, insulin 
stimulated eNOS
S615 phosphorylation and NO release in HAEC (Ritchie et al., 2007). By 
contrast, studies with eNOS phospho-mutants demonstrated that mimicked Ser615 
phosphorylation slightly downregulated NO release (Bauer et al., 2003). Phosphorylation 
of Ser615 was postulated to be an important modulator of phosphorylation at Ser1177 and 
increased the interaction of eNOS with hsp90 and PKB (Bauer et al., 2003). 
Phosphorylation of Ser633, which is also located in the FMN binding domain of eNOS, 
has been reported to increase eNOS activity. Similar to eNOS
S1177, eNOS
S633 is 
phosphorylated in response to shear stress, ATP, VEGF and bradykinin (Boo et al., 2002, 
Michell et al., 2002, Bauer et al., 2003). Site-directed mutagenesis of eNOS phospho-sites 
demonstrated that the bovine site Ser635 (equivalent to human Ser633) is an  important 
positive regulator of basal and ATP-stimulated NO release (Bauer et al., 2003). Mimicking 
phosphorylation at Ser635 been shown to contribute to eNOS activity in vitro (Michell et 
al., 2002).  
In contrast to eNOSS1177, eNOSS633 appears to play a role in mediating prolonged, rather 
than acute, eNOS activity, as eNOS
S633 phosphorylation occurred more slowly than 
eNOS
S1177 phosphorylation(Boo et al., 2002, Bauer et al., 2003). Phosphorylation of 
bovine eNOSS635 does not require a rise in intracellular Ca2+ to stimulate NO synthesis 
(Boo et al., 2003). PKA has been identified as a likely candidate for eNOS
S633 
phosphorylation, whereas PKB does not phosphorylate this site (Boo et al., 2002, Michell 
et al., 2002, Boo et al., 2003). 
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1.2.6.4  Interaction of eNOS with other molecules 
eNOS is known to form a complex with the molecular chaperone hsp90 and the activating 
kinase PKB. This complex has been proposed to permit rapid activation of eNOS (Garcia-
Cardena et al., 1998, Fontana et al., 2002, Takahashi & Mendelsohn, 2003). It has been 
proposed that hsp90 acts as a molecular scaffold by binding to the N-termini of eNOS and 
PKB, bringing these two molecules into close proximity and promoting eNOS activation 
(Fontana et al., 2002). This interaction is thought to be important for VEGF- and insulin-
stimulated activation of eNOS in vitro (Fontana et al., 2002, Takahashi & Mendelsohn, 
2003). 
An eNOS interaction partner called NOSTRIN (eNOS traffic inducer) has been identified 
by yeast-2-hybrid studies. This protein binds to eNOS in vitro and in vivo. In HUVEC, 
NOSTRIN colocalised wi th eNOS at the plasma membrane. NOSTRIN is postulated to 
influence the subcellular distribution and activity of eNOS (Zimmermann et al., 2002). 
NOSIP  (eNOS interacting protein) is a further interaction partner of eNOS that has been 
identified by yeast-2-hybrid experiments. NOSIP  is expressed in HUVEC and binds to the 
oxygenase domain of eNOS. It has been shown to mediate translocation of exogenously 
expressed eNOS from the plasma membrane to intracellular locations, thereby inhibiting 
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1.3  Insulin signalling 
Insulin is a polypeptide hormone that functions as an important mediator of metabolic and 
mitogenic cellular actions, including glucose, protein and lipid metabolism as well as cell 
growth and differentiation. It is produced from preproinsulin by proteolysis in pancreatic ß 
cells (see Figure 1-3), releasing C-peptide as a byproduct. Insulin secretion is stimulated by 
elevated blood glucose levels (Siddle, 2005).  
In this section, the metabolic and mitogenic insulin signalling pathways and their 
components will be described, along with the downstream effects of insulin signalling.  
   
 
     
 
 
Figure 1-3 Production of insulin from preproinsulin 
Insulin is produced from preproinsulin in the pancreatic ß cells after the N-terminal signal sequence 
and C-peptide have been cleaved by proteolysis. Diagram adapted from 
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1.3.1  The insulin receptor 
The existence of an insulin receptor was first proposed by House and Weidemann in 1970 
(House & Weidemann, 1970). However, it was not until 1978 that direct evidence for the 
existence of the insulin receptor was obtained by Yip and co -workers (Yip et al., 1978). 
The insulin receptor family belongs to the superfamily of receptor tyrosine kinases (RTKs) 
and contains three homologous, dimeric transmembrane receptors: the insulin receptor 
(IR), the insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor-related 
receptor (IRR). The RTK superfamily also compr ises the monomeric RTKs epidermal 
growth factor (EGF) receptor (Ebina et al., 1985), platelet-derived growth factor (PDGF) 
receptor and the vascular endothelial growth factor (VEGF) receptor (Fantl et al., 1993, 
Deller & Yvonne Jones, 2000).  
IR, IGF-1R and IRR share approximately 60% sequence identity (Ullrich et al., 1986, 
Zhang & Roth, 1992). It is known that IR subunits can form hybrids with IGF-1R subunits 
(Moxham et al., 1989, Soos & Siddle, 1989, Treadway et al., 1989), and possibly with IRR 
subunits. No ligand has yet been identified for the IRR, though its tyrosine kinase domain 
is capable of phosphorylating the same spectrum of substrates as the IR (Zhang & Roth, 
1992); therefore, the significance of these potentially occurring hybrids is unclear. 
 
1.3.1.1  Insulin receptor structure  
The functional insulin receptor is composed of two identical subunits, each being derived 
from a single, polypeptide pro-receptor (Siddle, 2005). Each subunit comprises an N-
terminal extracellular a-subunit and a C-terminal, transmembrane domain-containing ß-
subunit that extends into the cytoplasm and contains the tyrosine kinase (TK) domain 
(Kasuga et al., 1982, Ebina et al., 1985).  
One individual IR subunit is comprised of two ß-helical domains (named L1 and L2) 
flanking a cysteine-rich (CR) domain, three fibronectin type III repeats (Fn0, Fn1 and Fn2; 
of which Fn1 contains the cleavage site between the a- and ß-subunits), a juxtamembrane 
(JM) region, a tyrosine kinase (TK) domain and a CT domain, (see Figure 1-4). This 
domain structure is shared by the IGF-1R (Czech & Massague, 1982, Ullrich et al., 1986). 
The individual IR subunits are disulphide-bonded in a ß-a-a-ß fashion (Czech & 
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Figure 1-4 Insulin receptor domain structure 
The dimeric insulin receptor is composed of extracellular a subunits and transmembrane ß subunits 
that contain the tyrosine kinase activity. Figure adapted from (Zhang) 
 
1.3.1.2  Insulin binding to the insulin receptor 
The insulin receptor has a high affinity and specificity for insulin (Siddle, 2005). Either 
one or two molecules of insulin can bind to the IR, in a negatively cooperative fashion, the 
affinity for insulin being determined by the IR dimerisation domain encoded by exon 10 
(Surinya et al., 2002, Siddle, 2005). One hydrophobic and one polar conformational 
surface in the IR have been identified as essential for insulin binding (Ottensmeyer et al., 
2000, De Meyts & Whittaker, 2002).  
Binding of insulin to the IR induces conformational changes in the receptor, which 
activates the receptor TK domains to reciprocally autophosphorylate tyrosine residues in 
the ß-subunits. Several tyrosine residues in the JM, TK and CT regions can be 
autophosphorylated (Siddle, 2005) , but the tyrosine residues 1158, 1162 and 1163 in the 
regulatory loop of each ß-subunit have been identified as important for the metabolic arm 
of insulin signalling (Ellis et al., 1986, Frattali et al., 1992, Cann & Kohanski, 1997). In 
the closed, inactive state, this regulatory loop blocks a cleft in the insulin receptor structure 
that contains the active site, but autophosphorylation is thought to cause repositioning of 
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Autophosphorylation of an NPEY960 motif in the JM region of the IR is critical for creation 
of a binding site for the phosphotyrosine-binding (PTB) domains of insulin receptor 
substrate-1 and -2 (IRS-1 and -2) and Shc (Src-homology and collagen-like) proteins 
(Gustafson et al., 1995, Wolf et al., 1995); while the substrates APS (Hu et al., 2003) and 
Grb10 (Stein et al., 2003) bind to the phosphorylated tyrosine residues in the activation 
loop via their SH2 domains. Furthermore, autophosphorylation also plays a role in receptor 
internalisation.  
The activated insulin-IR complex is internalised via clathrin-coated vesicles and targeted to 
endosomes, where the acidic pH causes dissociation of insulin from its receptor 
(Carpentier, 1994). Insulin is subsequently degraded by endosomal and/or lysosomal 
proteases (Bondy et al., 1994, Carpentier, 1994, Di Guglielmo et al., 1998). The IR is then 
dephosphorylated (and thus inactivated) by phosphotyrosine phosphatases such as PTP1B 
(Elchebly et al., 1999, Klaman et al., 2000) and the majority of insulin receptors are 
recycled to the plasma membrane (Carpentier, 1994).  
 
1.3.1.3  Modulation of insulin receptor function 
It has been suggested that insulin signalling may be transiently but significantly prolonged 
by IR-bound insulin in the endosome compartment, where the IR may have access to 
intracellular substrates (Di Guglielmo et al., 1998). By contrast, serine/threonine 
phosphorylation of the IR by kinases, including several isoforms of protein kinase C 
(PKC), may downregulate receptor TK activity without affecting its insulin binding ability 
(Bollag et al., 1986, Liu & Roth, 1994, Bossenmaier et al., 1997, Strack et al., 2000). Such 
downregulation of IR TK function has been suggested to be responsible for glucose-
mediated inhibiton of insulin signalling (Berti et al., 1994, Mosthaf et al., 1995, Pillay et 
al., 1996) and to contribute to obesity-associated insulin resistance (Zhou et al., 1999). 
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1.3.2  Metabolic actions of insulin 
Upon stimulation by insulin, the insulin receptor phosphorylates several cellular substrates 
via its tyrosine kinase domain and thus initiates a number of intracellular signalling 
pathways. The most well defined pathways are the metabolic phosphatidylinositide 3-
kinase (PI3K)/protein kinase B (PKB) pathway, which stimulates glucose transporter 
translocation to the plasma membrane, as well as production of NO by eNOS in 
endothelial cells and stimulation of the mitogenic MAPK/ERK pathway.  
As discussed above, activation of the IR by autophosphorylation results in creation of 
substrate binding sites and the subsequent phosphorylation of these substrates by the IR. 
The insulin receptor substrates-1 and -2 (IRS-1 and -2) are major components of both 
metabolic and mitogenic insulin signalling (White, 1998, 2002). They are 180-190 kDa 
proteins (White et al., 1985) that contain tandem pleckstrin homology (PH) (Shaw, 1993, 
Sun et al., 1995) and phosphotyrosine binding (PTB) domains (Sun et al., 1995) and act as 
highly efficient scaffolding proteins in the recruitment of the lipid kinase PI3K (Sun et al., 
1991). With its tandem SH2 domains, PI3K then binds preferentially to the 
phosphotyrosine residues that are arranged in YxxM motifs of IRS-1 and -2 (White, 1998). 
Although there is some functional redundancy between IRS-1 and IRS-2, they also have 
specific roles (Bruning et al., 1997, White, 2002) and differ in their tissue-specific 
expression: IRS-1 is more prominent in skeletal muscle and IRS-2 more abundant in the 
liver (Kido et al., 2000). 
PI3K is composed of a p85/55 adaptor subunit and a p110 catalytic subunit, both of which 
exist in multiple isoforms (Shepherd et al., 1998). Phosphorylated IRSs recruit PI3K to the 
plasma membrane, where PI3K catalyses the conversion of its preferred substrate, the 
membrane phospholipid phosphatidyl inositol (4,5)bis -phosphate (PI(4,5)P2), to 
phosphatidyl inositol (3,4,5)tris-phosphate (PI(3,4,5)P3) (Siddle, 2005). PI(3,4,5)P 3 serves 
to anchor PI3K and the 3-phosphoinositide dependent protein kinase-1 (PDK-1) to the 
plasma membrane (Shepherd et al., 1998). PI(3,4,5)P3 also has a high affinity for the 57 
kDa protein kinase B (PKB, also known as Akt), which colocalises with PI(3,4,5)P3 at the 
plasma membrane.  
The phosphatase PTEN (Phosphatase-and-tensin-homologue-deleted-on-chromosome-10) 
counteracts PI3K activity by dephosphorylating PI(3,4,5)P3  to PI(4,5)P2, thereby 
negatively regulating PI3K activity (Oudit et al., 2004). PTEN is also involved in the 
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various pathological conditions, including the metabolic syndrome (Shen  et al., 2006a, 
Shen et al., 2006b, Wang et al., 2006). 
PDK-1 and PDK-2 activate PKB in a PI3K-dependent manner (Burgering & Coffer, 1995, 
Kroner et al., 2000). PKB is phosphorylated by PDK-1 at threonine 308 (Wick  et al., 
2000), and by PDK-2 at serine 473 (Kroner et al., 2000). Activated PKB then 
phosphorylates a variety of substrates, including glycogen synthase kinase-3 (GSK-3), 
phosphofructokinase-2 (PFK-2), the proapoptotic BAD proteins and caspase 9 
(Vanhaesebroeck & Alessi, 2000, Lawlor & Alessi, 2001, Vivanco & Sawyers, 2002, 
Whiteman  et al., 2002). This triggers further signalling cascades that, in the case of glucose 
transport, result in the translocation of glucose transporter 4 (GLUT4)-containing vesicles 
to the plasma membrane of adipocytes and striated muscle, thus enabling glucose transport 
into the cell (Wang et al., 1999, Whiteman et al., 2002).  
Importantly, insulin can dose-dependently stimulate eNOS activity in endothelial cells 
(Aljada & Dandona, 2000) via calcium-independent, PI3K- and PKB-dependent 
phosphorylation at serine 1177 (Zeng & Quon, 1996, Dimmeler et al., 1999, Fulton et al., 
1999, Zeng et al., 2000). This phosphorylation activates eNOS-mediated production of NO 
(see Figure 1-5). Insulin also stimulates the uptake by endothelial cells of the NOS 
substrate L-arginine via the L-arginine transporter y+ (Sobrevia et al., 1996), thus ensuring 
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Figure 1-5 The metabolic insulin signalling pathway and NO production 
Insulin binds to its receptor (IR) and triggers IR autophosphorylation. The IR then phosphorylates 
the IR substrate (IRS), which in turn binds to PI3K and recruits it to the plasma membrane. PKB is 
dually phosphorylated by PDK-1 and PDK-2 in a PI3K-dependent manner. Activated PKB then 
activates eNOS by direct phosphorylation at Ser1177, stimulating NO synthesis. Christine F. Kohlhaas     Chapter 1, 39 
 
1.3.3  Mitogenic actions of insulin 
Another major signalling pathway triggered by insulin is the extracellular-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK) pathway, which regulates the 
transcription of genes required for cell growth and division (Denton & Tavare, 1995, Lazar 
et al., 1995, Azpiazu et al., 1996), as well as the genes for insulin-like-growth-factor-
binding protein 1 (IGFBP-1) and the glucose-6-phosphatase (G6Pase) catalytic subunit 
(O'Brien & Granner, 1996, O'Brien et al., 2001). The insulin receptor phosphorylates IRSs 
and Shc (Src-homology and collagen-like) proteins (Kovacina & Roth, 1993, Pronk et al., 
1993), both of which are capable of binding the adaptor protein Grb2 (Skolnik et al., 
1993), which then activates the ERK/MAPK pathway through binding of SOS and 
activation of Ras and Raf (Avruch et al., 1994, Okada et al., 1998, Siddle, 2005).  
The mitogenic pathway also contributes to regulation of glucose metabolism, as insulin-
mediated inhibition of the expression of phosphoenolpyruvate carboxykinase (PEPCK) and 
G6Pase in the liver leads to suppression of hepatic gluconeogenesis (O'Brien & Granner, 
1996, Patel et al., 2003). Patients with type I and type II diabetes show lack of insulin-
mediated suppression of gluconeogenesis (Basu  et al., 2004), as has also been 
demonstrated  in experimental animal models (Barzilai & Rossetti, 1993, Hofmann et al., 
1995). Overexpression of PEPCK in animals causes impaired glucose tolerance and insulin 
resistance (Valera et al., 1994), while elevated G6Pase expression in mice gives rise to a 
state resembling type II diabetes (Trinh et al., 1998).  
 
1.3.4  Other aspects of insulin signalling 
Additional pathways that are modulated by insulin action include the CAP/Cbl/TC10 
pathway, which plays a role in glucose transport (Baumann & Saltiel, 2001, Saltiel & 
Pessin, 2003), and the JAK-STAT pathway, which exerts effects on gene expression (Gual  
et al., 1998, Sawka-Verhelle et al., 2000, Le et al., 2002). Furthermore, an additional 
insulin receptor substrate, IRS-4, is postulated in humans to bind PI3K and Grb2 (Lavan  et 
al., 1997a). IRS-3 is found only in rodents and has no functional human orthologue (Lavan  
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1.4  Insulin resistance and hyperinsulinaemia 
Insulin resistance can be defined as dysregulated glucose-insulin homeostasis, in which 
peripheral tissues (such as skeletal muscle and adipose tissue) show decreased glucose 
uptake in response to insulin. Obesity and physical inactivity are the environmental factors 
most strongly associated with insulin resistance, but genetic factors also add to 
susceptibility  (Chisholm et al., 1997, Wheatcroft et al., 2003).  
Hyperinsulinaemia is commonly described as a compensatory mechanism triggered by 
insulin resistance, rather than the cause of resistance (Ginsberg, 2000). Nevertheless, 
hyperinsulinaemia may also contribute to the maintenance of insulin resistance, since 
experimental hyperinsulinaemia causes insulin resistance in rats (Juan et al., 1999) and 
mice (Marban et al., 1989), and because insulin sensitivity in obese subjects generally 
improves following weight loss (Reaven, 2005).  
Insulin resistance and hyperinsulinaemia are both independent risk factors for a number of 
pathological disorders, such as cardiovascular disease (Despres et al., 1996, Bokemark et 
al., 2001), hypertension (Welborn et al., 1966, Ginsberg, 2000), atherosclerosis (Howard et 
al., 1996, Stolar & Chilton, 2003, Wheatcroft et al., 2003), dyslipidaemia (Ginsberg, 
2000), and type II di abetes (Stolar & Chilton, 2003). However, insulin 
resistance/hyperinsulinaemia likely acts in concert with other risk factors in the 
pathogenesis of all of these diseases, as patients with insulin-secreting tumours 
(insulinomas) do not tend to have hypertension (Haffner et al., 1992) or atherosclerosis 
(Leonetti et al., 1993). 
The involvement of hyperinsulinaemia/insulin resistance in the context of endothelial 
dysfunction is discussed below, and some of the mechanisms that have been postulated to 
contribute to the causes and effects of insulin resistance and hyperinsulinaemia are 
described. 
 
1.4.1  Insulin resistance and endothelial dysfunction 
Insulin resistance is strongly linked to endothelial dysfunction, but it is still debated 
whether insulin resistance is a cause or a result of endothelial dysfunction (Wheatcroft et 
al., 2003). The course of pathological events in animal models of insulin resistance 
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2001, Mather et al., 2001, Wheatcroft et al., 2003). However, it has also been postulated 
that peripheral endothelial dysfunction, at the arteriolar and capillary level, is the main 
cause for the development of insulin resistance and its associated metabolic disturbances, 
while central, large vessel endothelial dysfunction promotes atherogenesis without 
significantly affecting metabolism. Thus, insulin resistance may be a marker, rather than a 
causative agent, of peripheral endothelial dysfunction (Pinkney  et al., 1997). In keeping 
with this hypothesis, eNOS-knockout mice develop insulin resistance (Shankar et al., 
2000). In humans, pathological and experimental hyperinsulinaemia are linked to impaired 
vasodilation, suggesting that hyperinsulinaemia may be not only a contributor to, but also a 
cause of endothelial dysfunction (Steinberg  et al., 1996, Balletshofer et al., 2000, Cleland 
et al., 2000). 
Insulin sensitivity and basal NO production in humans are closely and positively correlated 
(Petrie et al., 1996). Insulin-resistant patients show defective endothelium-dependent 
vasodilation (Steinberg  et al., 1996, Laine et al., 1998, Cleland et al., 2000). Furthermore, 
endothelial dysfunction is also evident in first-degree relatives of patients with type II 
diabetes (Balletshofer et al., 2000).  
Many insulin-resistant patients have elevated endothelin-1 levels proportional to the degree 
of hyperinsulinaemia (Mather et al., 2001). A possible cause for this observation is the 
ability of insulin to directly stimulate the production of endothelin-1 in vitro (Yanagisawa 
et al., 1988). At the vascular level, increased endothelin-1 production could further 
aggravate the imbalance between vasodilators and vasoconstrictors, as NO and endothelin-
1 can reciprocally regulate one another at several levels, including the transcriptional level 
(Mather et al., 2001). Endothelin-1 has been shown to inhibit the PI3K pathway in vascular 
smooth muscle cells (Jiang et al., 1999b). If endothelin-1 also inhibits the endothelial PI3K 
pathway, imbalanced production of NO and endothelin-1 could potentially exacerbate 
impaired vasodilation and endothelial dysfunction. 
 
1.4.2  Insulin resistance and proinflammatory mediators 
Inflammation has been implicated in the pathogenesis of insulin resistance and is also 
strongly linked to endothelial dysfunction (Kubes et al., 1991, Yudkin et al., 1999, Aljada 
et al., 2000, Ziccardi  et al., 2002, Wheatcroft et al., 2003, Dandona et al., 2004). Elevated 
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necrosis factor a (TNFa) and IL-6 have all been postulated as inflammatory mediators of 
endothelial dysfunction and insulin resistance (Feinstein et al., 1993, Valverde et al., 1998, 
Winkler et al., 1999, Yudkin et al., 1999, Halse et al., 2001, Bastard et al., 2002, Ritchie et 
al., 2004). It is known that these proinflammatory cytokines trigger a positive feedback 
loop: via phosphorylation of I?B and activation of NF?B, they mediate their own 
transcription, as well as that of cell adhesion molecules (ICAM-1 and VCAM-1), 
monocyte chemoattractant protein-1 (MCP-1) and CRP (Dandona et al., 2002). 
Obese individuals present with elevated adipose-derived TNFa concentrations, and this 
correlates with hyperinsulinaemia and insulin resistance (Winkler et al., 1999, Yudkin et 
al., 1999, Ritchie et al., 2004). Pharmacological administration of TNFa in humans gives 
rise to insulin resistance, and TNFa knockout mice do not develop obesity-induced insulin 
resistance (reviewed in (Wheatcroft et al., 2003)). TNFa is known to impair the 
phosphorylation of the insulin receptor by triggering serine phosphorylation of IRS-1, 
which blocks insulin receptor kinase activity (Hotamisligil et al., 1994a, Hotamisligil et 
al., 1994b, Hotamisligil et al., 1996), thus likely blunting the insulin-stimulated response. 
Furthermore, TNFa enhances PKB dephosphorylation and inactivation in endothelial cells, 
thus potentially triggering pro-apoptotic signalling cascades in these cells (Ritchie et al., 
2004). TNFa also promotes monocyte adhesion through increased expression of adhesion 
molecules (Ritchie et al., 2004). 
Insulin can counter inflammatory stimuli in human aortic endothelial cells in vitro and in 
human mononuclear cells in vivo via the inhibition of NF?B and the stimulation of I?B 
(Dandona et al., 2001). Physiological levels of insulin were thus able to suppress 
expression of ICAM-1 and MCP-1 in vitro (Aljada et al., 2000, Aljada et al., 2001). 
Consistent with this observation, the insulin-sensitising thiazoledinedione drugs inhibit 
NF?B and thus block TNFa-mediated insulin resistance (Peraldi et al., 1997, Dandona et 
al., 2002). Furthermore, administration of the anti-inflammatory drug aspirin improves 
insulin sensitivity by inhibiting hepatic gluconeogenesis (Dandona et al., 2002, Hundal  et 
al., 2002). These data provide evidence for an anti-inflammatory effect of insulin at 
physiological concentrations (Dandona et al., 2002). 
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1.4.3  Endothelial dysfunction and leukocyte adhesion 
Increased leukocyte adhesion to endothelial cells is a feature of endothelial dysfunction. 
This process is proatherogenic, forming a key early event in the formation of 
atherosclerotic plaques. Likewise, transendothelial migration of leukocytes contributes to 
the initiation of atherosclerosis (Okouchi et al., 2002a) and possibly to the rupture of 
atherosclerotic plaques (van der Wal et al., 1994). Transendothelial migration (also known 
as transmigration or diapedesis) is regulated through the expression of endothelial adhesion 
molecules and chemotactic molecules including monocyte chemotactic protein-1 (MCP-1). 
In vitro studies routinely use leukocyte subtypes such as neutrophils and monocytic cell 
lines to study leukocyte migration behaviour. 
A number of studies have demonstrated that elevated insulin concentrations alter the 
expression of cellular adhesion molecules in endothelial cells. In vitro, insulin was reported 
to upregulate the expression of PECAM-1 and to promote neutrophil transendothelial 
migration in a dose-dependent manner via the MAPK pathway (Okouchi et al., 2002a). 
Likewise, the MAPK pathway was also implicated in promoting in vitro neutrophil 
transendothelial migration and elevated expression of intercellular adhesion molecule-1 
(ICAM-1) in human umbilical vein endothelial cells (HUVEC) exposed to 
pathophysiological concentrations of insulin (Okouchi et al., 2002b, Okouchi et al., 2003). 
Conversely, Aljada and co-workers (Aljada et al., 2000) found that experimental  
hyperinsulinaemia decreased the expression of ICAM-1 mRNA and protein in cultured 
human aortic endothelial cells (HAEC) through increased eNOS expression and 
endothelial NO production, thereby acting as an antiatherogenic stimulus. A potential 
explanation for these conflicting findings may be the use of different endothelial cell types 
in these studies.  
Expression levels of vascular cell adhesion molecule-1 (VCAM-1) were reported to be 
upregulated through the MAPK pathway, when HUVEC were treated with 
pathophysiological concentrations of insulin for up to 24 hours (Madonna et al., 2004). 
However, in vivo data from a study using the euglycaemic hyperinsulinaemic clamp 
demonstrated that short-term hyperinsulinaemia has no adverse effect on the levels of 
circulating soluble ICAM-1, VCAM-1 or E-selectin in healthy males (Jilma et al., 2000). 
In support of this, although plasma concentrations of soluble VCAM-1 are elevated in 
diabetic patients, hyperinsulinaemia did not upregulate VCAM-1 expression in vitro or 
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It is possible that membrane-bound and secreted (soluble) adhesion molecules serve 
different purposes. Adhesion molecules on the surface of endothelial cells anchor 
leukocytes to the endothelium, thus promoting plaque formation. By contrast, secreted 
adhesion molecules may bind to the integrins expressed on the surface of leukocytes, thus 
preventing them from binding to the vascular endothelium and counteracting 
atherogenesis. The precise role of secreted adhesion molecules requires further 
clarification. Therefore, the overall effect of hyperinsulinaemia on endothelial expression 
and secretion of adhesion molecules and the resulting impact on atherogenesis remain 
unclear. 
Chemokines play a crucial role in the attraction of monocytes to the vascular endothelium. 
Vascular endothelial cells have been shown to secrete a number of chemokines, including 
MCP-1, -2 and -3, MIP-1a and  -1ß, MIG, Eotaxin, RANTES, GRO and IP-10  (Pellegrino 
et al., 2005, Simionescu, 2007). MCP-1 has been implicated in monocyte recruitment to 
the vascular endothelium (Charo & Taubman, 2004, Simionescu, 2007) , but the precise 
roles of endothelial chemokines in atherogenesis are still under investigation. 
 
1.5  Hyperglycaemia 
All tissues in the body use glucose as an energy source, though only the brain and 
erythrocytes have an absolute requirement for glucose. The main target tissues for glucose 
disposal after a meal are muscle, liver and adipose tissue, which store excess glucose as 
glycogen (in liver and muscle) and triglycerides (in adipose). Muscles store about 90% of 
ingested glucose. Stored glucose is used to meet energy demands of the tissue. The liver is 
the only organ able to release glucose into the circulation in response to decreasing blood 
glucose levels. The liver produces glucose through glycogenolysis and gluconeogenesis.  
Hyperglycaemia is a consequence of dysregulated glucose homeostasis. It is characterised 
by pathologically elevated blood glucose concentrations (fasting >7 mmol/L; post-prandial 
>11.1 mmol/L), and is a defining feature of overt diabetes. In Type I diabetes, insulin-
secreting pancreatic ß cells are destroyed by an autoimmune response that eventually leads 
to a complete loss of insulin secretion. Hyperglycaemia becomes diagnostic of Type II 
diabetes when secretion of insulin by pancreatic ß cells can no longer meet the demand of 
insulin-resistance for insulin, and undergo cell death as a result. In Type II diabetes, 
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resistance to insulin. As a consequence of inappropriate or absent insulin secretion, glucose 
is no longer appropriately taken up into target tissues and hepatic gluconeogenesis is not 
inhibited, causing a rise in blood sugar levels (see Figure 1-6). 
 
 
 
 
Figure 1-6 Correlation between insulin sensitivity and the development of Type II 
diabetes 
With progressive loss of insulin sensitivity, endothelial function and the control of blood sugar 
levels worsen and type II diabetes develops. Figure adapted from (Wheatcroft et al., 2003) 
 
 
1.6  Insulin resistance, hyperglycaemia and associated disorders 
Insulin resistance/hyperinsulinaemia and hyperglycaemia are strongly associated  with 
several disorders, including obesity, Type II diabetes, atherosclerosis, hypertension and 
cardiovascular disease (for reviews, see (Ginsberg, 2000, Stolar & Chilton, 2003, 
Wheatcroft et al., 2003). It is estimated that about 25% of the adult population in the UK 
and the United States have some degree of insulin resistance, many of whom will go on to 
develop Type II diabetes (Ritchie et al., 2004).  
The metabolic syndrome (also known as insulin-resistance syndrome or syndrome X) is a 
term used for a specific cluster of metabolic disorders that frequently manifest together, 
especially in the obese. These disorders comprise insulin resistance, hyperinsulinaemia, 
hyperglycaemia, central (visceral) obesity, hypertension, dyslipidaemia (especially 
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concentrations), endothelial dysfunction and impaired fibrinolysis (Stolar & Chilton, 
2003).  
 
1.6.1  Obesity 
There is a clear correlation between obesity and the degree of insulin resistance (Steinberg  
et al., 1996, Yudkin et al., 1999, Ritchie et al., 2004). Most obese individuals present with 
some degree of insulin resistance (Ritchie et al., 2004). According to the World Health 
Organisation’s report 2002, a high body mass index accounts for 75% (males) to 83% 
(females) of the total risk for type II diabetes (World Health Organisation, 2002), which is 
itself a common consequence of insulin resistance. Weight loss, even as little as 5-10% of 
the body weight, has significant beneficial effects on insulin sensitivity, vascular 
endothelial function and NO bioavailability  (Ziccardi et al., 2002, Ritchie et al., 2004, 
Reaven, 2005). Since obesity is characterised by increased adiposity, it is reasonable to 
speculate that the bioactive adipocytokines secreted by adipose tissue are involved in the 
regulation of endothelial function and insulin sensitivity (Ritchie et al., 2004). In fact, 
adiposity has been postulated to cause a state of chronic, low level inflammation due to its 
secretion of proinflammatory molecules, which in turn may induce endothelial dysfunction 
and insulin resistance (Yudkin et al., 1999). 
 
1.6.2  Diabetes mellitus 
Diabetes mellitus has traditionally been classified as either early-onset, hereditary “Type I 
diabetes” or maturity-onset “Type II diabetes”. However, it is becoming increasingly clear 
that not all diagnosed cases of diabetes fit into these broad categories, and the boundaries 
between these two classes are often blurred. Type II diabetes is now increasingly found in 
the young. Conversely, Type I diabetes, which can occur as early as the neonatal stadium 
and traditionally has most commonly been diagnosed before the age of 20, is now 
sometimes diagnosed significantly later in life.  
Type II diabetes (previously called “non-insulin-dependent diabetes mellitus” (NIDDM)) 
is a complex, multisystem disorder characterised by hyperglycaemia and insulin resistance 
(Stolar & Chilton, 2003). It is primarily associated with obesity and physical inactivity, but 
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Indians (Stolar & Chilton, 2003) suggests that genetic factors predispose to type II 
diabetes. Type II diabetes accounts for 90-95% of all diabetes cases (Stolar & Chilton, 
2003, Schulze & Hu, 2005). The remaining 5-10% are attributable to insulin-dependent 
(type I) diabetes, an autoimmune disease to which sufferers are genetically predisposed 
(Friday et al., 1999). Type II diabetes develops secondary to insulin resistance and 
hyperinsulinaemia, and, like obesity, has been postulated to be a proinflammatory state 
(Pickup et al., 1997, Dandona et al., 2002, Wellen & Hotamisligil, 2005).  
Subjects in the prediabetic state present with endothelial dysfunction and insulin resistance, 
but not with hyperglycaemia. The current aetiologic theory is that the pancreatic beta-cells 
secrete more insulin in response to peripheral insulin resistance (thus causing 
hyperinsulinaemia), but the increasing secretory burden accelerates apoptosis of the ß cells; 
insulin secretion declines progressively and is eventually lost. This process brings with it 
dysregulated glucose homeostasis, since glucose is no longer appropriately taken up into 
muscle and adipose tissue. In addition, hepatic gluconeogenesis is no longer suppressed 
(Basu et al., 2004); therefore, hyperglycaemia ensues, which requires therapeutic 
intervention (Stolar & Chilton, 2003). Furthermore, because insulin suppresses lipolysis 
and thereby regulates the plasma concentrations of free fatty acids (FFA) under normal 
physiological conditions, loss of insulin secretion will also affect the levels of plasma free 
fatty acids. Once insulin resistance ensues, plasma FFA concentrations rise. In addition, 
low/absent insulin concentrations are no longer sufficient to suppress hepatic 
gluconeogenesis. This, together with dysregulated postprandial glucose uptake, contributes 
to hyperglycaemia (Reaven, 1988).  
Type II diabetes is frequently associated with the components of the metabolic syndrome, 
and bears a two-fold increased risk of premature death (Centers for Disease Control and 
Prevention, 2003). Patients with type II diabetes suffer microvascular and macrovascular 
complications. Diabetic microvascular complications are the main cause of nephropathy 
(kidney failure), retinopathy (blindness) and non-traumatic amputations (Schulze & Hu, 
2005). Macrovascular disorders, such as infarction and stroke, are the major cause of death 
in diabetic patients (Centers for Disease Control and Prevention, 2003), accounting for 
75% of all deaths amongst adult type II diabetics (Laakso, 1995, Stolar & Chilton, 2003). 
Overall, Type II diabetes was the sixth most common cause of death in the United States in 
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Type II diabetes is highly prevalent, in particular in so-called “westernised” countries, 
where the population tends to eat energy-dense, high-fat, high-sugar diets (Schulze & Hu, 
2005). The global incidence of Types I and II diabetes in adults over 20 years of age was 
estimated to be 171 million cases in the year 2000, and is expected to rise to 366 million 
cases by 2030 (Wild et al., 2004). The World Health Organisation reports that diabetes 
mellitus caused 987,816 deaths worldwide in 2002, which made up approximately 1.7% of 
all deaths in that year (World Health Organisation, 2002). In 2001, there were an estimated 
1.8 million people affected by Type II diabetes in the UK, plus another one million thought 
to have not yet been diagnosed (Diabetes UK, 2001). The public health and economic 
burden of type II diabetes and its associated morbidity and mortal ity is enormous (Wild et 
al., 2004), and annually accounts for many years of life spent either with disability or lost 
(World Health Organisation, 2002, Hedner et al., 2005). 
In the context of hyperglycaemia and diabetes, it has frequently been shown that 
endothelial function and NO bioavailability are impaired ((Calver et al., 1992, McVeigh et 
al., 1992, Hogikyan et al., 1998); reviewed in (De Vriese et al., 2000, Rask-Madsen & 
King, 2007) ), and that this association is independent of the presence of the complicating 
risk factors, obesity and hypertension (Hogikyan  et al., 1998). Consequently, patients with 
diabetes have an increased propensity to cardiovascular and microvascular disease and 
associated morbidity and mortality (Stratton et al., 2000, Rahman  et al., 2007).  
The degree o f insulin resistance predicts the extent of impairment of endothelium-
dependent vasodilation (Ardigo et al., 2006), and the risk for vascular complications 
strongly correlates with the level of hyperglycaemia in patients (Stratton et al., 2000). 
However, this association is not definite, since two studies suggested that insulin-induced 
vasodilation was similar in the coronary vasculature of healthy and Type I diabetic subjects 
and was not impaired by short-term hyperglycaemia (Smits et al., 1993, Sundell et al., 
2002). It may be that the extent and/or nature of endothelial dysfunction differs in Type I 
and Type II diabetes. 
 
1.6.3  Atherosclerosis 
Hyperinsulinaemia and hyperglycaemia are often associated with oxidative stress and 
endothelial dysfunction, marked by adhesion of inflammatory cells to vascular endothelial 
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transform into foam cells by ingestion of oxidised low-density lipoprotein (LDL) 
cholesterol, and eventually undergo apoptosis, thus forming so-called fatty streaks, while T 
lymphocytes contribute to inflammation through the release of cytokines (Stolar & Chilton, 
2003). All of these factors contribute to the formation of atherosclerotic plaques, which, 
once formed, can turn into unstable plaques that rupture, resulting in unstable angina or 
myocardial infarction. This process is called atherogenesis.  
Because insulin resistance-mediated endothelial dysfunction is also characterised by 
increased platelet activation/decreased platelet inhibition, elevated procoagulant 
expression, and impaired fibrinolysis, patients with Type II diabetes are also at increased 
risk of thrombus formation (Carr, 2001, Stolar & Chilton, 2003), which in turn affects the 
risk for cardiovascular events such as stroke. Figure 1-7 illustrates the parallel progression 
between insulin resistance and atherogenesis. 
 
 
Figure 1-7 The parallel progression between insulin resistance and atherogenesis 
Hyperinsulinaemia promotes endothelial dysfunction, which greatly increases the risk for both type 
II diabetes and atherosclerosis. Figure adapted from (Hsueh & Law, 2003) 
 
1.6.4  Animal models 
A number of animal models have been developed to study various aspects of insulin 
resistance, hyperglycaemia/diabetes, obesity, and endothelial dysfunction. Briefly, these 
animal models include the “Zucker” (fa/fa) rat model  for insulin resistance (Kasiske et al., 
1992), the “non-obese diabetic” (NOD) mouse and BioBreeding (BB) rat models for 
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model for Type II diabetes and associated disorders (Kobayashi et al., 2000), the obese 
(ob/ob) mouse model of obesity (Tschöp & Heiman, 2001), the “insulin receptor 
knockout” (IRKO) mouse (Wheatcroft et al., 2004) and the “vascular endothelial insulin 
receptor knockout” (VENIRKO) mouse (Vicent et al., 2003) for the study of IR function 
and insulin signalling, and “eNOS knockout” (eNOS
-/-) mouse (Huang et al., 1995) for the 
assessment of eNOS function in vivo.  
In addition, non-genetic models such as streptozotocin-induced diabetes in rats and mice 
(Cameron & Cotter, 1992, Hink et al., 2001, Ho et al., 2001, Kurlawalla -Martinez et al., 
2005, Song et al., 2007, Fukuda et al., 2008), and short-term hyperglycaemia induced by 
intraperitoneal glucose injection (Stalker et al., 2003) have been used in research.  
 
1.6.5  Oxidative stress in endothelial dysfunction 
Reactive oxygen species (ROS) such as hydrogen peroxide and O2
- are generated by 
enzymes such as NADPH oxidase and uncoupled eNOS. ROS are detrimental to 
endothelial function because they reduce NO bioavailability and thus interfere with 
vasodilation. Superoxide, for example, can react with NO, leading to formation of both 
peroxynitrite and nitrate (Reiter et al., 2000).  Peroxynitrite in turn can reduce NO 
bioavailability through oxidation and uncoupling of eNOS, leading to enhanced superoxide 
production and decreased NO synthesis (Zou et al., 2002). 
It has been demonstrated that experimental hyperinsulinaemia equivalent to concentrations 
typically encountered in insulin-resistant states, impairs endothelium-dependent 
vasodilation in the large conduit arteries in healthy humans (Arcaro et al., 2002). In the 
study of Arcaro and co -workers (Arcaro et al., 2002), oxidant stress was postulated to be 
the underlying reason for hyperinsulinaemia-induced endothelial dysfunction, since the 
antioxidant vitamin C completely reversed the adverse effects of experimental 
hyperinsulinaemia. It should be noted, though, that this was a study of short-term 
hyperinsulinaemia, and may not be representative of the in vivo state in patients. 
In small coronary arteries from obese Zucker rats, a model of insulin resistance, insulin 
caused the production of superoxide anions that resulted in diminished NO bioavailability 
and increased vasoconstriction  (Katakam et al., 2005). Furthermore, when NADPH 
oxidase was inhibited pharmacologically, or when ROS were neutralised by the enzyme Christine F. Kohlhaas     Chapter 1, 51 
 
superoxide dismutase, insulin’s vasodilatory function was restored in these arteries. 
Interestingly, the coronary arteries of these obese Zucker rats expressed higher levels of 
eNOS, which was speculated to be a compensatory mechanism for the decreased NO 
bioavailability (Katakam et al., 2005).  
Previous work has shown that exposure to high glucose concentrations impaired 
vasodilation in rabbit aorta (Tesfamariam et al., 1990) and increased superoxide anion 
generation in HAEC (Cosentino et al., 1997) and rat aorta (Hink et al., 2001). Oxidative 
stress has been proposed as a physiological mediator of endothelial dysfunction (De Vriese 
et al., 2000, Hink et al., 2001, Srinivasan et al., 2004), although this link is subject to 
ongoing  investigation and debate.  
 
1.7  AMPK 
The AMP-activated protein kinase (AMPK) is an enzyme involved in the regulation of 
energy homeostasis at the cellular and whole body level. AMPK was first discovered in 
1973 on account of two of its enzymatic activities, which were later attributed to the same 
kinase (Beg et al., 1973, Carlson & Kim, 1973, Carling et al., 1987, Sim & Hardie, 1988).  
AMPK is a heterotrimeric complex composed of a catalytic a-subunit, a glycogen-binding 
domain-containing ß-subunit and a ?-subunit, which binds AMP and/or ATP. The N-
terminal domain of the a-subunit contains the kinase domain (see Figure 1-8). AMPK is 
expressed ubiquitously. For each AMPK subunit, several isoforms exist, which exhibit 
different tissue expression patterns (Towler & Hardie, 2007).  
AMPK is phosphorylated on Thr172 by the upstream kinase LKB1, a tumour suppressor 
protein. Phosphorylation and activation of AMPK is triggered by increases in the cellular 
AMP:ATP ratio. Binding of AMP makes AMPK a worse substrate for AMPK 
phosphatases (Towler & Hardie, 2007), thereby increasing the proportion of 
phosphorylated AMPK. In a limited number of cell types, such as neurones and T cells, 
AMPK can be phosphorylated at Thr172 and activated in a calcium-dependent manner by 
the Ca
2+/CaM-dependent protein kinase kinase (CaMKK) (Hawley et al., 2005, Woods et 
al., 2005).  
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1.7.1  Roles of AMPK 
As a regulator of energy homeostasis, AMPK is activated in response to metabolic stress, 
switching off energy-consuming pathways and activating ATP-producing pathways. Its 
main roles include stimulating glycolysis, glucose uptake and fatty acid oxidation, and 
inhibiting the synthesis of glycogen, fatty acids and cholesterol. AMPK also negatively 
regulates transcription and translation, as well as cell growth and proliferation  (Towler & 
Hardie, 2007). 
Importantly, AMPK has been shown to directly activate eNOS in human aortic endothelial 
cells by phosphorylation at Ser1177  in vitro, and increases endothelial NO synthesis in 
cultured HAEC in response to AICAR and VEGF (Morrow et al., 2003, Reihill et al., 
2007). Therefore, AMPK is an attractive target for antidiabetic drugs, as it promotes an 
antiatherogenic phenotype and is involved in the regulation of glucose homeostasis. 
 
 
 
 
 
Figure 1-8 AMPK subunit structure 
AMPK consists of one kinase domain-containing a-subunit, a glycogen binding domain-containing 
ß-subunit and a ?-subunit containing the AMP/ATP binding domains. Splice variants of subunits 
are shown. Figure adapted from (Towler & Hardie, 2007) Christine F. Kohlhaas     Chapter 1, 53 
 
1.7.2  Regulation of AMPK activation 
AMPK can be regulated by a number of factors, including blood glucose levels, hypoxia, 
adipocytokines, insulin and pharmacological agents (Towler & Hardie, 2007). Activation 
of AMPK in pancreatic ß cells and the liver by low blood glucose levels is dependent on 
the expression of glucokinase in these cells (Salt et al., 1998, da Silva Xavier et al., 2000). 
Glucokinase has a low affinity for glucose, thereby acting as a glucose sensor, so that 
cellular ATP levels fall with decreasing blood glucose levels as a result of decreased 
glycolysis. This in turn raises the AMP:ATP ratio, thus activating AMPK.  
In some cell types, ligands acting on Gq-coupled receptors can activate AMPK, presumably 
through CaMKK-mediated AMPK phosphorylation. Bradykinin has been reported to 
activate recombinant AMPK expressed in Chinese hamster ovary (CHO) cells by a G-
protein coupled mechanism (Kishi et al., 2000), while thrombin dose- and time-
dependently activates AMPK in HUVEC via a Gq-protein-mediated pathway that is 
independent of the cellular ATP:AMP ratio (Stahmann et al., 2006).  
The so-called adipocytokines (also known as adipokines) leptin and adiponectin are able to 
regulate AMPK activity. Adipocytokines are secreted from adipose cells and have been 
implicated in the regulation of whole body energy homeostasis and inflammation. Leptin 
has been shown to activate AMPK in the muscle of rats, leading to stimulation of fatty acid 
oxidation (Minokoshi et al., 2002). Conversely, leptin inhibited  AMPK activity in the 
paraventricular region in the hypothalamus of fasted mice, lowering food intake 
(Minokoshi et al., 2004). Adiponectin has a blood glucose-lowering effect, as it stimulates 
glucose uptake and fatty acid oxidation in muscle, and inhibits gluconeogenesis in the liver 
by activating AMPK (Tomas et al., 2002, Yamauchi et al., 2002).  
Insulin inhibited AMPK activity in all hypothalamic areas of fasted mice, thus reducing 
food intake. Furthermore, expression of dominant-negative AMPK in mice led to weight 
loss, whereas constitutively active AMPK expression resulted in increased food intake 
(Minokoshi et al., 2004). These data suggest that modulation of AMPK activity alone can 
affect food intake and weight gain. 
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1.7.3  AMPK and insulin signalling 
In general, the insulin signalling and AMPK pathways have opposite effects. In cardiac 
myocytes, insulin has been reported to inhibit AMPK, yet the two pathways also have 
similar effects on glucose homeostasis, since both pathways promote glucose uptake in 
skeletal muscle and suppress the transcription of enzymes involved in gluconeogenesis in 
the liver (Towler & Hardie, 2007). Like insulin, AMPK stimulates eNOSS1177 
phosphorylation, promoting NO synthesis (Morrow et al., 2003, Reihill et al., 2007). 
 
1.7.4   AMPK as a target for antidiabetic drugs  
The widely prescribed hypoglycaemic drug metformin has been shown to activate AMPK 
in a LKB1-dependent fashion (Zhou et al., 2001, Shaw et al., 2005), thereby presumably 
inhibiting gluconeogenesis. Similarly, the related drug phenformin, which is no longer 
prescribed, also stimulates AMPK activity in vitro (Hawley et al., 2003). 
Insulin-sensitising drugs such as the thiazoledinediones (TZDs) troglitazone, rosiglitazone 
and pioglitazone, have been widely used in the treatment of Type II diabetes (Chisholm et 
al., 1997, Peraldi et al., 1997, Fujiwara & Horikoshi, 2000, Ritchie et al., 2004). TZDs 
bind with high affinity to PPAR?, a transcription factor that regulates the expression and 
release of adipocytokines and free fatty acids. TZDs stimulate the release of adiponectin, 
which inhibits gluconeogenesis in the liver by activating AMPK (Tomas et al., 2002, 
Yamauchi et al., 2002).  
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1.8  Summary 
The vascular endothelium is a key player in the maintenance of vascular health and is 
involved in the regulation of vascular tone and leukocyte adhesion. Dysregulated 
endothelial function is associated with insulin resistance, diabetes and atherosclerosis. At 
normal physiological concentrations, insulin is an important regulator of endothelial 
function, as it promotes NO-mediated vasodilation and potentially inhibits atherogenic 
processes, but these effects are attenuated or abrogated in hyperinsulinaemic and 
hyperglycaemic states.  
The metabolic energy sensor AMPK is involved in the regulation of energy homeostasis at 
the cellular and whole body level. AMPK is important as a drug target for insulin-
sensitising drugs, as AMPK activity improves glucose homeostasis. Activation of AMPK 
stimulates endothelial NO release, thereby promoting an antiatherogenic phenotype.  
The precise molecular mechanisms underlying endothelial dysfunction are unclear, and 
their clarification may aid our understanding of vascular endothelial cell function and lead 
to novel therapeutic approaches. 56  
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2.1  Materials 
 
2.1.1  List of materials and suppliers 
Supplier  Materials 
Acros Organics (Geel, Belgium)  Glacial acetic acid (nitrogen -flushed) 
NaNO2 
Tetrasodium pyrophosphate (NaPPi) 
 
Becton Dickinson Biosciences (Oxford, 
UK) 
Corning cell culture flasks, 10 cm-diameter cell 
culture dishes and multiwell plates, transwell 
plates for migration assays  
 
Beckman CoulterTM                             
(High Wycombe, UK) 
 
Ultra-ClearTM ultracentrifuge tubes 
 
BioSource Europe S.A. (Nivelles, 
Belgium) 
 
Human Chemokine Multiplex Bead 
Immunoassay 
BOC Gases (Manchester, UK)  N2, O2 
 
Finnzymes (Espoo, Finland)  DyNAmo
TM SYBR® Green 2-step RT-PCR kit Christine F. Kohlhaas    Chapter 2, 58 
 
 
Fisher Scientific UK Ltd 
(Loughborough, UK) 
Acetone 
D-glucose 
Ethanol 
Glycine 
Microscope slides 
Coverslips (22 mm-diameter and 22 x 22 mm) 
NaOH 
Tris base 
Tricarboxylic acid (TCA) 
 
GE Healthcare UK Ltd (Little  
Chalfont, Buckinghamshire, UK) 
 
ECL
TM HRP -linked secondary antibodies 
 
Hopkin & Williams (Chadwell 
Heath,UK) 
NaN3 
Hycor Biomedical Ltd (Edinburgh, 
UK) 
Glasstic® slides 
 
Inverclyde Biologicals                             
(Bellshill, Lanarkshire, UK) 
Nitrocellulose membrane, 0.45 µm pore size 
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Invitrogen Ltd (Paisley, UK)  AlexaFluor488- and AlexaFluor 568-linked 
secondary antibodies 
Dulbecco’s Modified Eagle Medium (DMEM) 
and Roswell Park Memorial Institute (RPMI) 
1640 cell culture media 
Foetal calf serum (EU origin) 
L-glutamine 
Moloney Murine Leukaemia Virus (M-MuLV) 
reverse transcriptase + first strand buffer + DTT 
for RT-PCR 
Penicillin and streptomycin 
Trypsin (0.05% (v/v) in 0.53 mM EDTA•4Na) 
 
Kodak Industrie (Chalon-sur-Saône, 
France) 
 
Kodak MXB film 
Lonza Walkersville Inc. (formerly 
Cambrex Bio Science Walkersville 
Inc.) (Walkersville, MD, USA) 
 
Human aortic endothelial cells (HAEC) 
Endothelial cell basal medium (EBM®-2) + 
supplements 
Melford Laboratories Ltd (Ipswich, 
UK) 
DTT Christine F. Kohlhaas    Chapter 2, 60 
 
 
Neuro Probe, In c., Gaithersburgh, MD, 
USA; via Receptor Technologies Ltd., 
Adderbury, UK 
Polyvinylpyrrolidone (PVP) -free polycarbonate 
track-etch (PCTE) membranes for migration 
assays (2 µm pore size) 
 
New England Biolabs (Hitchin, UK) 
 
Prestained protein marker 
Novo Nordisk (Crawley, UK)  Actrapid® human insulin (for acute 
stimulation) 
Porcine insulin (for long-term stimulation) 
 
Premier International Foods Ltd 
(Spalding, UK) 
 
Dried skimmed milk 
Promega (Southampton, UK)  Taq DNA polymerase + buffer + molecular 
grade MgCl2 
dATP, dCTP, dGTP, dTTP 
 
PromoCell GmbH (Heidelberg, 
Germany) 
Human aortic endothelial cells 
 
Qiagen (Crawley, UK)  RNA extraction kit Christine F. Kohlhaas    Chapter 2, 61 
 
 
Sartorius Biotech GmbH (Göttingen, 
Germany) 
Sterile syringe filters (0.2 µm) 
Severn Biotech Ltd (Kidderminster, 
Worcester, UK) 
 
Acrylamide:Bisacrylamide (37.5:1; 30% (w/v) 
Acrylamide) 
Sigma-Aldrich (Steinheim, Germany; 
Seelze, Germany; St Louis, MO, USA), 
including all Riedel-de-Haën chemicals 
Ammonium peroxydisulphate (APS) 
Bromophenol blue 
Bovine serum albumin (BSA)  
Benzamidine 
D-mannitol 
DAPI (4',6-Diamidino-2-phenyindole) 
Deoxycholic acid 
Dimethyl sulphoxide (DMSO)  
EDTA (ethylenediamine tetraacetic acid) 
EGTA (ethylene glycol-bis (ß-amino-
ethylether)-N,N,N’,N’-tetraacetic acid) 
37% (w/v) formaldehyde solution  
Glycerol 
Hexanucleotide primers Christine F. Kohlhaas    Chapter 2, 62 
 
Isopropanol 
L-NAME (NG-nitro-L-arginine methyl ester) 
Luminol (5-Amino-2,3-dihydro-1,4-
phthalazinedione) 
Methanol 
NADPH (?-Nicotinamide adenine dinucleotide 
2’-phosphate reduced tetrasodium salt hydrate) 
NaF 
NaHCO3 
Na2HPO4 
NaH2PO4 
NaI (nitrogen-flushed) 
Na4VO3 
Nonidet
TM P-40 substitute (mixture of 15 
homologues) 
OptiPrep® Density Gradient Medium, 60% 
(w/v) iodixanol (5,5’-[(2-hydroxy-1,3-
propanediyl)-bis(acetylimino)]bis-[N,N’-
bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-
benzenedicarboxamide]) in water     
p-Coumaric acid 
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Soy bean trypsin inhibitor (SBTI) 
Sodium dodecyl sulphate (SDS) 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) 
Triton X-100 (4-(1,1,3,3-
Tetramethylbutyl)phenyl-polyethylene glycol) 
Trypan blue 
Tween-20 (Polyethylene glycol sorbitan 
monolaurate) 
Type IV collagen 
TCS CellWorks (Botolph Claydon, 
UK) 
Human aortic endothelia l cells 
Large vessel endothelial cell basal medium + 
supplements  
 
Thermo Fisher Scientific Inc. 
(Pittsburgh, PA, USA) 
Immu-Mount mounting medium for coverslips 
 
Toronto Research Chemicals (Toronto, 
ON, Canada) 
AICAR (5-aminoimidazole-4-carboxamide-1-
bet a-4-ribofuranoside) 
VWR International (Lutterworth, 
Leicestershire, UK),                      
including all BDH chemicals 
Borosilicate coverslips (22 mm diameter) 
CaCl2 solution 
FalconTM 10 cm-diameter cell culture dishes Christine F. Kohlhaas    Chapter 2, 64 
 
and multiwell plates 
30% (v/v) H2O2 
HEPES 
KCl 
KH2PO4 
MgCl 2 
NaCl 
Na2HPO4 
NaH2PO4 
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2.1.2  List of specialist equipment and suppliers 
 
 
Supplier  Equipment 
Analytix Ltd (Durham, UK)  Sievers® Nitric Oxide Analyzer 280 
Exmire microsyringe and needles for NO 
analysis 
 
Beckman CoulterTM (High 
Wycombe, UK) 
J2-21 centrifuge, OptimaTM MAX 
ultracentrifuge, JA-20 rotor 
TLS-55 rotor 
TLA-110 and TLA 110.4 rotors 
 
Becton Dickinson (Franklin Lakes, 
NJ, USA) 
 
FACScan Flow Cytometer 
Biometra biomedizinische 
Analytik GmbH                 
(Göttingen, Germany) 
 
TGradient Thermocycler 
Bio-Rad Laboratories           
(Hemel Hempstead, UK) 
Agarose gel (Mini-Sub/Wide Mini-Sub Cell GT)  
Protein gel casting and Western blotting 
equipment (Mini Protean III)  
Luminex 100TM detection system for Human Christine F. Kohlhaas    Chapter 2, 66 
 
Chemokine Multiplex Bead Immunoassay 
analysis 
 
Carl Zeiss Ltd (Welwyn Garden 
City, Hertfordshire, UK) 
Axiovert 135 microscope  
LSM Exciter laser scanning microscope 
 
Fisher Scientific UK Ltd 
(Loughborough, UK) 
 
Polycarbonate freezing container 
Herolab (Wiesloch, Germany) 
 
UVT-28 MP UV transilluminator 
Neuro Probe, Inc., Gaithersburgh, 
MD, USA; via Receptor 
Technologies Ltd., Adderbury, UK  
AP48 Boyden chamber 
Optika Microscopes (Ponteranica, 
Italy) 
 
XDS-1B light microscope 
Shimadzu Europa GmbH 
(Duisburg, Germany) 
 
UV-1201 spectrophotometer 
WPA (Cambridge, UK)  S2000 spectrophotometer  
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2.1.3  List of antibodies and conditions of use 
 
2.1.3.1  Primary antibodies for Western blotting 
Table 2-1 List of primary Western blotting antibodies and their conditions of use 
All rodent antibodies, as well as the rabbit anti-JNK, the rabbit anti-P-I?Ba Ser32 and anti-
phospho-p44/42 MAPK, are monoclonal; TBST: Tris-buffered saline; Discntd: discontinued; n/a: 
not applicable.  
Epitope  Host 
species 
Dilution  Diluent (w/v in 
TBST) 
Source   Catalogue 
number 
a-AMPKa1  Sheep  1:1000  1% milk  In-house from 
University of 
Dundee (Woods et 
al., 1996) 
n/a 
a-AMPK T172  Rabbit  1:200  5% BSA  Cell Signaling  2531 
a-Caveolin-1  Mouse  1:1000  TBST  Transduction 
Laboratories 
610058 
a-CAP  Rabbit  1:1000  3% milk  Upstate  06-994 
a-Cbl  Mouse  1:1000  3% milk  Upstate  05-440 
a-eNOS  Rabbit  1:5000  1% BSA  Sigma  N-2643 
a-eNOS S116 
(Ser114) 
Rabbit  1:1000  5% milk  Upstate  07-357 
a-eNOS T495  Rabbit  1:1000  5% milk  Upstate  Discntd Christine F. Kohlhaas    Chapter 2, 68 
 
a-eNOS T495  Rabbit  1:1000  5% BSA  Cell Signaling  9574 
a-eNOS S617 
(Ser615) 
Rabbit  1:1000  5% milk  Upstate  07-561 
a-eNOS S635 
(Ser633) 
Rabbit  1:1000  5% milk  Upstate  07-562 
a-eNOS S1177   Rabbit  1:1000  5% BSA  Cell Signaling  9571 
a-GAPDH 
(clone 6C5) 
Mouse  1:1500  5% milk  Ambion  4300 
a-I?Ba  Rabbit  1:1000  3% milk  Upstate  06-494 
a-IKBa Ser32 
(clone 14D4) 
Rabbit  1:1000  5% milk  Cell Signaling  2859 
a-IKKß  Mouse  1:500  3% milk  Upstate  05-535 
a-JNK (56G8)  Rabbit  1:1000  5% BSA  Cell Signaling  9258 
a-JNK 
T183/Y185 
Rabbit  1:1000  5% BSA  Cell Signaling  9251 
a- p44/42 
MAPK  
Rabbit  1:1000  5% BSA  Cell Signaling  9102 
a-Na+/K+-
ATPase a 
Mouse  1:4000  3% milk  Upstate  05-369 Christine F. Kohlhaas    Chapter 2, 69 
 
a-NF?B p65  Rabbit  1:1000  3% milk  Kind gift of Dr T. 
Palmer 
n/a 
a-p38 MAPK   Rabbit  1:1000  5% BSA  Cell Signaling  9212 
a-p38 MAPK 
T180/Y182 
Rabbit  1:1000  5% BSA  Cell Signaling  9211 
a-PDK-1  Sheep  1:1000  5% milk  Upstate  07-047 
a-PI3K-p85  Rabbit  1:1000  3% milk  Upstate  06-497 
a-PI3K-p110ß  Rabbit  1:1000  3% milk  Santa Cruz  sc-602 
a-PKBa  Sheep  1:1000  3% milk  Upstate  07-416 
a-PKB  Rabbit  1:1000  5% milk  Cell Signaling  9272 
a-PKB T308  Rabbit  1:1000  3% milk  Upstate  05-802 
a-PKB S473  Rabbit  1:1000  5% BSA  Cell Signaling  9271 
a-PTEN  Rabbit   1:1000-
1:2000 
3% milk  Upstate  07-016 
a-Rab 4  Rabbit  1:1000  5% milk  Abcam  ab13252 
a-Rab 11a  Rabbit  1:1000  5% milk  Zymed 
Laboratories 
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a-Syntaxin 6  Mouse  1:1000  1% BSA  Transduction 
Laboratories 
610635 
 
2.1.3.2  Secondary detection agents for Western blotting 
Table 2-2 List of secondary Western blotting detection agents and their conditions of 
use  
n/a: not applicable 
Linked 
molecule 
Epitope   Host 
species 
Dilution  Diluent       
(w/v in 
TBST) 
Source  Catalogue 
number 
HRP  Mouse IgG  Sheep   1:1000-
1:2000 
1% milk  GE 
Healthcare 
NA931 
HRP  Rabbit IgG  Donkey  1:1000-
1:2000 
1% milk  GE 
Healthcare 
NA934 
HRP  Rat IgG  Goat  1:1000-
1:2000 
1% milk  GE 
Healthcare 
NA935 
HRP  Streptococcus 
sp. Protein G 
n/a  1:1000-
1:2000 
1% milk  Sigma  P8170 
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2.1.3.3  Primary antibodies for immunocytochemistry 
Table 2-3 List of primary immunocytochemistry antibodies and their conditions of 
use 
PB: permeabilisation buffer 
Epitope   Host 
species 
Dilution  Diluent          
(w/v in PB) 
Source  Catalogue 
number 
a-Caveolin-1  Mouse  1:100  3% BSA  Transduction 
Laboratories 
610058 
a-eNOS  Rabbit  1:100  3% BSA  Sigma  N-2643 
 
 
2.1.3.4  Secondary antibodies for immunocytochemistry 
Table 2-4 Secondary antibodies for immunocytochemistry and their conditions of use 
 
Linked 
molecule 
Epitope  Host 
species 
Dilution  Diluent  
(w/v in PB) 
Source  Catalogue 
number 
AlexaFluor488  Rabbit IgG  Goat  1:100  3% BSA  Invitrogen  A11008 
AlexaFluor568  Mouse IgG  Goat  1:100  3% BSA  Invitrogen  A21043 
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2.1.4  Standard solutions 
Unless stated otherwise, all buffers and reagents were made up with distilled water. 
 
Bradford’s Reagent 
35.0 mg/L Coomassie brilliant blue 
  5.0% (v/v) Ethanol 
  5.1% (v/v) Orthophosphoric acid 
Bradford’s Reagent was filtered and stored in the dark. 
 
 
6X DNA loading buffer 
0.5% (w/v) Bromophenol blue 
15% (w/v) Ficoll 
 
 
Endothelial cell lysis buffer 
  50 mM Tris-HCl  pH 7.4 (at 4°C)     
  50 mM NaF                      
    1 mM Tetrasodium pyrophosphate (NaPPi)              
    1 mM EDTA                      
    1 mM EGTA                      
    1% (v/v) Triton X-100 
250 mM Mannitol  
    1 mM DTT 
    1 mM Na3VO4    added on day of use 
 0.1 mM Benzamidine  
 0.1 mM PMSF 
    5 µg/ml SBTI 
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Enhanced chemiluminescence (ECL) detection reagents 
Solution 1 
   0.1 mM Tris-HCl  pH 8.5  
450 mg/L Luminol in 2% (v/v) DMSO 
130 mg/L Coumaric acid in 1% (v/v) DMSO 
 
Solution 2 
0.1 mM Tris-HCl   pH 8.5 
1.83 x 10-4 % (v/v) H2O2 
 
 
HEPES-EDTA-Sucrose (HES) buffer 
  20 mM Hepes-NaOH  pH 7.4 
    1 mM EDTA 
250 mM sucrose 
    1 mM DTT 
    1 mM Na3VO4 
 0.1 mM Benzamidine  
 0.1 mM PMSF        added on day of use 
    5 µg/ml SBTI 
  50 mM NaF 
    1 mM NaPPi  
 
 
Krebs -Ringer-HEPES (KRH) buffer 
119.0 mM NaCl 
  20.0 mM HEPES-NaOH  pH 7.4 
    5.0 mM NaHCO3 
    5.0 mM Glucose  
    4.8 mM KCl 
    2.5 mM CaCl2 
    1.2 mM MgSO4 
    1.2 mM NaH2PO4  Christine F. Kohlhaas    Chapter 2, 74 
 
    0.1 mM L-Arginine 
Phosphate-buffered saline (PBS) (pH 7.2) 
 85 mM NaCl 
1.7 mM KCl 
   5 mM Na2HPO4 
0.9 mM KH2PO4 
 
 
Ponceau S Stain 
0.2% (w/v) Ponceau S 
   1% (v/v) Acetic acid 
 
 
SDS-PAGE running buffer 
190 mM Glycine 
  62 mM Tris 
 0.1% (w/v) SDS 
 
 
SDS sample buffer 
200 mM Tris-HCl  pH 6.8 
  40% (v/v) Glycerol 
    8% (w/v) SDS 
 0.4% (w/v) Bromophenol blue 
 
The above recipe for 4X SDS sample buffer was used neat, or diluted with distilled water 
to 2X or 1X working concentration as required. DTT was added to a final concentration of 
200 mM before use (i.e. 20% (v/v) from 1 M stock). 
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Tris-buffered saline + Tween-20 (TBST) 
     20 mM Tris-HCl  pH 7.5 
137.5 mM NaCl 
0.1% (v/v) Tween -20 
 
 
Transfer buffer 
  25 mM Tris base 
192 mM Glycine 
  20% (v/v) Ethanol 
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2.2  Methods 
2.2.1  Cell culture 
 
2.2.1.1  Revival and culture of cryopreserved HAEC and HUVEC 
Aliquots of cryopreserved (passage 2 or 3, depending on supplier) endothelial cells (EC) 
were rapidly thawed in a 37°C water bath. Cells were then added to complete endothelial 
cell medium pre-equilibrated in a humidified incubator containing 5% (v/v) CO2, 95% 
(v/v) air, at 37°C. The cell suspension was then divided equally between six to ten 25 cm2 
cell culture flasks and incubated at 37°C in a humidified incubator supplemented with 5% 
(v/v) CO2. Cell medium was replaced every 2-3 days with fresh complete medium. For 
experiments, EC were cultured on non-coated Falcon dishes and multiwell plates as 
required. No coating agent was used as FalconTM cell-cultureware, in conjunction with the 
extracellular matrix produced by EC, provided sufficient support for EC adhesion and 
growth.  
 
2.2.1.2  Determination of endothelial cell phenotype of cultured HAEC 
In order to prevent differentiation from the endothelial phenotype of HAEC and HUVEC, 
only EC in passages 4-6 were used for experiments. To assess the maintenance of the 
endothelial phenotype, the presence of the endothelial cell marker CD31 in cultured HAEC 
was ascertained by immunocytochemistry. Dr Ian Montgomery (University of Glasgow) 
carried out these studies. 
For immunocytochemistry, HAEC were grown on coverslips and fixed with methanol for 
10 minutes. After washing, the coverslips were attached to glass slides using vaseline and 
were circled using a Dako PAP pen to form a watertight seal. The cells were rinsed in PBS 
and blocked with 1:30 goat serum in PBS. Anti-CD31 primary antibody (1:40 dilution in 
PBS + 1% (w/v) BSA) was incubated in a humidified chamber on an orbital shaker for 1h. 
After washing in PBS, the coverslips were incubated with biotinylated goat anti-mouse 
IgG (1:20 dilution in PBS + 1% (w/v) BSA) for 30 minutes. After thorough washing in 
PBS, cells were incubated for a further 30 minutes in ExtrAvidin Peroxidase (1:20 dilution 
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prepared and incubated for 5 -10 minutes. Coverslips were then rinsed with distilled water, 
stained with haematoxylin for 1 minute and rinsed gently. The coverslips were carefully 
removed from the glass slides and mounted on clean slides using Aquamount mounting 
medium and left to dry overnight. Stained cells were examined using a Zeiss Axiophot 
microscope and images were captured using a JVC video camera and AverCAP video card 
in a Viglen computer. 
The plasma membrane of CD31-positive cells was rose-red to brownish-red, with weaker 
cytoplasmic staining, and the nucleus was stained pale blue/purple. Cytoplasmic staining is 
a feature of the antibody used. As a negative control, HAEC were stained in the absence of 
primary antibody (see Figure 2-1). 
  
2.2.1.3  Experimental hyperinsulinaemia treatment of HAEC 
For experimental hyperinsulinaemic conditions, HAEC complete medium was 
supplemented with 100 nM of purified porcine insulin (Novo Nordisk), dissolved in 10 
mM HCl and sterilised, for the indicated period of time (24-48h). Insulin was replaced as 
required when the cell culture medium was replaced.  
 
2.2.1.4  Experimental hyperglycaemia treatment of HUVEC 
For experimental hyperglycaemic conditions, complete EC medium, containing 4 mM 
glucose, was supplemented with 21 mM glucose to give a final concentration of 25 mM 
glucose. As an osmotic control, cells were cultured in complete EC medium supplemented 
with 20 mM mannitol and 1 mM glucose, to give a final concentration of 5 mM glucose 
and 25 mM total monosaccharide. EC were cultured under these conditions for 48h. Christine F. Kohlhaas    Chapter 2, 78 
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Figure 2-1 HAEC stained with anti-CD31 antibody and haematoxylin  
In order to confirm the endothelial phenotype of HAEC, immunocytochemistry was carried out by 
Dr Ian Montgomery as described in section 2.2.1.2. HAEC positive for the endothelial cell marker 
CD31 show red-stained plasma membrane (see arrows) and weaker cytoplasmic staining (panel A), 
while unlabelled control cells do not stain (panel B). Cell nuclei appear blue after staining with 
haematoxylin (both panels). 
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2.2.1.5  Passaging of HAEC and HUVEC 
For experiments, only EC in passages 4 to 6 were used. Cells were routinely subdivided 
1/3-1/7 in 75 cm2 tissue culture flasks. For passaging, EC (~80% confluence) were washed 
once in 2-4 ml of basal EC medium and detached with 1-2 ml trypsin (0.05% (v/v) in 
EDTA). Cells were briefly incubated at 37°C until the cells fully detached upon tapping of 
the cell culture flask. Trypsin was neutralised by addition of 1-3 ml of complete EC 
medium. Cells were pooled in a 50 ml centrifuge tube and centrifuged at 146 x g for 5 
minutes. The supernatant was aspirated and the cell pellet resuspended in 5 ml complete 
EC medium prior to dilution into an appropriate volume of complete EC medium. The cell 
suspension was divided between 75 cm2 tissue culture flasks (Corning) and 10 cm-
diameter cell culture dishes and/or multiwell plates (both Falcon), as required. 
 
2.2.1.6  Culturing of U937 and THP-1 pre-monocytic cells 
U937 cells and THP-1 cells were cultured in complete RPMI 1640 medium (supplemented 
with 10% (v/v) foetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 
mM L-glutamine) and subdivided every 2-3 days by 1/2 to 1/3 dilution with complete 
medium. Cells were incubated at 37°C in a humidified incubator, in an atmosphere of 5% 
(v/v) CO2:95% (v/v) air. U937 and THP-1 cells were generous gifts from Dr W. A. 
Sands/Dr T. Palmer and A. Edkins/Prof W. Cushley, respectively (all University of 
Glasgow). 
 
2.2.1.7  Cryopreservation and revival of U937 pre-monocytic cells 
U937 cells were cryopreserved after centrifugation at 146 x g and resuspension in 90% 
(v/v) FCS, 10% (v/v) DMSO, by overnight incubation in a polycarbonate freezing 
container at -80°C. The following day, cells were transferred to liquid nitrogen storage. To 
revive U937 pre-monocytic cells, cells were removed from liquid nitrogen and rapidly 
thawed in a 37°C water bath. Cells were then added to complete U937 cell medium pre-
equilibrated in a humidified incubator containing 5% (v/v) CO2, 95% (v/v) air, at 37°C. 
The cell suspension was then added to a 75 cm
2 cell culture flask and incubated at 37°C in Christine F. Kohlhaas    Chapter 2, 80 
 
a humidified incubator supplemented with 5% (v/v) CO2. Revived pre-monocytes were 
subdivided a few times before use in experiments. 
 
2.2.2  HAEC and HUVEC lysate preparation 
Unless otherwise stated, all treatments were carried out in duplicate for each experiment. 
EC, stimulated as indicated, were serum-starved by aspirating the cell culture medium, 
washing the cells once with 10 ml of fresh, pre-warmed Krebs-Ringer-HEPES (KRH) 
buffer and replacing it with 5 ml/100 mm-petri dish of fresh KRH buffer. Cells were 
incubated for 2-4h at 37°C. Subsets of cells were then acutely stimulated with 1 µM insulin 
for 10 minutes. Thereafter, the buffer was aspirated and dishes were placed on ice. To each 
petri dish, 0.4 ml fresh, ice-cold lysis buffer was added and cells were scraped off using a 
cell lifter. Resulting cell lysates were transferred to pre-cooled 1.5 ml-microcentrifuge 
tubes, vortexed for 10 seconds and centrifuged at maximum speed (17,530 x g) for 3 
minutes in a 4°C bench-top centrifuge. Lysate supernatants were transferred to fresh, pre-
cooled 1.5 ml-microcentrifuge tubes. The protein concentration of each sample was 
determined by spectrophotometric analysis at 595 nm according to the method of Bradford 
(see section 2.2.3) (Bradford, 1976). Samples were stored at -20°C short-term or at -80°C 
long-term. 
 
2.2.3  Protein concentration determination 
Spectrophotometric analysis of EC lysates according to the Bradford method (Bradford, 
1976) was carried out at 595 nm in a spectrophotometer using disposable plastic cuvettes. 
Duplicates of 2 µg, 4 µg and 6 µg BSA were made up to 100 µl with H2O and utilised as 
reference standards. Duplicates of 5 µl from each sample were added to 95 µl distilled 
H2O. To all samples and reference standards, 1 ml Bradford’s reagent was added and 
spectrophotometric analysis performed in a WPA 2000 spectrophotometer (WPA) within 
10 minutes of reagent addition. The mean absorbance for each sample duplicate was 
calculated and the protein concentration determined by comparison to the calculated mean 
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2.2.4  Iodixanol gradient centrifugation 
Iodixanol (5,5’-[(2 -hydroxy-1,3-propanediyl)-bis(acetylimino)]bis-[N,N’-bis(2,3-
dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide]) is a density gradient 
compound that forms a continuous gradient upon centrifugation, making it possible to 
collect high yields of cellular organelles at high purity (Graham et al., 1994). For 
subcellular fractionation by iodixanol gradient centrifugation, HAEC were grown in 10 
cm-dishes and serum-starved for 2h in KRH buffer before treatment with 1 µM human 
insulin for 10 minutes or no treatment. Cells were then scraped off the dishes in 0.3-0.4 ml 
of HES buffer and pooled according to treatment group (typically 4 dishes were used per 
treatment). The cells were homogenised with ten passes through a ball-bearing 
homogeniser with a 16 µm-ball. Nuclei were pelleted by spinning the homogenates for 3 
minutes at 5000 rpm (4088 x g). The resulting supernatants were diluted with 60% (w/v) 
iodixanol in HES buffer to a density of 40% (v/v), and 0. 5 ml thereof placed at the bottom 
of separate centrifuge tubes and overlaid sequentially with 0.5 ml each of 37.5%, 35%, 
32.5%, 30%, 25%, 20% and 10% (w/v) iodixanol in HES buffer. Samples were then 
centrifuged for 3h at 72,000 rpm (216,276 x g), 4°C, in a TLA-100.4 rotor. The resulting 
fractions were collected as eight separate 500 µl aliquots, starting with the least dense 
fraction from the top of the tube. Fractions were precipitated on ice for 30 minutes using 
0.015% (w/v) deoxycholic acid and 11 % (w/v) TCA. Precipitated proteins were pelleted 
by centrifugation at 17,530 x g, 4°C, for 3 minutes. The supernatants were aspirated and 
pellets were resuspended in 50 µl 2X SDS-sample buffer and 20 µl of 2 M Tris base prior 
to Western blot analysis (samples were not heated before loading onto SDS-gels). 
 
2.2.5  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-polyacrylamide gel electrophoresis was carried out according to the method of 
Laemmli (Laemmli, 1970). Cell lysate samples (see section 2.2.2) were mixed 3:1 with 4X 
SDS-containing sample buffer (SDS-SB) and heated to 95°C in a heating block for 2-5 
minutes. Subcellular fractionation samples (see section 2.2.4 ) were prepared in 4X SDS-
SB (supernatants) or 1X SDS-SB (pellets) and heated to 95°C as above, or heated to 37°C 
for 5 minutes if high temperature was not required. 
Unless otherwise indicated, SDS-gels for cell lysates routinely consisted of 8% (w/v) 
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fractionations, 10% (w/v) resolving gels with 5% (w/v) stacking gels were used. All gels 
were cast in Mini-Protean III gel casting equipment (Bio-Rad). Gel lanes were loaded with 
equal amounts of protein (3-10 µg). Samples were resolved at 80 V until the samples had 
reached the resolving gel, then the voltage was increased to 180 V and the samples were 
resolved until the dye front had migrated the entire length of the gel. Subcellular 
fractionation (iodixanol gradient) samples were usually resolved at 80-100 V. 
 
2.2.6  Western blotting and immunodetection of proteins 
Protein-containing samples were transferred from SDS-gels onto nitrocellulose membranes 
at 60V for 2h, or at 40 mA overnight, using Mini-Protean II/III equipment (Bio-Rad). 
Membranes were briefly stained with Ponceau to check for equal loading of the gels, and 
blocked for 1h in Tris-buffered saline (TBST) containing 5% (w/v) non-fat dried milk. 
Following brief washing in TBST, the membranes were incubated overnight with primary 
antibody, diluted as shown in Table 2-1. All washes and incubation steps were carried out 
under agitation. After primary antibody probing, membranes were washed three times in 
TBST and incubated for 1h in HRP-linked species-specific secondary antibodies, diluted 
1:1000-1:2000 in TBST containing 1% (w/v) milk (for primary antibodies raised in sheep, 
an HRP-conjugated protein G secondary detection agent was used; see Table 2-2). 
Following three washes with TBST, 2 ml of each of the ECL reagents (produced in-house) 
was added to each nitrocellulose membrane and incubated for 1 minute. 
Chemiluminescence was detected with a Kodak X-Omat using Kodak MXB blue-sensitive 
X-Ray film. In order to assess the genuine phosphorylation levels of a protein, the Western 
blot band intensity of a phosphorylated protein, detected with a site-specific phospho-
antibody, was measured and expressed as a ratio to the corresponding total protein within 
the same sample.  
 
2.2.7  Densitometric quantification of protein bands 
The antibody-detected bands on the developed film were scanned on a Mercury 1200c 
scanner, using Adobe Photoshop software. The intensity of the immunodetected protein 
bands on the film was measured using Scion Image or ImageJ software. Densitometric 
analysis was performed on different exposures of the same band to ensure that 
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2.2.8  Nitric oxide measurement 
Nitric oxide (NO) released from cells reacts with dissolved oxygen in the cell culture 
medium or buffer to form nitrate and, predominantly, nitrite. NO production by HAEC was 
hence analysed by a nitrite reduction method (described below) using a Sievers Nitric 
Oxide Analyzer 280 (see Figure 2-2). The NO analyser calculates the amount of NO 
produced by the cells from the amount of nitrite present in the cell culture supernatant 
sample.  
To set up the NO analyser for nitrite reduction, a reducing agent (composed of 5 ml 
nitrogen-flushed glacial acetic acid and 50 mg nitrogen-flushed NaI dissolved in 1.5 ml of 
de-ionised water) was added to the purge vessel and flushed with N2 gas to purge any 
traces of NO2
- from the vessel. After 30 minutes of purging, the purge vessel was sealed 
with a septum and the reducing agent was refluxed under N2 gas.  
Prior to each experiment, a nitrite standard curve was prepared: From a standard solution 
of 100 mM NaNO2, serial dilutions of 50 µM, 10 µM, 1 µM and 100 nM were prepared 
and injected into the purge vessel using an Exmire microsyringe. Under the nitrite-
reducing conditions used, nitrite present in the standards was reduced to NO as shown in 
Equation 1. The NO produced was then detected by the NO analyser, where it reacted with 
O2 to produce O3, which was detected by chemiluminescence. The chemiluminescence 
signal was converted to an electrical potential and displayed as mV by the NO analyser. 
The amount of NO produced by duplicates of each nitrite standard was recorded by the 
analyser and used to produce a calibration curve.  
After calculation of the standard curve, cell culture supernatant samples (prepared as 
described in 2.2.8.1) were injected into the purge vessel using an Exmire microsyringe. 
Samples were injected at 1 minute intervals to allow the output curve to return to baseline. 
The output in mV was then related to the amount of nitrite present in the sample using the 
nitrite standard curve prepared on that day. 
 
I- + NO2
- + 2H +    NO + ½I2 + H2O 
 
Equation 1 Production of nitric oxide from nitrite 
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Figure 2-2 The Sievers Nitric Oxide Analyzer 28 
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2.2.8.1  Preparation of cell culture supernatants for NO analysis 
HAEC were grown to near-confluency in 6-well plates and subsequently treated with 100 
nM porcine insulin for 48h or left untreated. The distribution of treatment conditions on the 
culture plates was randomised to avoid artefacts. After 48h, cells were washed once and 
serum-starved in serum-free medium for 2h at 37°C in a humidified incubator containing 
5% (v/v) CO2. Thereafter, cells were washed once in KRH, transferred to a 37°C water 
bath and acclimatised for 20-40 min. Samples (80 µl) of cell culture supernatant were taken 
prior (t = 0) to and 12 min (t = 12) after addition of 1 µM insulin, 3 µM ionomycin 
(positive control) or no treatment, and analysed immediately with a Sievers Nitric Oxide 
Analyzer 280, as described above.  
The calcium ionophore ionomycin is an antibiotic produced by Streptomyces conglobatus 
ATCC 31005, which binds extracellular Ca2+ ions and transports them across the cell 
membrane (Liu & Hermann, 1978). This raises intracellular Ca
2+ levels and thus activates 
eNOS in a calcium-dependent manner, leading to NO production. 
The calculated amount of NO obtained for each (t = 12) sample was then corrected for the 
amount of NO lost in the initial (t = 0) sample. The amount of NO produced/min (in nM) 
was calculated from the linear part of a sodium nitrite standard curve prepared prior to 
each assay. Per experiment, all treatments except the ionomycin controls were carried out 
at least in duplicate. 
 
2.2.9  Measurement of superoxide production 
Superoxide production in HUVEC was measured using the lucigenin method. Lucigenin is 
a chemiluminescence-based technique, with lucigenin-amplified chemiluminescence (LC) 
based on the following reactions:  
Reaction 1: O2
·- + LC2+ ? LC·+ + O2  
Reaction 2:  LC·+ + O2 ? LCO2 
Reaction 3:  LCO2 ? 2N-methylacridone + h?  Christine F. Kohlhaas    Chapter 2, 86 
 
The luminometer measures the photon of light emitted from the energy rich dioxetan 
molecule (LCO2). 
HUVEC were treated as described in section 2.2.1.4 and lysates were prepared as 
described in section 2.2.2 . Lysate (500µL) was added to 1.5 ml of KRH buffer and 
preincubated with 5 µM lucigenin (a kind gift from Dr C.M. Hamilton, BHF/GCRC, 
University of Glasgow) and 100 µM NADPH for six minutes. Single photon counts were 
measured over 3 minutes and the average value calculated over that time period. Counts 
per lysate were calculated by subtracting background ROS values (scintillation tubes 
containing 2 ml of KRH preincubated with lucigenin and NADPH as above), and were 
corrected to 1 µg/µl lysate.  
 
2.2.10   Monocyte adhesion assays 
HAEC were seeded into 24-well cell culture plates. At near-confluency, 10 wells of cells 
per treatment group were stimulated with 10-100 nM insulin for 24-48h as appropriate, or 
left untreated. As a positive control, 4 wells per plate were treated with 10 ng/ml TNFa for 
6h. Thereafter, the cell culture medium was aspirated and HAEC were overlaid with 
1x10
5/well U937 pre-monocytic cells in basal RPMI medium. The monocytes were 
allowed to attach at 37°C, 5% (v/v) CO2, for 1h. The cell suspension was then aspirated 
and all non-adherent monocytes were washed off by three washing steps with 1 ml/well 
basal DMEM. The cells were fixed with 0.5 ml/well 4% (w/v) paraformaldehyde (PFA), 
5% (w/v) sucrose in PBS, pH 7.2 overnight at 4°C. 
Adherent U937 monocytes were counted at X100 magnification by brightfield microscopy. 
Three separate fields per well of confluent HAEC were counted and the number of total 
U937 cells attached per field of confluent HAEC was expressed as an average of all 
replicates within a treatment group. If HAEC were not confluent, the number of HAEC in 
7 individual fields from seven separate wells was determined. The total number of attached 
monocytes/100 HAEC was then calculated and expressed as an average of all the wells 
within a treatment group. 
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2.2.11   Stimulation of HAEC chemokine production 
Per experiment, all treatments were carried out in duplicate and pooled according to 
treatment. Samples were stored at -80°C after preparation.  
HAEC were grown to ~80% confluency in 6-well plates (Falcon) and stimulated with 2 
mM AICAR for 45 min or 4h with or without co-incubation with 10 ng/ml TNFa for 4h 
and/or 200 µM L-NAME (all diluted in complete endothelial cell medium). All treatments 
were started so that the experiment was concluded at the same time. After this incubation 
period, HAEC were washed three times in serum-free (SF)-RPMI 1640 medium and 
incubated with 0.5 ml/well SF-RPMI for 1h at 37°C, 5% (v/v) CO2. After 1h, the 
conditioned SF-RPMI medium was collected. Controls included i) SF-RPMI medium (with 
and without L-NAME) incubated with untreated HAEC for 1h (basal HAEC control) and 
ii) conditioned medium from HAEC treated with 10 ng/ml TNFa (with and without L-
NAME) (positive control for stimulation of HAEC chemokine production).  
 
2.2.12   Analysis of HAEC chemokine production 
Conditioned medium from stimulated HAEC (see section 2.2.11) was used for chemokine 
analysis with a Multiplex Bead Immunoassay (BioSourceTM 10-Plex system), testing for 
the presence of human chemokines MCP-1, -2, -3, MIP-1a, MIP -1ß, Eotaxin, GRO, 
RANTES, IP-1- and MIG. This assay allows the simultaneous detection of several 
molecules bound specifically to beads coated with relevant antibodies. These beads have 
distinct spectral properties and are linked to fluorophores, which permit the Luminex 
100
TM detection system to distinguish between different beads, and thus, different 
antibody-bound molecules, while simultaneously measuring the quantity of associated 
fluorophore.  
The assay was carried out as per manufacturer’s instructions, but antibodies and enzyme 
substrates were used at half the recommended concentration. All steps were carried out at 
room temperature and in the dark. Briefly, 50 µl per sample of conditioned medium was 
added to 50 µl assay diluent and 50 µl incubation buffer, and incubated under shaking with 
primary antibody-coated beads for 2h. After two washes with wash solution, biotinylated 
detector antibody was added for 1h under agitation. Two further washes preceded 
incubation with streptavidin-RPE for 30 minutes. Prior to detection in a Bio-Plex system 
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chemokine standards were included in duplicate in each experiment as a reference, from 
which the chemokine concentrations in each sample were then calculated.  
 
2.2.13   Immunocytochemistry  
HAEC were grown to near-confluency on 22mm glass coverslips in 6-well cell culture 
plates and treated as indicated. Cells were serum-starved in KRH at 37°C for 2-3h and 
treated with 1 µM human insulin as indicated. Cells were washed once in PBS and 
coverslips were placed into fresh 6-well plates. Cells were fixed in 4% (w/v) formaldehyde 
in PBS for 10 minutes, followed (on most occasions) by a 10 minute blocking step in 20 
mM NH4Cl in PBS. Thereafter, all incubations were carried out at room temperature in a 
dark, humidified chamber. Following a brief wash in PBS, cells were permeabilised in PBS 
containing 0.5% - 1% (v/v) Triton X-100 for 5-10 minutes, washed in permeabilisation 
buffer (PB, PBS + 0.1% Triton X-100) and blocked for 30 min in 10% (v/v) goat serum in 
PB. Cells were washed once in PB before incubation with the primary antibody (anti-
eNOS and/or anti-caveolin-1 antibody, each diluted 1:100 in PB + 3% (w/v) BSA) for 2h. 
Cells were washed three times in PB and incubated with the secondary antibody 
(AlexaFluor 488-linked goat anti -rabbit antibody and/or AlexaFluor 568-linked goat anti-
mouse antibody, each diluted 1:100 in PB + 3% (w/v) BSA) for 1h. Following three 
washes in PBS, cells were stained with DAPI (1:10,000 in PBS) for 5 minutes. After three 
further washes in PBS, the coverslips were mounted onto microscope slides with mounting 
medium and allowed to dry overnight at room temperature in the dark before storage at 
4°C. Negative controls included i) no treatment with primary antibody and ii) treatment 
with primary antibody and irrelevant secondary antibody. 
 
2.2.13.1 Image acquisition and quantification of fluorescence intensity 
Immunolabelled samples were analysed using a Zeiss LSM Exciter laser scanning 
microscope and LSM imaging software. Cells were visualised with a Plan-Apochromat 
X63/1.4 Oil DIC objective and the relevant filter. The pinhole was set to 1 Airy unit, and 
the scan speed was maximal. The detector gain in the fluorescence channel was set such 
that the corresponding negative control sample appeared completely black to eliminate any 
false signals resulting from cell autofluorescence. Images from one visual field were Christine F. Kohlhaas    Chapter 2, 89 
 
acquired in all relevant channels and subsequently overlaid using LSM imaging software. 
DAPI-staining was visualised with a pseudo-DAPI setting (mercur y light source, FSet49 
beam splitter and NT 80/20 emission filter) at maximal pinhole opening. One to four 
images were taken per sample.  
The fluorescence intensity of individual antibody-labelled cells was quantified with ImageJ 
software. Square or rectangular boxes were drawn neatly around the areas of interest and 
the fluorescence intensity measured. The box size and shape were identical within 
individual cells, but varied between cells. Three measurements from different areas of the 
cytoplasm were taken per cell to obtain an average measurement for cytoplasmic 
fluorescence intensity. Three cells per image, and ten images per treatment group were 
analysed (n = 30 per treatment group). Data for each cell were expressed as fluorescence 
intensity relative to nuclear fluorescence intensity.  
 
2.2.14   Statistical analysis 
The “two-sample Student’s t-test assuming unequal variance” (“Student’s t-test”) or the 
“paired two-sample t-test for means” (“paired t-test”) were used for the statistical analysis 
of data as indicated in the results sections. Statistical significance was defined by a two-
tailed p-value of less than 0.05. 90  
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3.1  Introduction 
3.1.1  Background 
Insulin is a vasoactive hormone that stimulates increased blood flow through vasodilation 
(Scherrer et al., 1993); an effect that has subsequently been attributed to insulin-stimulated 
nitric oxide (NO) release (Scherrer et al., 1994). Insulin has been demonstrated to stimulate 
endothelial nitric oxide synthase (eNOS)-mediated NO production in human umbilical vein 
endothelial cells (HUVEC) by signalling through the insulin receptor (Zeng & Quon, 1996, 
Zeng et al., 2000). This process depends on phosphatidylinositol 3-kinase (PI3K) and 
protein kinase B (PKB) (Zeng et al., 2000) to activate eNOS at the activating residue 
Ser1177  (Dimmeler et al., 1999, Fulton et al., 1999), but is independent of the intracellular 
Ca2+ concentration (Montagnani et al., 2001). In several metabolic disease states, including 
the metabolic syndrome, insulin resistance and Type II diabetes, decreased nitric oxide 
bioavailability is a hallmark of endothelial dysfunction (Rask-Madsen & King, 2007). 
Nitric oxide is known to have vasoprotective properties (Gewaltig & Kojda, 2002, Hsueh 
& Quinones, 2003, Wheatcroft et al., 2003), and there is evidence that links decreased NO 
bioavailability to endothelial dysfunction and proatherogenic processes (Li et al., 2002, 
Dickhout et al., 2005, Rask-Madsen & King, 2005, Tesauro et al., 2005). Short exposures 
to physiological concentrations of insulin, as experienced under normal physiological 
conditions, are thought to be vasoprotective, maintaining appropriate vasodilation through 
stimulation of NO production, and preventing atherogenesis. By contrast, prolonged 
exposure to pathophysiological insulin concentrations, as encountered during 
hyperinsulinaemia/insulin resistance, are postulated to promote atherogenesis by 
selectively inhibiting NO release and increasing vasoconstrictive responses (Pandolfi et al., 
2005). 
Clinical studies, as well as animal and in vitro experiments, suggest that prolonged 
hyperinsulinaemia leads to dysregulation of vascular endothelial nitric oxide production. 
Patients with insulin resistance and Type II diabetes exhibit a smaller NO-mediated 
vasodilatory response to insulin than healthy subjects, and this decrease is proportional to 
the level of insulin resistance (Steinberg et al., 1996, Balletshofer et al., 2000, Cleland et 
al., 2000, Ardigo et al., 2006). While many groups reported this decreased vasodilatory 
effect as specific to endothelium-dependent (insulin- or acetylcholine-mediated) 
vasodilation (including (Hogikyan et al., 1998, O'Driscoll et al., 1999, Cheetham et al., 
2000, Cleland et al., 2000, Arcaro et al., 2002)), others have found that endothelium-Christine F. Kohlhaas    Chapter 3, 92 
 
independent vasodilation mediated by an NO donor such as glyceryl trinitrate (GTN), is 
also impaired (McVeigh et al., 1992).  
Impaired insulin-induced vasodilation can also be demonstrated in experimental animals: 
small coronary arteries from insulin-resistant obese Zucker rats were less responsive to 
insulin than vessels from Zucker lean rats (Fulton et al., 2004b, Katakam et al., 2005), but 
this effect was obliterated by pretreatment with the reactive oxygen species (ROS) 
scavenger, superoxide dismutase (SOD) (Katakam et al., 2005). By contrast, in vitro 
studies mimicking hyperinsulinaemia showed that unstimulated human coronary artery 
endothelial cells produced ~50% more NO than controls when cultured with 10-100 nM 
insulin for 24h (Ding et al., 2000). Thus, the effect of hyperinsulinaemia in cultured human 
endothelial cells appears to contradict observations in man and obese Zucker rats.  
Together, these data suggest that NO bioavailability is altered in insulin resistance and 
associated hyperinsulinaemia. However, the underlying molecular mechanisms responsible 
for the reduced vasodilation that is characteristic of clinical hyperinsulinaemia have not 
been fully addressed. Several studies have investigated the effect of insulin resistance or 
experimental hyperinsulinaemia on vasodilation, and a few studies have addressed the 
effect of experimental hyperinsulinaemia on cellular/vascular NO-production (Ding et al., 
2000, Pandolfi et al., 2005, Potenza et al., 2005). To date, however, no studies have looked 
at the effect of experimental hyperinsulinaemia on insulin-stimulated NO production and 
insulin signalling at the cellular level. A logical speculation would be that the insulin 
signalling pathway that leads to NO production is impaired by hyperinsulinaemia, thus 
resulting in lower NO bioavailability. This hypothesis has not been thoroughly 
investigated, and previous studies in human vascular endothelial cells have yielded 
contradicting results (Ding et al., 2000). 
3.1.2  Aims of the chapter 
The work presented in this chapter was designed to determine whether experimental 
hyperinsulinaemia blunted NO production by human vascular endothelial cells in response 
to acute stimulation with insulin (section  3.2.2 ). In addition, the expression and insulin-
responsive phosphorylation levels of the insulin signalling pathway components (PI3K, 
PTEN, PDK-1, PKB, eNOS and p44/42 MAPK) and the cellular energy sensor molecule 
AMPK, which might be involved in any such potential dysregulation were investigated 
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3.2  Results 
3.2.1  Selection of experimental conditions 
Given that culture of human coronary artery endothelial cells with 10-100 nM insulin for 
24h was sufficient to observe an effect on NO production (Ding et al., 2000), it was 
reasoned that 48h of culture in 100 nM insulin would be sufficient to see an effect on NO 
production in HAEC. These conditions are referred to as experimental hyperinsulinaemia 
in this text. For reasons of simplification, cells cultured under conditions of experimental 
hyperinsulinaemia are frequently referred to as “hyperinsulinaemic” in this thesis, despite 
not originating from donors who were known to have hyperinsulinaemia. 
Previous experiments in this laboratory have established that the short-term addition of 
insulin at concentrations as low as 5 nM results in eNOS-mediated nitric oxide production 
in human aortic endothelial cells (Salt et al., 2003). Pilot experiments showed that maximal 
stimulation was achieved with an insulin concentration of 1 µM, which caused an 
approximately 50% increase in NO production in HAEC, with concommitant stimulation 
of PKB
S473 and eNOS
S1177 phosphorylation at the molecular level (Ritchie et al., 2007). At 
the molecular level, acute stimulation of human umbilical vein endothelial cells with a 
range of insulin concentrations demonstrated that 1 µM insulin resulted in maximal 
stimulation of PKBS473 phosphorylation within 10 minutes (see Figure 3-1). Therefore, in 
all subsequent experiments, recombinant human insulin was used at a final concentration 
of 1 µM for acute (10 min) stimulation. Christine F. Kohlhaas    Chapter 3, 94 
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Figure 3-1 Acute stimulation of HUVEC with 1 µM insulin stimulates PKBS473 
phosphorylation. 
HUVEC were serum-starved in Krebs-Ringer-Hepes (KRH) buffer for 2h and stimulated acutely 
with 0 nM – 1 µM insulin. Cell lysates were prepared, and 10 µg of protein/sample were resolved 
by SDS-PAGE and Western blotted. A: Membranes were probed with antibodies as indicated. B: 
The intensity of the resulting immunolabelled protein bands was determined by densitometry. Data 
shown are the results of one experiment.  
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3.2.2  NO production in endothelial cells in response to experimental 
hyperinsulinaemia 
Based on the hypothesis that experimental hyperinsulinaemia would likely disrupt insulin-
stimulated, eNOS-mediated NO production, the production of NO by HAEC grown under 
experimental hyperinsulinaemic conditions was examined in response to an acute insulin 
stimulus. 
To this end, human aortic endothelial cells were cultured under normal or experimental 
hyperinsulinaemic conditions, serum-starved and stimulated acutely with 1 µM insulin to 
mimic a postprandial rise in insulin levels. As a positive control, the calcium ionophore 
ionomycin was used. Cell culture supernatants were analysed on a Sievers Nitric Oxide 
Analyzer 280 as described in section 2.2.8. The results of nine independent experiments 
are summarised in Figure 3-2. 
These experiments showed that acute treatment of HAEC with insulin causes a small but 
significant increase in NO production under control, but not hyperinsulinaemic conditions 
(11±3 % (p<0.05) and 17±6% over unstimulated control for normal and hyperinsulinaemic 
cells, respectively). Basal and acutely insulin-stimulated hyperinsulinaemic cells produced 
similar levels of total NO compared to the respective control levels. 
As expected, NO production in control cells was markedly sensitive to stimulation with the 
calcium ionophore ionomycin (49±12% increase, p <0.005 compared to basal control). 
Interestingly, hyperinsulinaemic cells showed a less pronounced increase in NO production 
upon ionomycin treatment (26±13% increase compared to basal control). Furthermore, the 
difference between insulin-stimulated and ionomycin-stimulated NO production was 
smaller in hyperinsulinaemic than control HAEC (9% and 38%, respectively). However, 
only two experiments (with cells from one donor) included ionomycin-treated 
hyperinsulinaemic cells, therefore, statistical analysis of these samples was not possible. 
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Figure 3-2 Experimental hyperinsulinaemia impairs nitric oxide production in 
HAEC.  
HAEC were cultured with 100 nM insulin for 48h (Hyperinsulinaemia) or left untreated. Insulin (1 
µM)- and ionomycin (3 µM)-stimulated NO synthesis over 12 minutes was measured as described 
in section 2.2.8. The data are derived from 9 independent experiments (from 5 different HAEC 
donors), and are presented as the mean percentage of amount of NO produced/min ± SEM, relative 
to the mean of the unstimulated control samples for each experiment. *p<0.05 for insulin-
stimulated compared to basal control, **p<0.005 for ionomycin-stimulated control compared to 
basal control (Student’s t-test). 
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3.2.3  Protein expression and phosphorylation under experimental 
hyperinsulinaemia 
Current evidence points to a role for NO in vasoprotection and a proatherogenic propensity 
in states of reduced NO bioavailability. There is strong evidence to suggest that disruption 
of the insulin signalling pathway contributes to endothelial dysfunction, as in vitro data 
from HUVEC carrying a mutant version of IRS-1 (G972R) (Federici et al., 2004) and 
clinical studies with G972R heterozygote carriers (Perticone et al., 2004) show (discussed 
in section 3.3.2).  
While no impairment of insulin-responsive, eNOS-mediated NO synthesis was observed in 
the present study (Figure 3-2), it was investigated whether experimental hyperinsulinaemia 
affected individual components of the metabolic insulin signalling pathway at the 
molecular level. In addition, pilot studies evaluated whether experimental 
hyperinsulinaemia affected the expression and phosphorylation of the mitogen-activated 
protein kinase, p44/42 MAPK (also known as externally-regulated kinase, ERK1/2), a 
component of the mitogenic insulin signalling pathway. This was done in order to 
determine whether hyperinsulinaemia differentially affects the metabolic and mitogenic 
branches of the insulin signalling pathway, as has been suggested by other studies (Jiang et 
al., 1999a, Cusi et al., 2000, Montagnani et al., 2002, He et al., 2006, Rask-Madsen & 
King, 2007). 
For these studies, HAEC were cultured under experimental hyperinsulinaemic conditions, 
following which protein expression and phosphorylation levels of key components of the 
metabolic insulin signalling pathway (PI3K, PTEN, PDK-1, PKB and eNOS), the 
mitogenic insulin signalling pathway molecule p44/42 MAPK and cellular energy charge 
(AMPK) were quantified by SDS-PAGE and Western blotting of HAEC lysates. All 
phosphoprotein levels were normalised to the amount of total protein of the same species, 
or to the protein levels of a molecule whose expression was unchanged by experimental 
hyperinsulinaemia. The results of these studies are summarised toward the end of this 
chapter in Table 3-1. Christine F. Kohlhaas    Chapter 3, 98 
 
3.2.3.1  eNOS and PKB 
The protein levels of total eNOS (Figure 3-3, panel A) showed a small and insignificant 
trend to increase during prolonged experimental hyperinsulinaemia (+14±6% and 
+25±12% in HAEC stimulated with 100 nM insulin for 24h and 48h, respectively, 
compared to untreated control HAEC). PKB protein expression (Figure 3-3, panel B) did 
not change with ongoing experimental hyperinsulinaemia.  
To demonstrate that stimulation with 1 µM insulin did not affect total protein expression 
levels, acute (10 min) stimulation with insulin is indicated on the Western blots in Figure 
3-3. From this figure, it is evident that there is no change in total protein expression levels 
between acutely insulin-treated cells and controls at all three time points tested. Hence, the 
protein expression data from acutely stimulated and untreated cells were collated 
separately for each time point. Consequently, in all subsequent figures, acute insulin 
stimulation is only indicated where protein phosphorylation levels were investigated.  Christine F. Kohlhaas    Chapter 3, 99 
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Figure 3-3 Experimental hyperinsulinaemia does not alter eNOS or PKB expression.  
HAEC were treated with 100 nM insulin for 24-48h or left untreated. Cells were then serum-
starved for 2h, and subsets of cells were stimulated acutely with insulin for 10 minutes. Cell lysates 
were prepared as described in section 2.2.2, and equal amounts of protein (3-10 µg) were resolved 
on SDS-polyacrylamide gels. After Western transfer, membranes were probed with antigen-
specific antibodies as indicated. Representative Western blots are shown. Protein expression of 
eNOS (panel A) and PKB (panel B) is unchanged by experimental hyperinsulinaemia. Data 
represent the mean + SEM expression of 5 independent experiments. HAEC were derived from 3 
different individual donors.  Christine F. Kohlhaas    Chapter 3, 100 
 
In order to determine whether eNOS was phosphorylated as expected for functional eNOS 
activity under experimental hyperinsulinaemia, the phosphorylation levels of the two best-
characterised phosphorylation sites of eNOS, Ser1177 (eNOS
S1177) and Thr495 (eNOS
T495) 
were quantified. NO production is proposed to require the coordinated regulation of these 
two phosphosites: Phosphorylation of the activating site Ser1177 is necessary for eNOS 
activity in response to growth factors (Dimmeler et al., 1999, Fulton et al., 1999, Michell 
et al., 2001), while experimental evidence suggests that the inhibitory site Thr495 is 
dephosphorylated for effective NO production (Chen  et al., 1999, Fleming et al., 2001, 
Greif et al., 2002, Fleming & Busse, 2003, Matsubara et al., 2003). Insulin can cause rapid 
phosphorylation of eNOS
S1177 (Kim et al., 2001) and simultaneous dephosphorylation of 
eNOST495 (Federici et al., 2004). 
As expected, acute stimulation  of HAEC with insulin caused an  increase over basal in 
eNOSS1177 phosphorylation under all conditions (fold increases over basal control were 
2.3 ±0.6  for insulin-stimulated control, 2.4±0.7 for 24h and 3.1±1.6 for 48h of 
experimental hyperinsulinaemia), although this was not statistically significant due to large 
interexperimental variation (Figure 3-4, panel A). There was a small and non-significant 
trend toward increased basal eNOSS1177 phosphorylation with ongoing hyperinsulinaemia 
(fold increases over basal control were 1.2±0.2 for 24h and 1.5±0.4 for 48h). 
The basal phosphorylation level of eNOST495 did not change during prolonged 
hyperinsulinaemia, as is evident from comparison to total eNOS levels (Figure 3-4, panel 
B). Acute insulin did not cause a significant change in eNOS
T495 phosphorylation at any 
time point tested. However, there was a tendency toward an increased eNOST495/eNOS 
ratio during experimental hyperinsulinaemia (fold-changes compared to corresponding 
unstimulated control were -1.3±0. 5 for control and +1.2±0.7for 48h). Again, large 
interexperimental variation was observed, and due to the low repeat number, no statistical 
analysis could be performed. 
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Figure 3-4 Experimental hyperinsulinaemia does not significantly alter 
phosphorylation of eNOS at Ser1177 or Thr495. 
HAEC lysates were subjected to immunoblotting analysis as described (section 2.2.6) to quantify 
the levels of eNOS
S1177 (panel A) and eNOS
T495 (panel B). Representative Western blots are shown. 
A: Data shown are the mean ± SEM expression from 5 independent experiments (3 different 
donors). B: Data are shown as mean ± range expression from 2 independent experiments (2 
donors).  Christine F. Kohlhaas    Chapter 3, 102 
 
In order to determine whether PKB phosphorylation was affected by experimental 
hyperinsulinaemia, the phosphorylation levels of the PKB activating site Ser473 (PKB
S473) 
were quantified from the same HAEC lysates that had been used for eNOS quantification. 
PKBS473 phosphorylation was used as an indicator of PKB activity. As illustrated in Figure 
3-5, phosphorylation of PKB
S473 was responsive to acute insulin stimulation under all 
conditions tested. However, there was a trend toward decreased insulin-mediated PKB
S473 
phosphorylation with ongoing hyperinsulinaemia, although this was not statistically 
significant. This trend was caused by increased basal and decreased insulin-responsive 
phosphorylation of Ser473. The fold increases of stimulated compared to corresponding 
basal phosphorylation were 6.8±4.7 for control, 4.2 ±2.6 for 24h and 3.4±1.8 for 48h. Due 
to large interexperimental variation, these fold stimulations were not statistically 
significant. Christine F. Kohlhaas    Chapter 3, 103 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 The insulin-sensitivity of PKBS473 phosphorylation decreases under 
experimental hyperinsulinaemia.  
HAEC lysates from 3 different donors were prepared and analysed as described (sections 2.2.2 and 
2.2.6). Data from 5 independent experiments are shown as mean ± SEM expression relative to 
basal control. Representative Western blots are shown along with densitometric quantification of 
the levels of PKB
S473/PKB (no statistically significant differences). 
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3.2.3.2  AMPK 
Given that insulin-responsive PKBS473 phosphorylation was not greatly impaired by 
experimental hyperinsulinaemia (Figure 3-5), PKB activity was likely to be normal and 
thus unlikely to negatively affect eNOS
S1177 phosphorylation (Figure 3-4). The AMP-
activated kinase AMPK is known to phosphorylate eNOS at Ser1177 (Chen  et al., 1999, 
Fleming & Busse, 2003, Morrow et al., 2003). Therefore, the expression levels of AMPK 
and the phosphorylation status of its activating site Thr172 were investigated, to determine 
whether AMPK could be an effector of the slightly increased basal eNOS
S1177 
phosphorylation at 24h and 48h of experimental hyperinsulinaemia. The majority of the 
samples used in these experiments were identical to those used for the quantification of 
eNOS and PKB expression.  
Total AMPK expression levels showed a slight and non-significant trend to decline during 
experimental hyperinsulinaemia (fold changes with respect to control were 0.88±0.1 and 
0.90±0.07 for 24h and 48h, respectively; see Figure 3-6, panels A and B). Basal 
phosphorylation of AMPKT172 was increased ~2.2±1.2-fold after 48h of experimental 
hyperinsulinaemia. Acute stimulation with insulin increased AMPK
T172 phosphorylation 
under control conditions and after 24h of experimental hyperinsulinaemia (fold increase 
for stimulated compared to corresponding basal control were 2.7±1.2 for control and 
2. 8±1.1 for 24h). However, after 48h of experimental hyperinsulinaemia, basal AMPKT172 
phosphorylation was 2.2±1.2-fold higher than basal control, while insulin-stimulated 
phosphorylation was 3.0-fold lower than insulin-stimulated control, and comparable to 
basal control levels (see Figure 3-6, panels A and C). There was a 2.5-fold reduction in 
insulin-stimulated compared to basal phosphorylation at 48h. Due to variation within 
treatment groups, none of these changes were statistically significant. Christine F. Kohlhaas    Chapter 3, 105 
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Figure 3-6 AMPK expression is unchanged, while insulin-stimulated AMPK
T172 
phosphorylation is decreased after 48h of experimental hyperinsulinaemia.  
HAEC lysates were prepared, resolved by SDS-PAGE and subjected to Western blotting as 
described in sections 2.2.2 and 2.2.6. Representative Western blots are shown  (panel A). While 
AMPK expression levels were unchanged (panel B), the basal and insulin-stimulated 
AMPK
T172/AMPK ratios after 48h of experimental hyperinsulinaemia are inversed with respect to 
control (panel C) (no statistically significant differences). Data shown are the mean ± SEM 
expression of 3 independent experiments with HAEC derived from 2 individual donors.  Christine F. Kohlhaas    Chapter 3, 106 
 
3.2.3.3  PDK-1, PI3K and PTEN 
To further characterise the effect of experimental hyperinsulinaemia on the metabolic 
insulin signalling pathway, the expression levels of the 3-phosphoinositide-dependent 
protein kinase-1 (PDK-1), which phosphorylates PKB, and the regulatory (p85) and 
catalytic (p110ß) subunits of the upstream phosphatidylinositol 3-kinase, PI3K, which is 
required for PDK-1 activity, were quantified. For these experiments, the same HAEC 
lysates that had been used to quantify eNOS and PKB levels were used . The results are 
shown in Figure 3-7, panels A (PDK-1) and B (PI3K-p85 and -p110ß).   
It was also investigated whether the protein levels of the phosphatase PTEN were affected 
by experimental hyperinsulinaemia. PTEN dephosphorylates PI(3,4,5)P3 to PI(4,5)P2, 
thereby negatively regulating PI3K activity  (Oudit et al., 2004). PTEN is also involved in 
the inhibition of eNOS activation via insulin signalling pathway components in response to 
various pathological conditions, including the metabolic syndrome (Shen  et al., 2006a, 
Shen et al., 2006b, Wang et al., 2006), and therefore represents a potential –  albeit indirect 
– regulator of eNOS phosphorylation in the present system. The majority of the samples 
used for PTEN analysis were identical to those used for the quantification of eNOS and 
PKB expression levels (see Figure 3-8). 
While PDK-1 expression appeared to be slightly upregulated after 48h of experimental 
hyperinsulinaemia (1.2±0.09-fold; Figure 3-7, panel A), this increase was not statistically 
significant. Quantification of the expression of the PI3K p85 regulatory subunit and the 
p110ß catalytic subunit revealed that neither of these expression levels changed under 
hyperinsulinaemic conditions (Figure 3-7, panel B). The expression of the phosphatase 
PTEN declined over the time course of experimental hyperinsulinaemia, resulting in 
decreased protein levels by 48h (fold changes compared to control were 0.95±0.01 and 
0.82±0.03 for 24h and 48h, respectively) (see Figure 3-8). 
In addition to the above molecules, the expression levels of the insulin receptor substrates 
(IRS)-1 and -2 were investigated. However, these experiments yielded insufficient results 
due to poor antibody recognition of these proteins (data not shown). Christine F. Kohlhaas    Chapter 3, 107 
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Figure 3-7 Experimental hyperinsulinaemia does not alter PDK-1 and PI3K levels.  
HAEC lysates were prepared and equal amounts of protein used for SDS-PAGE and Western 
transfer (see sections 2.2.5 and 2.2.6). Representative Western blots are shown. A: PDK-1 
expression levels are not altered by experimental hyperinsulinaemia. Data (mean ± SEM 
expression) are derived from 3 independent experiments with HAEC from 2 individual donors. B: 
PI3K-p85 and –p110ß expression remain unchanged during experimental hyperinsulinaemia. Data 
shown are the mean ± SEM expression of 4 independent experiments (3 individual donors) for the 
PI3K-p85 subunit, or 3 independent experiments (2 individual donors) for the p110ß subunit. 
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Figure 3-8 Expression of PTEN shows a trend to decreases during experimental 
hyperinsulinaemia.  
HAEC were treated as above and equal amounts of protein (3-10 µg) subjected to SDS-PAGE and 
Western transfer. Densitometric analysis demonstrated that the amount of PTEN protein declined 
with ongoing experimental hyperinsulinaemia. Data (mean + range expression; no statistical 
analysis possible) from 2 independent experiments with HAEC from one donor are shown along 
with a representative Western blot. Christine F. Kohlhaas    Chapter 3, 109 
 
3.2.3.4  p44/42 MAPK 
In order to investigate whether experimental hyperinsulinaemia had an effect on the 
mitogenic insulin signalling pathway, the expression and phosphorylation levels of the 
mitogen-activated protein kinase, p44/42 MAPK, were quantified in the same HAEC 
lysates that had been used to quantify the expression levels of the metabolic insulin 
signalling pathway components.  
Panel B in Figure 3-9 shows that the expression of p44/42 MAPK is upregulated 1.2±0.13-
fold compared to control by 24h of experimental hyperinsulinaemia, but declines to control 
levels by 48h. These changes were not statistically significant. 
The results of these studies are summarised below in Table 3-1. 
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Figure 3-9 Experimental hyperinsulinaemia does not change p44/42 MAPK 
expression. 
HAEC lysates were prepared as above and subjected to immunoblot analysis. A representative 
Western blot is shown. Expression levels of p44/42 MAPK are unchanged during experimental 
hyperinsulinaemia. Data shown are the mean ± SEM expression of 3 independent experiments with 
HAEC from 3 individual donors.  Christine F. Kohlhaas    Chapter 3, 111 
 
Table 3-1 Experimental hyperinsulinaemia has no marked effect on the expression 
levels of several signalling proteins.  
This table summarises the findings of the present expression and phosphorylation level 
quantification studies carried out in HAEC.  
Molecule  Effect of experimental hyperinsulinaemia  
eNOS  Time-dependent increase of protein expression (1.25-fold at 
48h); not statistically significant 
eNOSS1177/eNOS  Insulin-responsive under all conditions; increase in basal 
phosphorylation (1.5-fold) at 48h; not statistically significant 
eNOS
T495/eNOS  Tendency toward inversed  insulin-responsive phosphorylation 
(-1.3-fold under control conditions, +1.2-fold at 48h); not 
statistically significant 
PKB  No change in expression levels 
PKBS473/PKB  Insulin-responsive under all conditions tested; trend toward 
decreased insulin-stimulated phosphorylation (6.8-fold under 
control conditions, 3.4-fold after 48h); not statistically 
significant 
AMPK  Unchanged expression levels 
AMPK
T172/AMPK  2.2-fold increased basal and 3-fold reduced insulin-stimulated 
phosphorylation at 48h compared to respective controls; no 
statistically significant differences 
PDK-1  Tendency toward increased expression over time (1.2-fold at 
48h); not statistically significant 
PI3K-p85 and -p110ß  No change in expression 
PTEN  Time-dependent decline (0.8-fold of control at 48h); not 
statistically significant 
p44/42 MAPK  1.2-fold increased expression at 24h (not statistically 
significant), expression  back to control levels after 48h 
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3.2.4  Assessment of monocyte adhesion to hyperinsulinaemic HAEC 
The effect of experimental hyperinsulinaemia on monocyte attachment to HAEC was 
investigated. HAEC were incubated in the presence or absence of 10-100 nM insulin for 
24-48h, and subsets were stimulated with 10 ng/ml TNFa for 6h. Thereafter, HAEC were 
washed thoroughly and overlaid with U937 pre-monocytic cells. Monocytes were allowed 
to attach for 1h before unbound U937 cells were washed off and attached U937 cells were 
fixed with paraformaldehyde (see section 2.2.10 for a detailed description).  
Under control and hyperinsulinaemic conditions, few U937 cells attached to HAEC but, as 
expected, TNFa-treatment resulted in marked  stimulation of monocyte adhesion, although 
this was not significant due to interexperimental variation. Experimental hyperinsulinaemia 
did not exacerbate TNFa-stimulated monocyte adhesion (see Figure 3-10).  Christine F. Kohlhaas    Chapter 3, 113 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10 Experimental hyperinsulinaemia does not increase monocyte adhesion. 
HAEC were stimulated with 0-100 nM insulin for the times indicated in the presence or absence of 
TNFa. Monocytes were allowed to attach to HAEC for 1h after which time unbound monocytes 
were washed off. Attached monocytes were counted microscopically at X100 magnification. Data 
shown are mean + SEM attached monocytes per field of HAEC from 3 independent experiments (1 
experiment for TNFa + insulin-treated cells). The means were calculated for each experiment. The 
total number of separate fields counted per treatment group was 540 (control), 270 (insulin, 24h), 
270 (insulin, 48h), 188 (TNFa) and 24 (TNFa + insulin). TNFa-treatment caused a non-significant 
increase in monocyte adhesion. 
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3.3  Discussion 
3.3.1  Nitric oxide production 
The present study shows that insulin stimulated a small but significant increase in nitric 
oxide production in HAEC under control conditions, as has been demonstrated previously 
in HUVEC (Zeng & Quon, 1996, Zeng et al., 2000). In addition, this study demonstrates 
that insulin stimulated NO production in HAEC under hyperinsulinaemic conditions , but 
this increase was not statistically significant (see Figure 3-2). Under control conditions, 
HAEC were more responsive to the calcium ionophore ionomycin than to insulin. In 
hyperinsulinaemic cells, this response to ionomycin was attenuated, but the small number 
of experiments performed under these conditions limits the significance of these findings.  
The stimulation of NO synthesis by insulin was less than expected in these experiments, 
reaching only ~11% under control conditions. This indicates that the HAEC model 
employed in this study is not particularly insulin-sensitive, and is therefore of limited use 
as a model for experimental hyperinsulinaemia. However, because this small increase was 
consistent, it was statistically significant. In a previous study, a ~35% increase in NO 
release from mouse aorta ex vivo elicited by 1 µM insulin was reported  (Hartell et al., 
2005). It is noteworthy though, that Hartell and co-workers used the fluorescent dye DAF-
2, which reacts with intracellular NO but is strongly affected by divalent cation 
concentration in the system and by incident light (Broillet et al., 2001). This experimental 
approach is therefore difficult to control and standardise, and as such is of limited use.  
In the present study, the overall NO levels produced by HAEC were not decreased by 
experimental hyperinsulinaemia. However, the difference between basal and insulin-
stimulated NO production was no longer significant. In the light of the limited insulin-
sensitivity of the HAEC used here, this finding will have to be verified in a more sensitive 
model. The current findings stand in contrast to other studies: In skin fibroblasts from 
insulin-resistant individuals, insulin failed to augment eNOS activity (as measured by the 
conversion of [3H]-L-Arginine to [3H]-L-Citrulline, an indirect marker of NO production), 
whereas activity was increased ~1.7-fold in fibroblasts from insulin-sensitive individuals 
(Pandolfi et al., 2005). Potenza and co -workers reported that experimental rats with 
hyperinsulinaemia (spontaneously hypertensive rats, SHR) showed a 20% smaller 
vasodilation response to insulin than control rats (Potenza et al., 2005). Likewise, gracilis 
arteries of hyperinsulinaemic obese Zucker rats showed only half the control dilation 
response to acetylcholine in vivo (Fulton et al., 2004b). Arcaro and co-workers showed that Christine F. Kohlhaas    Chapter 3, 115 
 
short-term hyperinsulinaemia abrogated endothelium-dependent vasodilation in femoral 
and brachial conduit arteries of healthy subjects (Arcaro et al., 2002). All of these previous 
reports point to a negative effect of hyperinsulinaemia on nitric oxide synthesis and 
bioavailability, which is not mirrored in the present study. This discrepancy may reflect the 
mixture of tissues used and the length of hyperinsulinaemia studied. 
While limited stimulation of NO production was observed in the experiments presented 
here, it is, of course, possible that NO synthesis was stimulated to a greater extent than 
evident from the measurement of nitrite in these experiments. For example, the levels of 
reactive oxygen species may have been high in the cells used. If this was the case, ROS 
would have reacted with NO. Superoxide, for example, can react with NO, leading to 
formation of both peroxynitrite and nitrate (Reiter et al., 2000).  Peroxynitrite in turn can 
reduce NO bioavailability through oxidation and uncoupling of eNOS, leading to enhanced 
superoxide production and decreased NO synthesis (Zou et al., 2002). It is therefore 
possible that a proportion of the NO produced by the HAEC in this experimental system 
was not detected due to rapid reaction with ROS.  
Duncan and co-workers postulated that endothelial cell superoxide production during mild 
hyperinsulinaemia in older insulin receptor knockout (IRKO) mice may be a mechanism 
underlying early reduction in NO bioavailability (Duncan et al., 2007). Indeed, an earlier 
study by Shinozaki and co -workers had also demonstrated decreased eNOS activity and 
vasorelaxation in the aortae of hyperinsulinaemic, insulin-resistant fructose-fed rats 
(Shinozaki  et al., 1999). Interestingly, not only was endothelium-dependent vasorelaxation 
impaired in these rats, but NO production was decreased in response to the calcium 
ionophore A23187, while superoxide generation was increased. Reduced ionophore-
stimulated NO production in hyperinsulinaemic cells was also seen in the present study 
(Figure 3-2), pointing to a potential mild dysregulation of NO bioavailability in this 
system. It remains to be determined whether this may be due to increased superoxide/ROS 
production. 
With the set-up used in these experiments, the nitric oxide analyser measures nitric oxide 
and its reaction product nitrite, but not nitrate or peroxynitrite. Because any potential 
reaction between ROS/superoxide and NO diminishes the amount of nitrite formed, the 
levels of nitrite formed under these conditions may not be representative of the total 
amount of NO produced. It is therefore conceivable that enhanced NO production is 
masked by elevated nitrate and/or peroxynitrite formation in these cells, if the cells were Christine F. Kohlhaas    Chapter 3, 116 
 
suffering from oxidative stress. Suitable means for detecting oxidant stress under these 
experimental conditions include the use of lucigenin-based chemiluminescence assays for 
the detection of superoxide (Liochev & Fridovich, 1997) and the use of fluorescein-
phenol-coupling-based assays for the detection of ROS (Heyne et al., 2006). In future 
experiments, oxidative stress of the cells could be controlled by the addition of 
antioxidants such as ascorbic acid to the cell culture medium/buffer (Dr Carol Colton, 
Duke University Medical Centre, personal communication).  Christine F. Kohlhaas    Chapter 3, 117 
 
3.3.2  Protein expression and phosphorylation 
Quantitative analysis of molecular components of the metabolic (eNOS, PKB, PI3K, PDK-
1 and PTEN) and mitotic (p44/42 MAPK) insulin signalling pathways, as well as the 
cellular energy sensor molecule AMPK, revealed that experimental hyperinsulinaemia 
does not markedly alter the expression levels of these molecules within 48h. Similarly, the 
phosphorylation levels of eNOSS1177, eNOST495, PKBS473 and AMPKT172 were not 
significantly changed during experimental hyperinsulinaemia, although some trends 
toward a less NO-productive environment were observed (see Table 3-1). For instance, the 
degree of insulin-stimulated PKBS473 phosphorylation decreased by ~50% over time with 
ongoing  hyperinsulinaemia, and insulin-responsive AMPKT172 phosphorylation was 
decreased 3-fold after 48h of experimental hyperinsulinaemia. In their phosphorylated 
state, both of these molecules promote eNOS
S1177 phosphorylation, and can lead to NO 
production. Under the same conditions, acute insulin failed to promote eNOST495 
dephosphorylation, which is thought to enhance NO production. Overall, these findings 
indicate that 48h of experimental hyperinsulinaemia may begin to promote a less insulin-
sensitive phenotype at the molecular level in HAEC. Below, these observations are 
discussed in the light of the current literature.  
The finding of ~1.25-fold increased eNOS protein expression during experimental 
hyperinsulinaemia (Figure 3-3), while not statistically significant in the present study, is in 
line with previous reports of increased eNOS expression (~1.4-fold) in human coronary 
artery endothelial cells cultured with 10 or 100 nM insulin for 24h (Ding et al., 2000). 
Furthermore, Aljada & Dandona reported an insulin dose-dependent increase in eNOS 
expression in HAEC during experimental hyperinsulinaemia (Aljada & Dandona, 2000). 
Two studies with obese Zucker rats, an animal model of hyperinsulinaemia and insulin 
resistance (Chua et al., 1996), suggested that eNOS protein expression was increased in 
small coronary arteries (~7.2 -fold) (Katakam et al., 2005) and in aorta lysates (Toba et al., 
2006). Others, however, found that eNOS expression was unaltered in whole aorta lysates 
of obese Zucker rats (Fulton et al., 2004b, Naruse et al., 2006), and in the hearts of two 
further animal models of insulin resistance, the fructose-fed rat and the ob/ob mouse 
(Fulton et al., 2004b).  
In an animal model of mild hyperinsulinaemia, the heterozygous insulin receptor knockout 
(IRKO) mouse, eNOS protein levels were increased ~5-fold in the aortae of 6 month-old 
mice, while eNOS mRNA levels were comparable to wild-type controls (Duncan et al., 
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eNOS mRNA levels were reduced by 30-60% in endothelial cells, aorta and heart 
compared to controls. By six months of age, VENIRKO mice had developed mild insulin 
resistance, but remained glucose-tolerant (Vicent et al., 2003). The differences between 
these various models described above emphasise the complexity of physiological systems 
and the ensuing difficulty in defining the mechanisms underlying a model’s responses to 
stimuli such as insulin. 
In the context of vasorelaxation, a decrease in eNOS expression would be predicted to be 
associated with elevated blood pressure due to decreased production of the vasodilator NO. 
Indeed, heterozygous and homozygous eNOS knockout mice show increased blood 
pressure that is attributable to the decrease/loss of eNOS protein expression (Shesely et al., 
1996). By contrast, elevated eNOS protein levels during hyperinsulinaemia do not 
necessarily have to correlate with increased NO levels, but may equally represent a greater 
proportion of uncoupled eNOS. This, in turn, could diminish NO synthesis and enhance 
superoxide generation (Zou et al., 2002), leading to impaired vasodilation. This has been 
demonstrated in IRKO mice, which show increased aortic eNOS protein levels with 
increased endothelial ROS and blunted endothelium-dependent vasodilation  (Duncan et 
al., 2007). While vasodilation cannot be assessed in the present system, superoxide levels 
in HAEC can be measured, which would represent an interesting extension to the present 
body of work. 
In the present study, experimental hyperinsulinaemia mildly increased the basal and 
insulin-stimulated phosphorylation of eNOS at Ser1177 (~1.5-fold increase of basal, and 
1.4 -fold increase of insulin-stimulated phosphorylation at 48h compared to the 
corresponding controls; see Figure 3-4, panel A). These findings are corroborated by the 
observation that basal eNOS
S1177 phosphorylation (as normalised to total eNOS expression) 
was elevated in hyperinsulinaemic obese Zucker rats compared to control rats. However, 
two other animal models of hyperinsulinaemia , the fructose-fed rat and the ob/ob mouse 
showed no difference in the eNOS
S1177/eNOS ratio compared to controls. None of these 
models demonstrated a statistically significant change in the basal eNOS
T495/eNOS ratio 
(Fulton et al., 2004b). This agrees with the present results, which demonstrate that 
experimental hyperinsulinaemia does not change basal eNOST495 phosphorylation in 
HAEC. 
Studies with IRS-1 G972R polymorphic HUVEC, which have a known insulin signalling 
defect, showed decreased basal and up to 51% reduced insulin-stimulated eNOS
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phosphorylation compared to wild type HUVEC (Federici et al., 2004). At the same time, 
basal eNOS
T495 phosphorylation in these variant HUVEC was upregulated compared to 
control HUVEC. Acute insulin stimulation caused an increase in eNOS
T495 
phosphorylation above basal, and a 40% increase compared to insulin-stimulated wild type 
cells (Federici et al., 2004). Assuming that experimental hyperinsulinaemia impairs insulin 
signalling, the present eNOS
T495 findings (see Figure 3-4, panel B) agree with the mutant 
HUVEC data reported by Federici and co-workers, in that eNOST495 phosphorylation in 
acutely stimulated hyperinsulinaemic HAEC was greater than in control cells in the present 
study. The present data on eNOS
S1177 do not agree with the study by Federici and co-
workers. 
PKB expression (Figure 3-3) and PKB Ser473 phosphorylation (Figure 3-5) were largely 
unchanged in the present experiments, although a trend toward decreased insulin-
responsive Ser473 phosphorylation was observed. These changes in PKB phosphorylation 
are not reflected by decreased insulin-stimulated eNOS
S1177 phosphorylation; therefore, 
further studies with PI3K inhibitors such as wortmannin, which prevent PKB 
phosphorylation, are required to verify that PKB is indeed the kinase that phosphorylates 
eNOSS1177 under the present experimental conditions. Toba and co-workers reported that 
PKB and PKB
S473 levels were upregulated in the aortae of hyperinsulinaemic rats (Toba et 
al., 2006), while another group found that insulin failed to stimulate PKB
S473 
phosphorylation in vivo (as measured in whole aorta preparations from hyperinsulinaemic 
obese Zucker rats), but caused a 3 ±1-fold rise in control rats (Naruse et al., 2006). G972R 
variant HUVEC showed a smaller PKB
S473/PKB ratio under basal and insulin-stimulated 
(40% reduction) conditions than control HUVEC (Federici et al., 2004).  
Phosphorylation of the kinase AMPK at Thr172 was quantified as an indirect marker of 
AMPK activity. Insulin stimulated AMPK
T172 phosphorylation under control conditions 
and after 24h of experimental hyperinsulinaemia, but had no stimulating effect after 48h 
(Figure 3-6). Instead, basal phosphorylation of AMPK
T172 was increased to insulin-
stimulated control levels after 48h of experimental hyperinsulinaemia, whereas Thr172 
phosphorylation was decreased after acute insulin treatment. While activated AMPK is a 
mediator of eNOSS1177 phosphorylation (Chen  et al., 1999, Morrow et al., 2003), it has not 
previously been shown to phosphorylate eNOS in response to insulin. However, increased 
basal AMPK
T172 phosphorylation may be responsible for the significantly higher basal 
eNOSS1177 phosphorylation observed in the present study, but this will have to be verified 
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This hypothesis is indirectly supported by studies in fibroblasts that stably express human 
insulin receptors, which showed that co-transfection with eNOS and a dominant-negative 
AMPK mutant did not prevent eNOS
S1179 (homologous to human eNOS
S1177) 
phosphorylation in response to insulin (Chen et al., 2003). Similarly, the findings of 
Morrow and co -workers demonstrated that knockdown of AMPK does not affect insulin-
stimulated eNOS
S1177 phosphorylation. This suggests that AMPK does not play a crucial 
role in eNOS phosphorylation in response to insulin in the fibroblast model system, but it 
cannot be excluded that AMPK contributes to the elevated basal eNOSS1177 
phosphorylation levels in HAEC subjected to experimental hyperinsulinaemia.  
PI3K is a critical mediator of cellular insulin signalling and lies upstream of PKB (Franke 
et al., 1995, Zeng et al., 2000). The PI3K p85a subunit has been shown to be a critical 
regulator of insulin sensitivity, using p85a knockout mice (Taniguchi et al., 2006). The 
data presented here illustrate that experimental hyperinsulinaemia did not affect the 
expression levels of the PI3K p85 regulatory and p110ß catalytic subunits (Figure 3-7, 
panel B). By contrast, PI3K mRNA expression was increased in aortae of 
hyperinsulinaemic rats (Toba et al., 2006). However, mRNA levels do not necessarily 
reflect the amount of protein present in a cell, and changes in mRNA expression may be 
translated into altered protein levels at a later time point. In another study, insulin-
stimulated PI3K activity in IRS-1  variant HUVEC was reduced compared to controls 
(Federici et al., 2004). Since PI3K levels were unaffected by experimental 
hyperinsulinaemia in the present study, this demonstrates that dysregulation of insulin 
signalling in HAEC does not occur at the level of PI3K  expression within the time scale 
tested, although any potential effect on PI3K activity remains to be investigated.  
PDK-1 is a downstream effector of PI3K that phosphorylates PKB at the primary 
activating site Thr308 (Alessi et al., 1996, Vanhaesebroeck & Alessi, 2000). PDK-1 
expression levels were modestly increased after 48h of experimental hyperinsulinaemia 
(not statistically significant, see Figure 3-7, panel A). It is therefore possible that elevated 
PDK-1 levels caused  greater phosphorylation of PKB at Thr308, thus resulting in greater 
PKB activity despite normal PKBS473 phosphorylation. Phosphorylation of both Thr308 
and Ser473 is necessary for PKB activity, but the sites are independent of one another 
(Alessi et al., 1996). If disparate phosphorylation of PKB were the case here, it could 
account for the rise in eNOS
S1177 phosphorylation induced by long-term hyperinsulinaemia 
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example by direct measurement of PKB enzyme activity and quantification of the 
PKB
T308/PKB protein ratio under these conditions. 
PTEN expression levels were mildly reduced after 48h of experimental hyperinsulinaemia 
(not statistically significant, see Figure 3-8). To date, no data concerning vascular 
endothelium-specific expression of PTEN under hyperinsulinaemic conditions have been 
reported, but several studies looking at the role of PTEN in muscle and adipose tissue have 
been published. Mice with an adipose tissue -specific deletion of PTEN displayed 
heightened insulin sensitivity and 1.8-fold greater PKB
S473 phosphorylation (Kurlawalla-
Martinez et al., 2005). Further, a muscle-specific PTEN deletion protected mice from diet-
induced hyperinsulinaemia, insulin resistance and diabetes (Wijesekara et al., 2005). When 
fed a high-fat diet, these mice had twice the control level of insulin-induced PKB
T308 
phosphorylation in soleus, but not extensor digitorum longus muscles. By contrast, on a 
normal diet, these mice showed a reduced insulin-responsive PKBT308/PKB ratio 
(Wijesekara et al., 2005). In line with these findings, hyperinsulinaemic obese Zucker rats 
had raised PTEN mRNA and protein levels in soleus muscle (Lo et al., 2004).  
These and other data document that PTEN is a negative regulator of insulin signalling and 
insulin sensitivity in fat and muscle. If this is the case in vascular endothelial cells, 
decreased PTEN expression would imply increased insulin sensitivity, providing a possible 
explanation for increased basal eNOSS1177 phosphorylation. However, given the time scale 
of the present study, the modest changes in eNOS
S1177 phosphorylation and PTEN 
expression and the lack of effect of experimental hyperinsulinaemia on PKB
S473, further 
studies are necessary to determine the effect of reduced PTEN expression in this system. 
The expression and phosphorylation of p44/42 MAPK, a component of the mitogenic 
insulin signalling pathway, was studied. It is well-documented that the metabolic and the 
mitogenic branch of the insulin signalling pathway can be differentially affected in 
hyperinsulinaemia and Type II diabetes  (Jiang et al., 1999a, Cusi et al., 2000, Montagnani 
et al., 2002, He et al., 2006, Rask -Madsen & King, 2007). A modest (not statistically 
significant) increase of p44/42 MAPK expression was seen after 24h, but not after 48h of 
experimental hyperinsulinaemia (Figure 3-9, panel B). Further studies of the mitogenic 
pathway, including the activity levels of its pathway components, during experimental 
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While the molecular mechanism(s) underlying the changes observed in the present study 
are not clear, alternative mechanisms that have not been investigated may play a role. For 
example, increased basal phosphorylation of eNOS
S1177 and upregulated insulin-stimulated 
eNOST495 phosphorylation could be due to reduced dephosphorylation of these sites, rather 
than increased phosphorylation. PKC activation has been proposed to mediate 
dephosphorylation of eNOS at Ser1177 and phosphorylation at Thr495. The phosphatases 
PP1 dephosphorylates Thr495, while PP2A can dephosphorylate both Thr495 and Ser1177 
(Michell et al., 2001, Greif et al., 2002). Moreover, other kinases could be responsible for 
altered eNOS phosphorylation, including PKA (Michell et al., 2001), PKG and CAMKII 
(Fleming et al., 2001) (reviewed in (Mount et al., 2007)).  
Given that eNOS activity is thought to be determined by a concerted regulation of several 
phosphosites (Michell et al., 2001, Bauer et al., 2003, Mount et al., 2007), including 
negative regulation by tyrosine phosphorylation (Garcia-Cardena et al., 1996a, Huang et 
al., 2002), it is unclear whether an altered eNOS phosphorylation profile necessarily 
creates a (measurable) change in eNOS activity. Experimental hyperinsulinaemia might 
also affect transcription, myristoylation (Busconi & Michel, 1993, Liu & Sessa, 1994, 
Shaul et al., 1996), palmitoylation (Lamas et al., 1992) and association of eNOS with other 
cellular components, thus potentially further affecting eNOS regulation. As these potential 
modes of regulation were not investigated in the current study and eNOS activity was not 
measured directly, it cannot be concluded that eNOS is dysregulated by experimental 
hyperinsulinaemia.  
The differences between the effects of experimental hyperinsulinaemia observed in the 
present system and published studies highlight the discrepancy between different 
experimental models and the ensuing difficulty in drawing a consensus conclusion. Since 
the in vitro and in vivo models used in these studies varied, and the conditions of 
hyperinsulinaemia differed, the results document that hyperinsulinaemia has different 
effects in heterologous systems. Overall, the effects of hyperinsulinaemia seem to be 
exacerbated in certain in vivo models compared to in vitro models. Therefore, for example, 
it cannot be said with certainty that eNOS protein levels are increased in hyperinsulinaemic 
states, although there is strong in vitro evidence in favour of this thought.  
Taking into account the present NO synthesis data and the fact that eNOSS1177 and 
eNOST495 phosphorylation levels were only modestly affected, it is likely that in the 
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eNOS at Ser1177 and Thr495 without significantly affecting eNOS activity and NO 
production. Whether ionomycin-stimulated, calcium-dependent NO production is affected 
by experimental hyperinsulinaemia, requires further investigation that is beyond the scope 
of this work. The changes observed  here may suggest that hyperinsulinaemic HAEC have a 
subtle insulin signalling impairment, which  differs in some aspects to other experimental 
and clinical systems discussed above.  
Overall, the HAEC used in the present study were a weak model for insulin resistance, 
since their response to acute insulin treatment was often small and varied greatly between 
different experiments. This may, in part, reflect the insulin-sensitivity of individual HAEC 
donors, but experimental error may have contributed to this variation. There is little 
evidence that the HAEC used here became insulin resistant after 48h of experimental 
hyperinsulinaemia. The present studies were carried on because initial results indicated 
robust insulin-responsiveness under control conditions along with more substantial 
changes induced by experimental hyperinsulinaemia.  
It is likely that the short time scale of experimental hyperinsulinaemia employed in the 
present study is insufficient to cause substantial alterations in endothelial insulin signalling. 
Potentially, exposure of vascular endothelial cells to longer periods of experimental 
hyperinsulinaemia might exacerbate these changes. Ideally, healthy human vascular 
endothelial cells should therefore be cultured under hyperinsulinaemic conditions for 
several days or even weeks. However, since insulin’s action as a gr owth factor and the 
growth characteristics of these cells in vitro present a challenge to such future studies, 
explanted vascular endothelial cells from patients with established hyperinsulinaemia 
might provide a suitable alternative model system. However, the potential presence of 
other confounding disease factors that might affect insulin signalling makes this model 
impractical. Refined experimental systems and further studies are required to define how 
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3.3.3  Monocyte adhesion to HAEC 
This study investigated whether experimental hyperinsulinaemia affected monocyte 
attachment to hyperinsulinaemic HAEC. Experimental hyperinsulinaemia in the present 
study was found not to affect the adhesion of monocytic cells to HAEC cultured with 10 
nM, 50 nM or 100 nM insulin for up to 48h (Figure 3-10). This stands in contrast to the 
hypothesis that hyperinsulinaemia promotes proinflammatory activation of HAEC, thus 
increasing monocyte attachment. Given that patients with clinical hyperinsulinaemia are 
thought to experience a state of persistent, low-level inflammation, along with endothelial 
activation (Fernandez-Real & Ricart, 2003), an extension of the present study is necessary 
to investigate the effects of experimental hyperinsulinaemia on vascular endothelial 
adhesion molecule expression and chemokine production. 
Previously, several studies have reported that experimental hyperinsulinaemia can affect 
the expression of chemokine and adhesion molecule mRNA and protein (Aljada et al., 
2000) (Aljada et al., 2001). This correlated with enhanced leukocyte adhesion and was 
postulated to enhance neutrophil transendothelial migration (Okouchi et al., 2002a). 
Furthermore, incubation of mouse lung endothelial cells with insulin alone (10 nM, 24h) 
did not significantly increase rolling adhesion and arrest of monocytes, but simultaneous 
inhibition of PI3K resulted in significantly enhanced monocyte-endothelial cell 
interactions (Montagnani et al., 2002). By contrast, circulating levels of the soluble 
adhesion molecules ICAM-1, VCAM-1 and E-selectin in the plasma of healthy individuals 
were found not to be elevated after 6 hours of euglycaemic hyperinsulinaemic (3 
mU/kg/min) clamp, suggesting that short-term hyperinsulinaemia does not induce 
endothelial cell adhesion molecule protein expression (Jilma et al., 2000). 125  
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4.1  Introduction 
4.1.1  Background 
Functional endothelial nitric oxide synthase (eNOS) activity is vital to vascular health, as 
eNOS is involved in vasorelaxation through the production of nitric oxide. As discussed in 
chapter 3, NO can be produced in response to insulin (Zeng & Quon, 1996) and is thought 
to have vasoprotective properties (Gewaltig & Kojda, 2002, Wheatcroft et al., 2003). 
Phosphorylation of eNOS at Ser1177 plays an importa nt part in insulin-stimulated NO 
production, which may involve the concerted regulation of several other phosphorylation 
sites (Michell et al., 2001, Bauer et al., 2003, Mount et al., 2007).  
In the context of hyperglycaemia and diabetes, it has frequently been reported that 
endothelial function and NO bioavailability are impaired ((Calver et al., 1992, McVeigh et 
al., 1992, Hogikyan et al., 1998); reviewed in (De Vriese et al., 2000, Rask-Madsen & 
King, 2007) ), and that this association is independent of the presence of the complicating 
risk factors, obesity and hypertension (Hogikyan  et al., 1998). Consequently, patients with 
diabetes have an increased propensity to cardiovascular and microvascular disease and 
associated morbidity and mortality (Stratton et al., 2000, Rahman  et al., 2007). The risk for 
vascular complications strongly correlates with the level of hyperglycaemia in patients 
(Stratton et al., 2000).  
Despite the proposed association between hyperglycaemia and endothelial dysfunction, 
two small studies suggested that insulin-induced vasorelaxation was similar in the coronary 
vasculature of healthy and Type I diabetic subjects and was not impaired by short-term 
hyperglycaemia (Smits et al., 1993, Sundell et al., 2002). Taking into account the small 
study populations (11 and 9 patients with diabetes, respectively), and the fact that the 
vasodilation response v aries even within the healthy population (Ardigo et al., 2006), it is 
possible that these studies are not representative. Furthermore, patients with diabetes are 
likely to suffer recurrent and/or prolonged, rather than short-term, periods of 
hyperglycaemia prior to diagnosis. This will increase their risk of suffering vascular 
complications due to endothelial dysfunction (Stratton et al., 2000). Therefore, it is 
important to assess the impact of hyperglycaemia on vascular endothelial cell function to 
inform our understanding of the events that contribute to vascular disease risk. 
Previous work has shown that exposure to high glucose concentrations impaired 
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generation in HAEC (Cosentino et al., 1997) and rat aorta (Hink et al., 2001). Oxidative 
stress has been proposed as a mediator of endothelial dysfunction  (De Vriese et al., 2000, 
Hink et al., 2001, Srinivasan et al., 2004), although this is subject to ongoing debate.  
Experimental hyperglycaemia has been reported to impair the metabolic insulin signalling 
pathway and its individual components (Sobrevia et al., 1998, Federici  et al., 2002, Salt et 
al., 2003). Human umbilical vein endothelial cells (HUVEC) isolated from women with 
gestational diabetes were less sensitive to insulin and showed reduced insulin-responsive 
nitric oxide synthesis after culture with 25 mM glucose (Sobrevia et al., 1998). Likewise, 
insulin-stimulated NO production was impaired in human aortic endothelial cells (HAEC) 
following culture in 25 mM glucose for 48h (Salt et al., 2003), although these conditions 
did not affect the phosphorylation of eNOS at the activating site Ser1177. By contrast, 
insulin-stimulated eNOS
S1177 phosphorylation was reduced in human coronary artery 
endothelial cells (HCAEC) cultured with 20 mM glucose, while eNOS glycosylation was 
increased, leading to reduced insulin-responsive eNOS activity  (Federici  et al., 2002). 
Since the precise causes leading to endothelial dysfunction in hyperglycaemia/diabetes are 
uncertain, the underlying molecular mechanisms need to be further investigated.  Christine F. Kohlhaas    Chapter 4, 128 
 
4.1.2  Aims of the chapter 
Previous studies in this laboratory have indicated that experimental hyperglycaemia 
differentially affects certain aspects of insulin signalling in HAEC. Experimental 
hyperglycaemia was shown to specifically inhibit insulin-stimulated NO synthesis without 
changing eNOS Ser1177 or Thr495 phosphorylation or PKB activity, but it did reduce 
insulin receptor substrate (IRS)-2 expression and PI3K recruitment to IRS-1 and -2 (Salt et 
al., 2003). Furthermore, the insulin-regulated CAP-Cbl pathway was also deregulated by 
experimental hyperglycaemia (Salt et al., 2003), indicating a negative effect of 
hyperglycaemia on vascular endothelial cell signalling. 
The effect of experimental hyperglycaemia on  the eNOS phosphorylation status at sites 
other than Ser1177 and on  other insulin-responsive pathways has yet to be fully 
investigated in vascular endothelial cells. Therefore, the work presented in this chapter was 
designed to assess whether the metabolic insulin signalling pathway, and eNOS 
phosphorylation in particular, may be involved in mediating endothelial dysfunction during 
experimental hyperglycaemia (section 4.2.2). Furthermore, the contribution of several 
other insulin-responsive pathways, some of which regulate eNOS function, was 
investigated (section 4.2.3 ). Superoxide production under hyperglycaemic and 
normoglycaemic conditions was quantified as an indicator of endothelial dysfunction 
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4.2  Results 
4.2.1  Selection of experimental conditions 
Previous work in this laboratory has been carried out in HAEC, which are large conduit 
vessel endothelial cells. For the present study, human umbilical vein endothelial cells 
(HUVEC) were chosen as a model system. These are peripheral vein endothelial cells, 
which may respond differently to stimuli such as glucose and insulin in the blood. 
Furthermore, work carried out during this study demonstrated that HUVEC are more 
robust with respect to insulin responsiveness than HAEC (data not shown). Commercially 
obtained HUVEC possess the advantage that each lot is pooled from 20 individual donors; 
therefore, the variation between different lots of cells is greatly reduced compared to 
single-donor HAEC. This may be part of the reason for the more robust insulin-
responsiveness of HUVEC.  
Experimental hyperglycaemia is a model for overt clinical hyperglycaemia as seen in both 
Type I and Type II diabetes. The glucose concentration (25 mM) chosen for experimental 
hyperglycaemia in these studies corresponds to high pathophysiological plasma glucose 
concentrations seen in the clinic (Ohmura et al., 2005). 
HUVEC were cultured in the presence of 25 mM glucose (“glucose”, G) or 20 mM 
mannitol plus 5 mM glucose (“mannitol”, M), to obtain a total concentration of 25 mM 
monosaccharide as an osmotic control, for 48h. In addition, “standard control” cells (C) 
were cultured in normal vascular endothelial cell medium containing 4 mM glucose alone 
to detect any osmotic effects caused by either glucose or mannitol. As described for 
hyperinsulinaemic HAEC (chapter 3), HUVEC were serum-starved after 48h and subsets 
of cells were stimulated with 1 µM insulin for 10 minutes prior to preparation of whole cell 
lysates. 
In order to assess the effect of experimental hyperglycaemia on the expression of eNOS 
and the phosphorylation levels of its phosphorylation sites Ser114 (eNOS
S114), Thr495 
(eNOS
T495), Ser615 (eNOS
S615), Ser633 (eNOS
S633) and Ser1177 (eNOS
S1177), vascular 
endothelial cell lysates were prepared and protein levels quantified by Western blotting and 
densitometric analysis. The levels of phospho-protein were expressed as a ratio to total 
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All data for these studies have been derived from a pool of four independent experiments 
using one lot of HUVEC; hence, the expression and phosphorylation levels of the 
molecules investigated can be related to one another, as they have been measured in the 
same pool of samples.  
For reasons of simplification, cells cultured under conditions of experimenta l 
hyperglycaemia are frequently referred to as “hyperglycaemic” in the text, despite not 
originating from donors who were known to have hyperglycaemia or diabetes. Likewise, 
cells cultured with mannitol are referred to as “normoglycaemic”. 
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4.2.2  eNOS expression and phosphorylation under experimental 
hyperglycaemia 
4.2.2.1  eNOS 
Previous work in this laboratory has demonstrated that, in HAEC, insulin-responsive 
eNOS phosphorylation at the main insulin-responsive site Ser1177 and at Thr495 is not 
altered by experimental hyperglycaemia (Salt et al., 2003). Little is known about the effect 
of hyperglycaemia on the three other eNOS phosphorylation sites (Ser114, Ser633 and 
Ser615), or indeed their roles in insulin-responsive signalling. Therefore, in order to 
characterise more fully the effects of acute insulin and experimental hyperglycaemia on 
eNOS expression and phosphorylation at these five main phosphorylation sites, their 
phosphorylation status in HUVEC under normoglycaemic, hyperglycaemic and standard 
control (4 mM glucose, no mannitol) conditions, in presence or absence of acute 
stimulation with insulin, was measured by Western blotting (see sections 2.2.1.4  and 
4.2.1). 
The data in Figure 4-1 show that total eNOS expression in hyperglycaemic cells is 
unchanged compared to normoglycaemic cells (94±16% of normoglycaemic samples). 
Culturing cells in mannitol for 48h also caused no significant change in eNOS expression 
levels with respect to cells cultured under standard conditions (110±14% of standard 
control (4 mM glucose, no mannitol)). As expected, acute stimulation with insulin had no 
effect on total eNOS expression under any condition tested and is therefore not indicated 
on the Western blot. All subsequent phospho-eNOS levels were expressed as a ratio to the 
unaltered levels of total eNOS. 
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Figure 4-1 eNOS expression is unaffected by experimental hyperglycaemia. 
HUVEC were cultured with 25 mM glucose (G) or 20 mM mannitol plus 5 mM glucose (M) for 
48h. Control (C) cells were cultured with 4 mM glucose. Prior to lysis preparation, cells were 
serum-starved for 2-4h in KRH buffer. Equal amounts of protein (3-10 µg) were resolved by SDS-
PAGE and Western blotted onto nitrocellulose membranes. An eNOS-specific antibody was used 
to detect immunoreactive bands, which were then quantified by densitometric analysis. Data shown 
are the mean + SEM expression of 3 independent experiments (treatments in quadruplicates) with a 
single lot of HUVEC. A representative Western blot is shown. Christine F. Kohlhaas    Chapter 4, 133 
 
4.2.2.2  eNOSS615 and eNOSS1177 
Phosphorylation of the eNOS sites Ser615 and Ser1177 has been shown to be responsive to 
insulin (Dimmeler et al., 1999, Fulton et al., 1999, Ritchie et al., 2007). Therefore, the 
effect of experimental hyperglycaemia on the insulin-stimulated phosphorylation status of 
these sites was investigated.  
Data from the present study confirm that, under standard control conditions, eNOS
S615 and 
eNOSS1177 are phosphorylated after acute (10 min) stimulation with insulin to 1.4±0.3 -fold 
and 2.4±0.7-fold of basal levels, respectively (Figure 4-2). While these changes were clear, 
they were not statistically significant due to interexperimental variation. Insulin elicited 
smaller increases in Ser615 and Ser1177 phosphorylation under normoglycaemic 
conditions (1.2±0.4-fold and 1.4±0.3-fold increases compared to unstimulated 
normoglycaemic cells, respectively; no statistically significant differences). However, 48h 
of experimental hyperglycaemia abrogated insulin-stimulation of eNOS
S615 
phosphorylation with respect to normoglycaemic and standard control cells (0.76-fold and 
0.79-fold of stimulated normoglycaemic and standard control levels, respectively). This 
was partly due to increased basal phosphorylation of eNOS
S615 under hyperglycaemic 
conditions (see Figure 4-2, panel B).  
There was no difference in basal phosphorylation of eNOS
S1177 under experimental 
hyperglycaemia, but insulin-stimulated phosphorylation of eNOS
S1177 was reduced to 0.84-
fold of stimulated normoglycaemic phosphorylation and 0.6-fold of stimulated 
phosphorylation in standard control. The insulin-stimulated increase over unstimulated 
eNOS
S1177 phosphorylation was 1.5±0.3-fold in hyperglycaemic cells. 
In addition to the above results, culturing of HAEC under the same experimental 
conditions as used for HUVEC resulted in loss of insulin-stimulated eNOS
S1177 
phosphorylation in  normoglycaemic (mannitol-treated) HAEC, while hyperglycaemic 
HAEC showed a 2.5-fold increase over basal in insulin-responsive eNOSS1177 
phosphorylation (data not shown; compare with Figure 4-2, panel C).  Christine F. Kohlhaas    Chapter 4, 134 
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Figure  4-2 Insulin increases phosphorylation of eNOSS615 and eNOSS1177. 
HUVEC were cultured as described (see section 2.2.1.4) and subsets of cells were stimulated wi th 
1 µM insulin for 10 min prior to preparation of cell lysates. After SDS-PAGE and Western blotting, 
antibodies were used as indicated and immunoreactive bands quantified with respect to total eNOS. 
Panel A shows representative Western blots. B: eNOS
S615/eNOS; C: eNOS
S1177/eNOS (*p<0.05 for 
basal compared to insulin-stimulated standard control; paired t-test). Data shown are the mean ± 
SEM expression from 3 independent experiments.  Christine F. Kohlhaas    Chapter 4, 135 
 
4.2.2.3  eNOSS633 
Ser633 is postulated to be another eNOS activating phosphorylation site (Michell et al., 
2002). In this study, acute stimulation with insulin resulted in a reduction of eNOSS633 
phosphorylation levels under standard control conditions to 0.7±0.1-fold of basal levels 
(not statistically significant; see Figure 4-3).  
Basal phosphorylation of eNOS
S633 was decreased under experimental hyperglycaemia to 
0.67±0.05-fold of basal normoglycaemic phosphorylation (not statistically significant). 
Basal phosphorylation in mannitol-treated cells was also reduced to 0.7±0.2-fold with 
respect to standard control, but this change was not statistically significant. The reduction 
in basal hyperglycaemic phosphorylation was therefore more pronounced with respect to 
standard control (0.5±0.2-fold of basal standard control levels), although this was not 
statistically significant due to interexperimental variation.  
Insulin treatment did not change eNOSS633 phosphorylation levels under normoglycaemic 
or hyperglycaemic conditions with respect to standard control, although slightly lower 
eNOS
S633 levels were measured in insulin-stimulated  hyperglycaemic cells than 
normoglycaemic cells. 
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Figure 4-3 Experimental hyperglycaemia does not affect eNOSS633 phosphorylation. 
HUVEC were treated as described before (section 2.2.1.4) and lysates were produced for Western 
blotting. Representative Western blots are shown. Data are the mean ± SEM eNOS
S633/eNOS 
expression of 3 independent experiments. Neither Mannitol (M) nor glucose treatment for 48h had 
any statistically significant effect upon  eNOS
S633 phosphorylation. Christine F. Kohlhaas    Chapter 4, 137 
 
4.2.2.4  eNOSS114 and eNOST495 
The phosphorylation status of the sites Ser114 and Thr495 was investigated under control, 
normoglycaemic and hyperglycaemic conditions.  
Basal eNOSS114 phosphorylation levels were comparable under all conditions (Figure 4-4, 
panels A and B). Acute treatment with insulin resulted in a small and not statistically 
significant reduction in eNOS
S114 phosphorylation under normoglycaemic and control 
conditions (to 0.6±1-fold and 0.8±0.2-3old of basal control, respectively). There was no 
statistically significant difference between insulin-responsive phosphorylation in 
normoglycaemic and standard control cells. Under hyperglycaemic conditions, insulin 
caused a marked but not statistically significant reduction in Ser114 phosphorylation levels 
(0.3±0.1 -fold of unstimulated hyperglycaemic cells). This was almost twice the reduction 
seen with normoglycaemic cells and 2.6-fold that of standard control. 
Unstimulated  phosphorylation of eNOST495 was unchanged under all three conditions 
(Figure 4-4, panels A and C). As expected, acute insulin significantly reduced eNOS
T495 
phosphorylation levels under normoglycaemic conditions (to 0.7±0.04-fold of basal 
normoglycaemic phosphorylation (p<0.05, paired t-test). The reduction under standard 
control conditions was less pronounced and not statistically significant (0.8±0.07 compared 
to basal control). There was no significant difference between insulin-responsive 
phosphorylation in normoglycaemic and control cells. Hyperglycaemic cells also showed 
strongly decreased  phosphorylation of Thr495 after insulin treatment (to 0.6±0.2 -fold of 
basal hyperglycaemic phosphorylation), but due to the spread of data points this was not 
statistically significant.  
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Figure 4-4 Acute insulin tends to reduce Ser114 and Thr495 phosphorylation. 
HUVEC lysates were prepared as described (see section 2.2.2) and equal amounts of protein were 
Western blotted. Representative Western blots are shown in panel A. Data from 3 independent 
experiments are given as mean ± SEM expression for eNOS
S114/eNOS in panel B and for 
eNOS
T495/eNOS in panel C (*p<0.05 for normoglycaemic cells in presence and absence of insulin; 
paired t-test). Christine F. Kohlhaas    Chapter 4, 139 
 
The phosphorylation status of the five investigated eNOS phospho-sites is summarised in 
Figure 4-5. Since mannitol reduced the basal phosphorylation of eNOS
S633 and diminished 
the insulin-responsive phosphorylation of eNOS
S1177 with respect to standard control, this 
suggests that high mannitol levels in the cell culture medium may exert an osmotic effect 
on cellular signalling pathways. Therefore, eNOS expression and phosphorylation levels 
are compared to standard control levels, here, to better model the difference between 
hyperglycaemic and normoglycaemic individuals with normal blood osmolarity.  
Panel A of Figure 4-5 shows the effect of experimental hyperglycaemia on basal 
phosphorylation of these sites as compared to unstimulated standard control. Panel B 
illustrates the insulin-stimulated phosphorylation status compared to stimulated control. 
Since the expression levels of total eNOS protein did not change upon acute stimulation 
with insulin, total eNOS levels in hyperglycaemic cells are expressed as the percentage of 
combined (basal + stimulated) control. There was no difference in eNOS expression 
between control and hyperglycaemic cells. 
Basal eNOS phosphorylation at Ser633 was reduced to 50% of control levels in 
hyperglycaemic samples (not statistically significant due to spread of data points), while 
basal eNOS
S615 levels were increased 1.9±0.6-fold (no statistically significant difference). 
No changes in basal phosphorylation were seen at the other phosphorylation sites 
investigated. Significantly, insulin-responsive dephosphorylation of eNOSS114/eNOS in 
hyperglycaemic HUVEC was 2.3-fold greater than in control cells (p<0.05; paired t-test). 
The ratio of insulin-stimulated eNOS
S1177/eNOS was also reduced to 72% of control levels 
under experimental hyperglycaemia (not statistically significant). No other statistically 
significant changes were seen in insulin-responsive phosphorylation.Christine F. Kohlhaas    Chapter 4, 140 
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Figure 4-5 Experimental hyperglycaemia modifies the eNOS phosphorylation profile. 
Lysates were prepared from hyperglycaemic and control HUVEC and subjected to Western 
blotting as described (sections 2.2.2 and 2.2.6). Data are shown as mean + SEM abundance and are 
derived from the same 3 independent experiments for all eNOS species. Given that total eNOS 
expression levels did not change during acute stimulation with insulin, the expression levels of total 
eNOS for both basal and stimulated cells are expressed as % control rather than % basal or % 
stimulated control. Phospho-eNOS species are expressed as a ratio to total eNOS in 
hyperglycaemic cells. A: Basal eNOS phosphorylation in hyperglycaemic compared to control cells 
B: insulin-stimulated eNOS phosphorylation in hyperglycaemic cells compared to stimulated 
controls; *p<0.05 compared to eNOS
S114 phosphorylation in insulin-stimulated control cells (paired 
t-test) Christine F. Kohlhaas    Chapter 4, 141 
 
4.2.3  The effect of experimental hyperglycaemia on insulin-regulated 
pathways 
Insulin triggers a number of signalling cascades in endothelial cells, which may also 
contribute to the transcriptional and post-translational regulation of eNOS in endothelial 
cells. Previously, work in this laboratory has shown that experimental hyperglycaemia 
disrupts metabolic insulin signalling at the level of IRS-2 expression and PI3K association 
with IRS-1 and -2, and decreases insulin-regulated CAP-Cbl signalling in HAEC (Salt et 
al., 2003). Therefore, it was decided to investigate more fully the effect of experimental 
hyperglycaemia on the expression and phosphorylation of components of these and other 
insulin-responsive signalling pathways in HUVEC. Pathways studied include the metabolic 
insulin signalling pathway (PI3K-p85, PDK-1, PTEN and PKB), the transcription-
regulating NFkB pathway (NF?B, I?Ba, IKKß and JNK) and the CAP-Cbl pathway. 
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4.2.3.1  The metabolic insulin signalling pathway 
The metabolic insulin signalling pathway is known to play a role in the regulation of eNOS 
phosphorylation in response to insulin (Zeng & Quon, 1996). Hence, the expression of its 
components PKB, PDK-1, PTEN and the regulatory p85 subunit of PI3K (PI3K-p85) were 
quantified, along with PKB phosphorylation, to determine whether there was any 
dysregulation of this pathway that could account for the altered eNOS phosphorylation 
status described above (section 4.2.2). 
As observed for eNOS, there was no effect of acute insulin stimulation on PKB expression 
under any condition tested; hence, insulin-stimulated samples are not indicated on the 
Western blot in Figure 4-6. PKB expression was unaffected by experimental 
hyperglycaemia (97±10% and 96±10% of normoglycaemic and standard control samples, 
respectively).  
Phosphorylation levels of the insulin-responsive PKB activating sites Thr308 and Ser473 
were quantified with respect to total PKB expression (Figure 4-7). Basal and insulin-
responsive phosphorylation levels of PKB
T308 were comparable for all three conditions, 
with insulin consistently stimulating Thr308 phosphorylation to 3.3±1.1-fold (control), 
3.7±0.7-fold (mannitol) and 3.5±0.5-fold (glucose) over basal control phosphorylation (no 
statistical analysis possible due to small repeat number; see Figure 4-7, panels A and B).  
By contrast, basal PKBS473 phosphorylation in HUVEC was reduced after 48h of glucose 
treatment (to 0.60±0.08-fold of basal normoglycaemic cells and 0.36±0.08-fold of basal 
standard control cells). Insulin-responsive Ser473 phosphorylation remained comparable 
under all conditions: Insulin stimulated Ser473 phosphorylation 1.4±0.3-fold (control), 
1.8±0.4-fold (mannitol) and 1.7±0.3-fold (glucose) above unstimulated standard control. 
Basal PKB
S473 phosphorylation was also reduced under normoglycaemic (0.6±0.06-fold 
compared to standard control conditions) (see Figure 4-7, panels A and C). No statistical 
analysis of these data was possible due to the small repeat number.  
Further to the study in HUVEC, insulin-stimulated  phosphorylation of PKBT308 was absent 
and was less pronounced for PKBS473 in normoglycaemic and hyperglycaemic HAEC 
(~1.2-fold and ~1.3-fold over basal, respectively) compared to HUVEC (data not shown; 
compare with Figure 4-7).  Christine F. Kohlhaas    Chapter 4, 143 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 4-6 PKB expression is unaffected by experimental hyperglycaemia. 
HUVEC were treated and lysed as described (sections 2.2.1.4 and 2.2.2) and subjected to Western 
blotting. Densitometric analysis of immunoreactive bands demonstrated that PKB expression does 
not change during experimental hyperglycaemia (G) or mannitol treatment (M) compared to 
control (C). Data shown are the mean + SEM expression of 3 independent experiments. A 
representative Western blot is shown.  Christine F. Kohlhaas    Chapter 4, 144 
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Figure 4-7 PKB phosphorylation remains insulin-responsive under experimental 
hyperglycaemia. 
HUVEC lysates were prepared as described (section 2.2.2) and subjected to Western blotting. 
Phospho-specific antibodies were used as indicated on the representative blots in panel A. Data 
shown are the mean ± range abundance of phospho-PKB/PKB derived from 2 independent 
experiments. Panel B: PKB
T308/PKB; Panel C: PKB
S473/PKB. C = control, M =  mannitol, G = 
glucose Christine F. Kohlhaas    Chapter 4, 145 
 
The expression levels of the upstream insulin signalling pathway components PI3K-p85, 
PTEN and PDK-1 were quantified and found to be unchanged by experimental 
hyperglycaemia with respect to mannitol treatment and standard control conditions. 
Percentage expression in hyperglycaemic compared to normoglycaemic (mannitol-treated) 
cells was 98±4% for PI3K-p85  (Figure 4-8, panel A), 95±4% for PTEN (Figure 4-8, panel 
B) and 89±12% for PDK-1 (Figure 4-9). All three molecules had comparable expression 
levels in mannitol-treated and standard control cells. 
In addition to the above data, the present study briefly investigated whether experimental 
hyperglycaemia affected the stress-activated p38 MAPK signalling pathway in HUVEC by 
quantifying the expression and insulin-stimulated phosphorylation levels of p38 MAPK. 
Data from one experiment indicated that expression of p38 MAPK in hyperglycaemic cells 
was unchanged compared to normoglycaemic cells. Under normoglycaemic and standard 
control and conditions, insulin treatment caused 1.5-fold and 1.3-fold increases in p38 
MAPK phosphorylation, respectively, but this stimulation was reduced to 1.2-fold in 
hyperglycaemic cells (data not shown). Christine F. Kohlhaas    Chapter 4, 146 
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Figure 4-8 PI3K-p85 and PTEN expression are unchanged after experimental 
hyperglycaemia 
Cell lysates from HUVEC, treated as described (section 2.2.1.4), were subjected to Western 
blotting with the antibodies indicated above. Representative blots are shown. Data represent the 
mean + range expression of 2 independent experiments (all samples in quadruplicates). A: PI3K-
p85; B: PTEN. No statistical analysis could be performed due to the small repeat number. C = 
control, M = mannitol, G = glucoseChristine F. Kohlhaas    Chapter 4, 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 PDK-1 expression is unaffected by experimental hyperglycaemia. 
HUVEC lysates were produced as described (section 2.2.2) and Western blotted. Data from one 
experiment (samples in quadruplicates) are shown as mean + range expression along with the 
Western blot. C = control, M = mannitol, G = glucose Christine F. Kohlhaas    Chapter 4, 148 
 
4.2.3.2  The NF?B pathway 
NF?B is a transcription factor that regulates the expression of genes involved in the innate 
and adaptive immune response, including cell adhesion molecules and inducible nitric 
oxide synthase (iNOS). In its inactive state, NF?B is bound to I?B, which undergoes 
proteosomal degradation upon phosphorylation by the upstream kinase IKK, thus releasing 
NF?B to enter the nucleus and bind to the promoters of target genes (reviewed in  (Gilmore, 
2006)). The c-jun N-terminal kinase (JNK) is a member of the mitogen-activated protein 
kinase (MAPK) family and forms part of a stress-activated pathway, which can p romote 
the ubiquitination (and thus the degradation) of I?Ba (Ki et al., 2007). Given the proposed 
proinflammatory and proatherogenic status during endothelial dysfunction, it was decided 
to investigate whether the NF?B and JNK pathways were dysregulated by experimental 
hyperglycaemia. Therefore, the expression levels of the molecules NF?B and IKKß, along 
with the expression and phosphorylation levels of JNK and I?Ba, were quantified.  
NF?B levels were comparable between hyperglycaemic and mannitol-treated, 
normoglycaemic cells in presence (90±19%) and absence (99±20%) of insulin (see Figure 
4-10). Under standard control conditions, the abundance of NF?B was slightly reduced to 
0.8±0.06-fold of basal levels by treatment with acute insulin (not statistically significant).  
Quantification of I?Ba levels showed that they remained stable under all conditions tested, 
with neit her acute insulin nor experimental hyperglycaemia having a statistically 
significant effect (% abundance in hyperglycaemic cells was 71±3% compared to 
unstimulated and 106±34% compared to stimulated normoglycaemic cells; see Figure 
4-11, panels A and B). There was no significant difference in I?Ba expression between 
normoglycaemic and standard control cells. 
Basal I?Ba Ser32 phosphorylation levels were similar under all conditions tested, although 
mannitol-treatment reduced basal phosphorylation to 0.6±0.3-fold of unstimulated standard 
control levels (no statistical analysis possible due to low repeat number). Acute insulin 
treatment reduced the ratio of Ser32-phosphorylated I?Ba to 0.4±0.06-fold (mannitol), 
0. 7±0. 003-fold (glucose) and 0 .3±0.08-fold (standard control) of unstimulated standard 
control phosphorylation (see Figure 4-11, panels A and C).  
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Figure 4-10 NF?B levels are not affected by experimental hyperglycaemia. 
HUVEC lysates were prepared as described (section 2.2.2) and subjected to Western blotting. A 
representative blot is shown along with data from 3 independent experiments expressed as mean ± 
SEM expression. Levels of NF?B were comparable under all conditions tested. C = control, M = 
mannitol, G = glucose 
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Figure 4-11 Hyperglycaemia tends to impair insulin-triggered I?Ba 
dephosphorylation. 
HUVEC lysates were prepared as described (section 2.2.2) and subjected to Western blotting. 
Representative blots are shown in panel A. B: Data are shown as mean ± SEM abundance of 3 
independent experiments. C: Levels of I?Ba
Ser32/I?Ba were reduced by acute insulin treatment 
under control but not experimental hyperglycaemic conditions in 2 independent experiments (mean 
± range abundance). C = control, M = mannitol, G = glucose 
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The expression levels of the upstream kinases IKKß and JNK were investigated for their 
potential dysregulation during experimental hyperglycaemia. There was no difference 
between normoglycaemic and hyperglycaemic expression of IKKß in the presence or 
absence of insulin. Hyperglycaemic and normoglycaemic IKKß levels in the presence and 
absence of insulin were also comparable to standard control levels in the presence of 
insulin; however, basal levels were significantly lower in standard control cells than 
hyperglycaemic and normoglycaemic (mannitol-treated) cells (0.6 -fold lower for standard 
control compared to hyperglycaemic cells). Hence, insulin stimulated a rise in IKKß levels 
only under standard control conditions. This increase was abrogated in the presence of 
glucose or mannitol (Figure 4-12). No statistical analysis was performed due to the low 
repeat number of experiments.  
The expression of the 54 kDa isoform of JNK and phospho-JNK were quantified. Levels of 
the 46 kDa isoform of JNK and phosphorylated JNK mirrored that of the 54 kDa isoform 
under all conditions tested (data not shown). Basal expression of the 54 kDa JNK isoform 
in HUVEC was comparable under all conditions tested. Insulin treatment resulted in small 
and comparable decreases in JNK abundance in all cases, which were not statistically 
significant (0.9±0.08 for control, 0.8±0.1 for normoglycaemic and 0.8±0.08 for 
hyperglycaemic cells compared to levels in absence of insulin; see Figure 4-13, panel B). 
In order to determine whether JNK phosphorylation might be affected during experimental 
hyperglycaemia, the phosphorylation levels of JNK at Thr183 and Tyr185 were quantified, 
serving as an indirect indicator of JNK activity. Acute stimulation with insulin had no 
marked effect on JNK phosphorylation. The ratio of phospho-JNK to total JNK indicated 
that experimental hyperglycaemia may cause an increase in basal phosphorylation 
(2.7±0.6-fold of basal normoglycaemic levels and 1.8±0.6-fold compared to basal control; 
Figure 4-13, panel C). No statistical analysis was performed due to the low repeat number 
of experiments.  Christine F. Kohlhaas    Chapter 4, 152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12 IKKß levels are increased after acute insulin treatment under control 
conditions. 
HUVEC lysates were prepared as described (section 2.2.2) and subjected to Western blotting. 
Representative blots are shown. Data are shown as mean ± range abundance of 2 independent 
experiments. Control IKKß levels are increased after insulin stimulation.                                              
C = control, M = mannitol, G = glucose Christine F. Kohlhaas    Chapter 4, 153 
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Figure 4-13 Basal JNK phosphorylation tends to  increase under experimental 
hyperglycaemia. 
Representative Western blots of hyperglycaemic and control  HUVEC lysates are shown in panel A. 
B: JNK expression was unchanged by experimental hyperglycaemia (data shown are the mean ± 
SEM abundance of 3 independent experiments). C: Levels of phosphorylated JNK (54 kDa) are 
expressed as a ratio to total JNK from 2 experiments (mean ± range).                                                                                        
C = control, M = mannitol, G = glucose Christine F. Kohlhaas    Chapter 4, 154 
 
4.2.3.3  The CAP-Cbl pathway 
The CAP-Cbl pathway is an insulin-stimulated pathway that plays a role in whole-body 
fuel homeostasis by regulating glucose transport (Baumann et al., 2000, Chiang et al., 
2001). Cbl is a proto-oncogene product that interacts with the insulin receptor via the 
adaptor protein CAP, and is phosphorylated by the tyrosine kinase action of the insulin 
receptor. Thereafter, the CAP-Cbl complex dissociates from the insulin receptor and binds 
to flotillin in caveolin-enriched lipid rafts, where it is thought to modulate glucose 
transport in adipocytes (Baumann et al., 2000).  
Previous work in this laboratory (Salt et al., 2003) has demonstrated that the expression of 
CAP and Cbl in HAEC was decreased under experimental hyperglycaemia, and that the 
phosphorylation of Cbl was also decreased in response to insulin. Hence, in order to 
investigate whether other insulin-responsive pathways were also dysregulated by 
experimental hyperglycaemia in HUVEC, CAP and Cbl expression was quantified. 
Expression levels of CAP demonstrated large inter-sample variation, and no statistically 
significant differences were found under any condition tested . However, basal levels in 
hyperglycaemic cells were 2.1±1. 8-fold higher than in normoglycaemic cells, while no 
difference in abundance was found between these two treatment groups in the presence of 
insulin. Under standard control conditions, insulin treatment caused an apparent rise in 
CAP abundance to  3±2-fold above basal. This insulin-mediated increase in CAP levels was 
abrogated in normoglycaemic and hyperglycaemic cells, in which the abundance of CAP 
was 0.5±0.6-fold and 0.6±0.07-fold of insulin-treated standard control (Figure 4-14, panel 
A). 
Basal expression of Cbl was comparable under all conditions, and acute insulin had no 
effect on Cbl levels in control or normoglycaemic HUVEC. However, following 
experimental hyperglycaemia, acute insulin treatment resulted in a reduction in Cbl 
abundance to 0.5±0.04-fold of basal levels in normoglycaemic and standard control cells 
(Figure 4-14, panel B). No statistical analysis was performed due to the low repeat number 
of experiments.  
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Figure 4-14 Cbl, but not CAP expression is modified by experimental 
hyperglycaemia. 
HUVEC lysates were prepared as described (section 2.2.2) and subjected to Western blotting with 
the relevant antibodies as indicated. A: Data shown are the mean ± SEM abundance of CAP from 3 
independent experiments. B: Data shown are the mean ± range abundance of Cbl from 2 
independent experiments. Sample Western blots are shown.                                                                     
C = control, M = mannitol, G = glucose 
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4.2.4  Superoxide production under experimental hyperglycaemia 
To investigate whether experimental hyperglycaemia affected superoxide (O2
-) production 
in HUVEC, superoxide levels were quantified in cells cultured under experimental 
hyperglycaemic or normoglycaemic conditions for 48h. In addition, the compound NG -
nitro-L-arginine methyl ester (L-NAME), which inhibits eNOS-mediated nitric oxide 
production, was used to determine the effect of NO bioavailability on superoxide levels. 
Superoxide levels in hyperglycaemic and normoglycaemic HUVEC lysates were measured 
by means o f a lucigenin-based chemiluminescence assay (see section 2.2.9 for a full 
description).  
Basal superoxide production in hyperglycaemic and normoglycaemic cells was 
comparable. Inhibition of NO production with L-NAME resulted in a ~2.5-fold 
(normoglycaemic cells) and a ~2.2-fold (hyperglycaemic cells) increase in O2
- generation 
compared to the respective basal levels. As expected, TNFa treatment caused increased O2
- 
synthesis compared to basal levels in both normoglycaemic and  hyperglycaemic cells 
(~1.6-fold and ~2.6-fold, respectively). Due to the low sample number, statistical analysis 
could not be performed.  
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Figure  4-15 Superoxide levels in HUVEC are increased by eNOS inhibition. 
HUVEC were cultured under experimental hyperglycaemic or normoglycaemic conditions in 
presence or absence of 100 µM L-NAME for 2h. Cells were serum-starved and subsets of cells 
treated with 10 ng/ml TNFa for 2h. Superoxide levels were measured in HUVEC lysates using a 
lucigenin-based chemiluminescence assay (described in section 2.2.9). Data are derived from one 
experiment (duplicates of vehicle and L-NAME samples; singlicates of TNFa samples) and are 
shown as mean ± range superoxide-related fluorescence. 
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4.3  Discussion 
4.3.1  eNOS expression 
The present study shows that experimental hyperglycaemia mildly modulates some aspects 
of insulin signalling in HUVEC. Several previous studies have investigated the effects of 
hyperglycaemia on various aspects of insulin signalling, and here, the present findings will 
be discussed in the light of these studies.  
Exposure to high levels of glucose has been shown to have different effects on eNOS 
expression and phosphorylation, depending on the length of exposure and the model 
system studied. In agreement with this study, no change in eNOS protein expression was 
observed in BAEC and rat aorta exposed to 30 mM glucose for 48h (Du et al., 2001), in 
HAEC after 48h of culture with 25 mM glucose (Salt et al., 2003), and in HUVEC after 30 
min of exposure to 25 mM glucose (Rojas et al., 2003). Other groups reported a ~25 % 
decrease in eNOS levels in human coronary artery endothelial cells (HCAEC) exposed to 
25 mM glucose for 7 days (Ding et al., 2000), and bovine aortic endothelial cells (BAEC) 
exposed to 22 mM glucose for 2 weeks were shown to express 20-30% less eNOS protein 
(Noyman et al., 2002). Expression of eNOS mRNA in HAEC cultured with 25 mM 
glucose was decreased by 25% and 46% after 3 and 7 days, respectively, while eNOS 
protein expression initially increased by 8% after 4h and then decreased by 64% after 7 
days (Srinivasan et al., 2004). Likewise, mRNA levels were decreased by 60% in diabetic 
(db/db) mouse aortic endothelial cells (MAEC) (Srinivasan et al., 2004). 
Conversely, several other studies demonstrated upregulated eNOS expression levels: 
Cosentino and co-workers reported a 2-fold increase in mRNA and protein levels in HAEC 
cultured with 22.2 mM glucose (Cosentino et al., 1997). In HUVEC, Lin and co-workers 
showed that eNOS protein expression was elevated after exposure to 33 mM glucose for up 
to 24h, and was maximal after 6h (~2-fold over control) (Lin et al., 2005), while another 
group reported that eNOS protein levels in HUVEC were elevated after 2-6h of exposure 
to 33 mM glucose (maximal at ~2.5 -fold over control), but gradually returned to control 
levels by 48h  (Ho et al., 1999). Quagliaro and co-workers demonstrated a ~2.7-fold 
increase over control in eNOS protein levels in HUVEC cultured with 20 mM glucose for 
14 days (Quagliaro et al., 2007).  
The discrepancies between these individual results highlight the differences between the 
various tissues used, and suggest that glucose concentration and length of exposure Christine F. Kohlhaas    Chapter 4, 159 
 
differentially affect the outcome. This is corroborated by findings from the present study, 
in which data obtained with HAEC subjected to the same conditions as described above for 
HUVEC, differed in some aspects from those observed in HUVEC: As previously shown 
in this laboratory (Salt et al., 2003), experimental hyperglycaemia did not affect insulin-
stimulated eNOS
S1177 phosphorylation in HAEC, which, in the present study, was 2.5-fold 
higher than basal (data not shown, compare to the 1.5 -fold increase in hyperglycaemic 
HUVEC, Figure 4-2, panel C) and thus comparable to the insulin-stimulated increase 
observed in HUVEC under standard control conditions. Mannitol-treatment abrogated 
insulin-stimulated eNOS
S1177 phosphorylation in HAEC (data not shown). Furthermore, 
insulin-stimulated phosphorylation of PKB
T308 was absent and was less pronounced for 
PKBS473 in  normoglycaemic and hyperglycaemic HAEC (~1.2-fold and ~1.3-fold over 
basal, respectively; data not shown) compared to HUVEC (Figure 4-7), indicating that 
HAEC were less insulin-sensitive than HUVEC under these conditions. These findings 
highlight discrepancies between different cell types used. 
Based on these findings, both high glucose and high mannitol affect different vascular 
endothelial cell types differently, accounting in part for the diversity of published results. It 
is tempting to speculate that the origin of these endothelial cells might affect their response 
to various treatments, such as insulin, glucose and mannitol, in this case. The glucose 
concentrations encountered by different vascular beds in man are likely to vary, as might 
their insulin-sensitivity. In general, efferent blood vessels, and conduit arteries in 
particular, ought to be more responsive to vasodilatory stimuli than afferent blood vessels 
(veins) and arterioles, where vasodilation may not play such an important role. Also, the 
blood glucose concentration in peripheral veins is likely to be lower than in arteries, given 
that glucose is taken up from the blood into insulin-responsive tissues such as muscle, fat 
and liver. An important exception here is the hepatic portal vein, which drains the small 
intestine and would thus encounter higher blood glucose concentrations. 
However, even with the same experimental model, different groups report varying results, 
as in the case of HUVEC cultured with 33 mM glucose: eNOS protein levels were reported 
to be upregulated only for up to 6h, and downregulated to near-control levels by 24h by 
one group (Ho et al., 1999), while another found increased protein levels for up to 24h (Lin 
et al., 2005). Similarly, comparable concentrations of glucose (22.2 mM and 25 mM) had 
different effects on HAEC with respect to eNOS mRNA and protein expression: in one 
study, the levels were increased 2 -fold (Cosentino et al., 1997), whereas they were 
decreased ~2 -fold in another study (Srinivasan et al., 2004). Such findings point out that Christine F. Kohlhaas    Chapter 4, 160 
 
experimental systems often respond dissimilarly in different hands, owing in part to small 
variations of experimental conduct.  
While no consensus conclusion regarding eNOS expression can be drawn from the studies 
described above, it is tentative to speculate that experimental hyperglycaemia has disparate 
short-term and long-term effects on eNOS expression: In the short-term (2-6h), 
hyperglycaemia appears to upregulate eNOS mRNA and protein expression, while longer-
term hyperglycaemia (24h+) has most frequently been reported to normalise or decrease 
eNOS levels. 
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4.3.2  eNOS phosphorylation 
In order to determine the effect of acute insulin treatment on the eNOS phosphorylation 
sites Ser114, Thr495, Ser615, Ser633 and Ser1177, cells cultured under standard control 
conditions (4 mM glucose, no mannitol) were included in the experimental design. In 
addition, an osmotic control (“normoglycaemic” cells cultured with 5 mM glucose and 20 
mM mannitol) was used to determine the effects of high (25 mM) glucose per se, 
independent of high osmolarity. Therefore, the present experimental design contains an 
inherent quality control by comparing the effects of high mannitol concentrations to 
standard control conditions. The effect of high mannitol on HUVEC is discussed at the end 
of this section. 
As has previously been demonstrated for eNOSS615 (Ritchie et al., 2007) and eNOSS1177 in 
HAEC (Salt et al., 2003), acute insulin stimulated the phosphorylation of eNOS
S615 and 
eNOS
S1177 in HUVEC under standard control conditions in the present study (see Figure 
4-2). Similarly, the insulin-stimulated decrease in eNOST495 phosphorylation previously 
observed in HUVEC (Federici  et al., 2004) was also observed in the present study (see 
Figure 4-4, panel C). In addition, this study reports the novel findings that acute insulin 
treatment decreased the phosphorylation of eNOS
S114 and eNOS
S633 in HUVEC under 
standard control conditions (see Figure 4-3 and Figure 4-4, panel B). Most of the insulin-
induced changes were small, and none were statistically significant. 
Based on these results, it is tentative to speculate on the roles of these eNOS 
phosphorylation sites in relation to eNOS activity in HUVEC. Phosphorylation of Ser114, 
Thr495 and Ser633 may inhibit basal eNOS activity, while their dephosphorylation in 
response to insulin may increase eNOS activity. Conversely, low basal phosphorylation 
levels of eNOSS615 and eNOSS1177 may translate into low basal eNOS activity, which is 
increased upon insulin-stimulated phosphorylation of these sites. These findings 
corroborate the activating roles of insulin-stimulated Ser615 and Ser1177 phosphorylation 
that have been reported  in vitro (Michell et al., 2002), in HAEC (Salt et al., 2003, Ritchie 
et al., 2007) and BAEC (Montagnani et al., 2001). Several other groups have demonstrated 
the activating properties of Ser615 and Ser1177 in response to other stimuli (Fleming et 
al., 1998, Michell et al., 2001, Michell et al., 2002, Bauer et al., 2003).  
The negative regulatory role of Thr495 phosphorylation on eNOS activity is well 
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vitro as well as in HUVEC and PAEC (Chen et al., 1999, Fleming et al., 2001, Michell et 
al., 2001, Greif et al., 2002, Fleming & Busse, 2003, Matsubara et al., 2003). This is in 
agreement with the present finding that insulin, a stimulator of eNOS activity, decreased 
eNOST495 phosphorylation. 
Current experimental evidence suggests that the role of eNOS
S114 phosphorylation may 
vary according to the nature of the stimulus. Shear stress and high density lipoprotein have 
been shown to increase Ser114 phosphorylation and eNOS activity (Gallis et al., 1999), 
whereas VEGF stimulation of eNOS activity lead to dephosphorylation of Ser114  and 
mimicry of Ser114 dephosphorylation increased eNOS activity (Kou et al., 2002). Site-
directed mutagenesis of bovine eNOS and subsequent transfection into COS-7 cells 
suggested that mimicking phosphorylation at Ser114 increased eNOS activity. 
Controversially, in the same study, both the phosphorylation and dephosphorylation 
eNOSS114 mutants increased stimulated NO release (Bauer et al., 2003). The present study 
suggests that insulin dephosphorylates eNOS
S114, but the impact on eNOS activity remains 
to be investigated. 
Several lines of evidence suggest that phosphorylation of Ser633 maintains eNOS activity 
after initial eNOS phosphorylation at Ser1177. Similar to eNOS
S1177, eNOS
S633 is 
phosphorylated by shear stress, ATP, VEGF and bradykinin (Boo et al., 2002, Michell et 
al., 2002, Bauer et al., 2003). Ser633 phosphorylation has been demonstrated to increase 
NO production in a Ca
2+-independent manner (Boo et al., 2003). This stands in contrast to 
the present result, in which insulin stimulated a decrease in eNOS
S633 phosphorylation. 
Studies of eNOS phospho-mutants, in which the amino acid residues of these 
phosphorylation sites have been mutated to mimic constitutive phosphorylation (aspartate 
mutants) or dephosphorylation (alanine mutants), have already provided important 
evidence about the role of each of the eNOS phosphorylation sites. A previous study with 
bovine eNOS phospho-mutants transfected into COS-7 cells has suggested that the sites 
equivalent to Ser633 and Ser1177 are important positive regulators of eNOS-mediated NO 
release in response to ATP (Bauer et al., 2003). In the same study, Ser615 phosphorylation 
slightly downregulated NO release, but was suggested to be important as a modulator of 
phosphorylation at the other eNOS phosphorylation sites and of protein-protein 
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Ser114 and Ser615 were postulated to be important positive modulators of phosphorylation 
at Ser1177 and increased the interaction of eNOS with hsp90 and PKB (Bauer et al., 
2003). Another report suggested that mimicking phosphorylation at the sites equivalent to 
Ser633 and Ser1177 contributed to eNOS activity in vitro, whereas Thr495 
phosphorylation decreased eNOS activity and Ser615 increased the activity of eNOS at 
lower concentrations of calmodulin without affecting maximal activity (Michell et al., 
2002). 
In order to define the clinical relevance of these findings, the proposed roles of individual 
eNOS phosphorylation sites will have to be verified in human vascular endothelial cells, 
and vascular explants, where possible. Their impact on eNOS activity in presence and 
absence of insulin and other stimuli will have to be measured, for example by using L-
arginine conversion assays and NO synthesis assays. Furthermore, it would be of great 
value to extend the present study to determine the effect of hyperglycaemia on eNOS 
activity.  
The effect of experimental hyperglycaemia on the phosphorylation state of eNOS 
phosphorylation sites Ser114, Thr495, Ser615, Ser633 and Ser1177 was investigated in the 
present study. Previous data from this laboratory demonstrated that experimental 
hyperglycaemia in HAEC did not affect eNOST495 or eNOSS1177 phosphorylation (Salt et 
al., 2003). The aim behind the present study was to investigate in HUVEC the 
phosphorylation status of eNOS at all five main phosphorylation sites. Other groups have 
previously studied the phosphorylation and activity levels of eNOS in the context of 
hyperglycaemia. Most available data concern the phosphorylation of the Ser1177 site, 
though a few studies have also investigated other eNOS phosphorylation sites. No 
published studies of prolonged (48h) hyperglycaemia have been carried out in HUVEC, 
though other cell types have been used for modelling 48h+ hyperglycaemia. 
In hyperglycaemic BAEC (48h) and diabetic rat aorta, basal eNOS
S1177 phosphorylation 
was decreased by 45% and 50%, respectively, while glycosylation at this site was 
increased 1.85-fold (BAEC) and 2.1-fold (rat aorta), resulting in 32% (BAEC) and 57% 
(rat aorta) decreases in eNOS activity (Du et al., 2001). In a study by Federici and co-
workers, 
32P-incorporation by constitutively active PKB into eNOS
S1177 
immunoprecipitated from hyperglycaemic HCAEC was also impaired (46% lower than 
control), while glycosylation of eNOS around the Ser1177 site was 2.9-fold higher than in 
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around the Ser1177 site and thus prevented its effective phosphorylation. Similarly, 
insulin-stimulated eNOS
S1177 phosphorylation after 72h of experimental hyperglycaemia 
was reduced by 37%, while insulin-stimulated eNOS activity was decreased 27% 
compared to control (Federici et al., 2002). By contrast, Salt and co-workers reported  no 
change in basal or insulin-stimulated eNOS
S1177 phosphorylation after 48h of experimental 
hyperglycaemia in HAEC (Salt et al., 2003).  
Studies of short-term experimental hyperglycaemia demonstrated that exposure to 25 mM 
glucose for 30 minutes induced a ~ 2.8 -fold increase over control in eNOS
S1177 
phosphorylation and increased L-citrulline production by hyperglycaemic HUVEC ~2.2-
fold, indicating greater eNOS activity than in control cells (Rojas et al., 2003). Also  in 
HUVEC, Lin and co -workers observed increased phosphorylation levels of eNOS after 2-
6h of high glucose (maximal at 4h with ~4.5-fold elevation), which returned to basal after 
24h (Lin et al., 2005). However, longer-term hyperglycaemia was demonstrated to have 
the opposite effect: Two weeks of experimental hyperglycaemia decreased eNOS activity 
by 25% in BAEC and abrogated insulin-stimulated eNOS activity (Noyman  et al., 2002). 
Similarly, unstimulated eNOS
S1177 phosphorylation 5 weeks post-induction of diabetes was 
decreased by 25% (without a change in total eNOS expression) in partially purified rat 
penile tissue (including vascular endothelium), while glycosylation was increased by 90% 
(Musicki et al., 2005). In their study, shear stress also failed to increase Ser1177 
phosphorylation (Musicki et al., 2005). 
In the present study, basal eNOS
S1177 phosphorylation was unchanged in hyperglycaemic 
HUVEC compared to control cells (Figure 4-5, panel A). However, insulin-stimulated 
Ser1177  phosphorylation was slightly and non-significantly reduced after 48h of 
experimental hyperglycaemia compared to control cells (Figure 4-2, panel B). The 
observed trend of decreased  insulin-responsive eNOS
S1177 phosphorylation agrees with 
findings in HCAEC (Federici et al., 2002) and contrasts other reports (Rojas et al., 2003, 
Salt et al., 2003), but given the variation in duration of experimental hyperglycaemia and 
the different cell types used, this only emphasises the discrepancies between different 
experimental models. 
Two groups have reported no changes to basal eNOS
T495 phosphorylation in 
hyperglycaemic HAEC (Salt et al., 2003) and diabetic rat penis (Musicki et al., 2005), 
which is in line with the present finding that neither basal nor insulin-stimulated eNOST495 
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study by Musicki and co-workers showed that basal eNOSS615 and eNOSS633 
phosphorylation was not affected by hyperglycaemia in diabetic rats (Musicki et al., 2005). 
This contrasts with the current results, where basal eNOS
S615 phosphorylation was 
increased by experimental hyperglycaemia, albeit not to statistical significance (Figure 4-2, 
panel B), and basal eNOS
S633 phosphorylation was reduced to 50% of control levels (not 
statistically significant; see Figure 4-3 and Figure 4-5, panel A). Site-directed mutagenesis 
studies have suggested that basal phosphorylation of eNOSS633 is important for eNOS 
activity (Bauer et al., 2003), which would imply that the trend toward reduced eNOSS633 
phosphorylation observed under experimental hyperglycaemia in the present study might 
reduce eNOS activity. 
No literature has been published regarding the effect of hyperglycaemia on eNOS
S114 
phosphorylation. In this study, insulin-stimulated Ser114 phosphorylation was significantly 
reduced compared to stimulated control samples (Figure 4-5, panel B).  
The effect of insulin on eNOS activity has been assumed to be stimulatory, based on the 
observation that insulin treatment increases eNOS-mediated NO production (Scherrer et 
al., 1994, Zeng & Quon, 1996). While phosphorylation of eNOS
S1177 is required for 
agonist-mediated NO synthesis (Dimmeler et al., 1999, Fulton et al., 1999, Michell et al., 
2001), and eNOST495 dephosphorylation is thought to enhance NO generation (Chen et al., 
1999, Fleming et al., 2001, Michell et al., 2001, Greif et al., 2002, Fleming & Busse, 2003, 
Matsubara et al., 2003), less is known about the roles of the other eNOS phosphorylation 
sites in insulin signalling.  
Based on the insulin-stimulated effect on eNOS phosphorylation sites under standard 
control conditions in the present study, phosphorylation of Ser114, Thr495 and Ser633 
may inhibit eNOS activity in HUVEC, while phosphorylation of Ser615 and Ser1177 most 
likely activates eNOS. During experimental hyperglycaemia, basal eNOS
S615 
phosphorylation showed a trend toward upregulated phosphorylation, whereas basal 
eNOSS633 phosphorylation tended to be downregulated with respect to standard control 
(see Figure 4-5, panel A). This suggests experimental hyperglycaemia may promote basal 
eNOS activity. Insulin-stimulated eNOS phosphorylation at Ser114 was significantly 
decreased with respect to standard control, whereas none of the other sites was 
significantly affected (see Figure 4-5, panel B). If Ser114 phosphorylation is indeed a 
negative regulator of eNOS activity in HUVEC, its decreased phosphorylation would 
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It is important to bear in mind that the phosphorylation status of each of these sites may 
influence that of others. Furthermore, some phosphorylation sites may not be important for 
insulin-stimulated eNOS activity, but rather serve to modulate eNOS interactions with 
other proteins, as has been suggested for Ser615 (Bauer et al., 2003). In order to determine 
the role of each of these phosphorylation sites in insulin-stimulated eNOS activity under 
normal and hyperglycaemic conditions, further investigations are therefore required. 
It is interesting to note that eNOS phosphorylation levels at eNOS
S633 and eNOS
S1177 
differed in mannitol-cultured (normoglycaemic) HUVEC compared to control cells 
cultured with 4 mM glucose alone. Although culture with 20 mM mannitol and 5 mM 
glucose had been designed as an osmotic control and was expected to have no effect on 
protein expression and phosphorylation, an osmotic effect seems to be precipitated by the 
addition of high levels of mannitol to the cell culture medium. Insulin-responsive 
phosphorylation levels of eNOSS1177 were altered in mannitol-treated cells, the stimulated 
increase being less pronounced than in control cells (see Figure 4-2). Furthermore, basal 
eNOS
S633 phosphorylation was also lower in normoglycaemic compared to control cells, 
and insulin-stimulated dephosphorylation was abrogated (Figure 4-3).  
Although neither of these changes was statistically significant with respect to the standard 
control, these findings suggest that mannitol, despite being cell-impermeable and thus not 
metabolised by cells, can interfere with normal insulin signalling. A recent report suggests 
that hyperosmotic mannitol (550 mM) can induce large structural changes in rat brain 
endothelial cells (Bálint et al., 2007), while previous findings demonstrated that 100 mM 
mannitol can cause apoptosis of endothelial cells (Malek et al., 1998). Although these 
mannitol concentrations are much higher than the concentration used here, it remains to be 
investigated whether high concentrations of mannitol have a biologically significant impact 
on cellular signalling processes.  
Investigating the effect of high mannitol concentrations on cellular function would be a 
relevant study, considering that several groups (Cosentino et al., 1997, Ho et al., 1999, Du 
et al., 2001, Federici  et al., 2002, Rojas et al., 2003, Salt et al., 2003, Srinivasan et al., 
2004, Quagliaro  et al., 2007) used mannitol as a negative control when studying the effects 
of experimental hyperglycaemia. None of these groups reported any osmotic effects with 
mannitol. Two groups compared cells cultured in normal versus mannitol-supplemented 
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any changes with mannitol compared to control medium regarding the parameters 
measured.  
Inclusion of an osmotic control is important for the study of experimental hyperglycaemia 
in cultured endothelial cells, though some groups (Ding et al., 2000, Noyman et al., 2002, 
Lin et al., 2005) have failed to include osmotic controls, instead comparing cells cultured 
in high glucose to cells cultured in normal medium with low glucose concentrations alone. 
Such an experimental design makes it impossible to determine whether the effects 
observed with high glucose are genuine or due to osmotic stress. An alternative control for 
experimental hyperglycaemia is the use of equimolar concentrations of non-metabolisable 
L-glucose, although the cost of this compound prevents its routine use for experiments 
such as those presented here. One group (Rojas et al., 2003) used equimolar L-glucose as 
an additional control, and reported no effect. 
The present study also puts into question whether the effects observed under experimental 
hyperglycaemia are actually glucose-specific, or whether they are, at least in part, due to 
osmotic effects. While it is vital to include an osmotic control in experiments investigating 
the effects of experimental hyperglycaemia, mannitol does not seem to be a suitable 
choice, since the present study showed that culture of HUVEC with 20 mM mannitol 
mildly affects the phosphorylation of eNOSS633, eNOSS1177, PKBS473 and I?BaS32 and the 
expression of IKKß (see also section 4.3.3), when compared to cells cultured with 4 mM 
glucose alone. While these osmotic effects may be specific to HUVEC, it is likely that 
other vascular endothelial cells are also affected by this phenomenon. Therefore, the results 
of studies which have used mannitol as an osmotic control without comparing the findings 
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4.3.3  Insulin-regulated pathways 
In order to determine whether some other insulin-responsive pathways were affected by 
experimental hyperglycaemia and are therefore potential candidates for dysregulated eNOS 
function under hyperglycaemic conditions, components of the metabolic insulin signalling 
pathway, the NF?B transcription pathway and the stress-activated JNK and CAP-Cbl 
pathways were assessed for expression and phosphorylation levels.  
PKB, which phosphorylates eNOS at Ser1177, showed no change in expression under any 
condition tested (Figure 4-6), and phosphorylation of its principal activating site Thr308 
was consistently stimulated >3 -fold by acute insulin (Figure 4-7, panel B). Likewise, 
insulin-stimulated phosphorylation of the second activating site, Ser473, increased >1.4-
fold over basal under control, normoglycaemic and hyperglycaemic conditions (Figure 4-7, 
panel C). Despite reduced unstimulated PKBS473 phosphorylation under normoglycaemic 
and hyperglycaemic conditions, these results indicate that PKB phosphorylation, and thus 
most likely PKB activity, are unaffected by hyperglycaemia in this experimental system 
and that PKB remains insulin-sensitive. Expression levels of the upstream components 
PI3K-p85, PTEN and PDK-1 were unaltered with respect to control, again suggesting that 
the upstream components of the metabolic insulin signalling pathway in HUVEC are not 
impaired by 48h of experimental hyperglycaemia.  
Previous studies have demonstrated that protein expression of PKBa, PI3K-p85 and -
p110ß, PTEN, PDK-1 and IRS-1 was unchanged in HAEC after 48h of experimental 
hyperglycaemia, while IRS-2 levels were reduced by 30% compared to control (Salt et al., 
2003). Insulin-stimulated PKBa activity
 was unaffected, which supports the present 
findings, although basal PKB activity was increased 2.4 -fold with respect to control (Salt 
et al., 2003). Unstimulated PKB serine phosphorylation in BAEC was unchanged after 2 
weeks of experimental hyperglycaemia  compared to control, but eNOS activity was 
reduced by 25% (Noyman et al., 2002).  
Unlike the present study, one group reported that insulin-dependent PKB
S473 
phosphorylation in HCAEC after 72h of experimental hyperglycaemia was 30% lower than 
in control cells (Federici et al., 2002). In the same study, PI3K activity was decreased by 
55%, and PI3K association with IRS-1 and IRS-2 was reduced by 20% and 40%, 
respectively, compared to control cells (Federici  et al., 2002). This is mirrored by findings 
that PI3K recruitment to IRS-1 was reduced by 24%, whereas PI3K recruitment to IRS-2, 
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hyperglycaemia (Salt et al., 2003), indicating a defect in PI3K and/or IRS function. 
Federici and co -workers also reported decreased phosphorylation of the insulin receptor 
(by 50%) and IRS-1 (by 55%), and simultaneous increases in the glycosylation of IRS-1 
(600%), IRS-2 (210%) and PI3K-p85 (200%) (Federici  et al., 2002), again suggesting that 
experimental hyperglycaemia may exert a damaging impact on insulin signalling through 
increased glycosylation of proteins.  
The reduction in basal PKB
S473 phosphorylation of ~67%, seen in hyperglycaemic HUVEC 
in the present study, was also reported for penile tissue of diabetic rats, where basal 
PKBS473 phosphorylation levels were decreased by 60% (Musicki et al., 2005). Shear stress 
induced phosphorylation of PKBS473 to levels comparable to control, indicating normal 
PKB function, but not phosphorylation of eNOS
S1177 (Musicki et al., 2005). Varma and co-
workers reported that 40 mM glucose decreased basal PKB
T308 phosphorylation by ~50% 
and PKB activity by ~75%, as well as reducing basal tyrosine phosphorylation of PI3K by 
~40%, in HUVEC exposed to experimental hyperglycaemia for 8 days (Varma et al., 
2005). This contrasts the present finding that basal PKB
T308 phosphorylation was unaltered 
by experimental hyperglycaemia.  
Overall, these findings suggest that, depending on the tissue used, defective eNOS 
phosphorylation under hyperglycaemic conditions is unlikely to be caused by impaired 
PKB activity alone. There is some evidence that hyperglycaemia induces changes in PI3K 
activity, which may likely affect eNOS regulation via PKB. Other factors, such as defects 
in other insulin signalling pathway components, or hyperglycaemia -induced glycosylation, 
may also contribute to the alterations in eNOS phosphorylation observed in this and other 
studies.  
Given the unchanged insulin-sensitivity of the metabolic insulin signalling pathway 
components investigated here, other insulin-responsive pathways were assessed for their 
potential dysregulation by experimental hyperglycaemia. Investigation of the NF?B 
pathway revealed that there were no changes in the expression levels of NF?B (Figure 
4-10) and I?Ba (Figure 4-11, panel B) under any condition tested . Phosphorylation of I?Ba 
at Ser32, however, was basally decreased under normoglycaemic and hyperglycaemic 
conditions compared to control, while insulin-induced dephosphorylation of Ser32 seen in 
control samples was mildly impaired under these conditions. The insulin-responsiveness of 
I?Ba  dephosphorylation would point to lower NF?B bioavailability, thus potentially 
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contrast, a slight decrease in NF?B levels following insulin treatment was observed  in the 
present study. However, there was a slight basal increase in NF?B levels after mannitol 
and glucose treatment, possibly as a result of increased basal phosphorylation (and thus 
degradation) of I?Ba under these conditions. 
Conversely, b asal levels o f the I?Ba-phosphorylating kinase IKKß were slightly and not 
statistically significantly increased under normoglycaemic and hyperglycaemic conditions 
(Figure 4-12), predicting increased phosphorylation of I?Ba, which was not observed in 
the present study. Acute treatment with insulin increased the abundance of IKKß in 
standard control samples, which contradicts the present finding of decreased IkBaS32 levels 
in insulin-stimulated control samples. However, these insulin-induced changes in IKKß 
and I?Ba
S32 levels were abolished in normoglycaemic and hyperglycaemic samples and 
were not statistically significant. Since IKKß activity was not measured in this study, no 
conclusion about the effect of raised IKKß levels on I?Ba phosphorylation can be drawn.  
Previously, dose-dependent activation of NF?B nuclear translocation by high (25-35 mM), 
but not lower (15 mM) concentrations of glucose has been observed in BAEC (Pieper & 
Riaz ul, 1997). NF?B activity was increased in nuclear fractions within 1h and was 
maximal at 2 -4h, suggesting that alteration of NF?B bioavailability is an early 
hyperglycaemia-induced event that may contribute to endothelial dysfunction and 
atherosclerosis (Pieper & Riaz ul, 1997). Similarly, incubation of BAEC with 30 mM 
glucose increased NF?B activation 1.8-fold (Nishikawa et al., 2000). These findings would 
have to be validated in HAEC, as the present study did not address NF?B activity, but only 
its expression levels.  
In the present study, acute insulin treatment induced very small decreases in JNK 
expression levels (not statistically significant), but did not change JNK phosphorylation 
levels (Figure 4-13). However, basal JNK phosphorylation was slightly elevated in 
hyperglycaemic cells compared to mannitol-cultured cells (not statistically significant), 
suggesting that high glucose levels may promote JNK phosphorylation in HUVEC. 
Previously, 25 mM glucose was shown to transiently increase JNK1 activity in bovine 
pulmonary artery endothelial cells (BPAEC) (activity being maximally increased (2 -fold) 
with respect to control at 24h) (Liu et al., 2000).  
The JNK pathway can be activated by oxidative stress and has been implicated in the 
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lacking JNK are protected from macrophage-mediated pancreatic beta-cell apoptosis and 
subsequent hyperglycaemia, which is likely due to reduced TNFa secretion from 
macrophages (Fukuda et al., 2008). This suggests that active JNK plays a crucial role in 
promoting cytokine-induced beta-cell destruction and aggravates the prodiabetic profile. 
The present study indicates that in HUVEC, increased hyperglycaemia-mediated JNK 
activation through phosphorylation is a potential prodiabetic candidate mechanism, 
although these results are preliminary and require further confirmation.  
The expression of CAP was largely unchanged under all conditions tested, although large 
inter-sample variation in expression levels prevente d the drawing of any definitive 
conclusions. Cbl expression levels were comparable under all conditions, except for 
insulin-treated hyperglycaemic cells, in which there was a 50% decrease with respect to 
unstimulated control and normoglycaemic cells (not statistically significant; see Figure 
4-14). Previous work in hyperglycaemic HAEC showed that CAP and Cbl expression was 
reduced to 54% and 60% of control levels, respectively, and that insulin-induced Cbl 
phosphorylation in control cells was abrogated in hyperglycaemic HAEC (Salt et al., 
2003). In mice, knockout of Cbl lead to macrophage activation and contributed to 
peripheral insulin resistance and glucose intolerance (Hirasaka et al., 2007). If Cbl is also 
downregulated by hyperglycaemia in humans, this would exacerbate glucose intolerance.  
It is interesting to note that acute treatment with insulin for 10 minutes seemed to have a 
modulatory, though not statistically significant, effect on the quantities of the molecules 
IKKß, JNK and Cbl, compared to their basal levels. Acute insulin treatment is unlikely to 
affect the actual protein expression levels of molecules within the 10-minute time scale 
tested. More likely, the small changes observed here are due to other factors, such as inter-
sample variation. It is, however, conceivable that insulin may trigger degradation of these 
molecules, or regulatory events other than those investigated here, such as 
phosphorylation, ubiquitination and myristoylation, which may render the molecules in 
question undetectable to the antibodies used here.  
The present study has shown that acute insulin treatment can lead to the rapid 
dephosphorylation of I?Ba, thus potentially decreasing levels of free NF?B and acting as 
an antiatherogenic mediator. However, in the present study, insulin-induced I?Ba 
dephosphorylation in control samples were not mirrored by equally reduced NF?B levels 
in the same samples. Insulin has not previously been reported to cause dephosphorylation 
of I?Ba
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here may be representative of the actual abundance levels of these molecules, a number of 
other factors, including inter-sample variation and the effectiveness of the protease 
inhibitors used during sample preparation, could have influenced these measurements. 
Quantification of further samples, preferably using other pools of HUVEC, would reduce 
inter-sample variation and provide more accurate results for the abundance levels of all 
molecules investigated here.  
Data from one experiment indicated that expression of the stress-activated p38 MAPK in 
hyperglycaemic cells was unchanged compared to normoglycaemic cells, whereas insulin-
stimulated p38 MAPK phosphorylation was reduced by ~24% in hyperglycaemic HUVEC 
(data not shown). Noyman and co -workers showed that experimental hyperglycaemia 
reduced basal p38 MAPK activation in BAEC to 43% of control levels (Noyman  et al., 
2002). In a previous report, the basal phosphorylation and activity of p44/42 MAPK, and 
the activity of p38 MAPK were not affected by culture of BPAEC in 25 mM glucose (Liu 
et al., 2000), indicating that hyperglycaemia does not interfere with the basal activity of 
these mitogenic insulin signalling pathway components. It would be interesting, however, 
to address the effect of experimental hyperglycaemia on insulin-stimulated 
phosphorylation and activity of these and other components more thoroughly.  
As observed for the phosphorylation levels of eNOSS633 and eNOSS1177, culture of HUVEC 
with 20 mM mannitol and 5 mM glucose also affected the basal expression level of IKKß 
and the unstimulated phosphorylation levels of PKB
S473 and I?Ba
S32. While only the 
decrease in basal PKB
S473 phosphorylation in normoglycaemic cells was statistically 
significant with respect to unstimulated control, these findings suggest that high 
concentrations of mannitol in the culture medium exert an osmotic effect on HUVEC. 
Further investigations are needed to determine whether this is a robust effect or merely an 
artefact of the experimental procedures. These findings put into question the use of 
equimolar mannitol concentrations as a suitable control for experimental hyperglycaemia, 
and will reduce the potency of any conclusions drawn from such experiments.  
Overall, the effects observed in HUVEC in the present study were small, and large 
interexperimental variation in cellular responsiveness to stimuli resulted in few statistically 
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4.3.4  Superoxide production 
Preliminary investigation of superoxide generation by HUVEC revealed that experimental 
hyperglycaemia had no effect on O2
- levels compared to normoglycaemic control (Figure 
4-15). In addition, O2
- levels were higher when co-incubating cells with the eNOS inhibitor 
L-NAME, indicating that functional NO synthesis reduces O2
- levels. This may suggest 
that inhibition of NO production may increase eNOS-mediated superoxide production, or 
that the superoxide produced during uninhibited eNOS activity rapidly reacts with NO to 
form peroxynitrite (Reiter et al., 2000), thus becoming undetectable by means of the 
lucigenin-based superoxide assay employed here. Greater TNFa-stimulated superoxide 
production in hyperglycaemic HUVEC may suggest that experimental hyperglycaemia 
sensitizes HUVEC to TNFa; however, given that TNFa treatment was carried out in 
singlicate, this thought is highly speculative. 
Several other studies have found that superoxide levels in vascular endothelial cells were 
altered by experimental hyperglycaemia, and were frequently linked to eNOS expression 
or activity levels: Culturing of HAEC with 22.2 mM glucose for 5 days increased eNOS 
mRNA and protein levels 2-fold and O2
- levels 3-fold, while increasing NO levels by only 
1.4 -fold, leading to an imbalance between O2
- and NO (Cosentino et al., 1997). Similarly, 
HUVEC showed a 40% increase in NO production and a 300% rise in O2
- generation, 
along with elevated eNOS expression, after 2 weeks of experimental hyperglycaemia (20 
mM) (Quagliaro  et al., 2007).  
High glucose concentrations (22 mM) abolished insulin-stimulated eNOS activity in 
BAEC, thus impairing the NO synthesis pathway, while simultaneously increasing 
oxidative stress as indirectly measured by 3-fold increased superoxide dismutase (SOD)-1 
expression in hyperglycaemic cells (Noyman et al., 2002). Du and co-workers reported 
decreased eNOS activity (as measured by L-arginine conversion) and O2
- overproduction 
in hyperglycaemic BAEC, although this overproduction was attributed to mitochondrial 
activity (Du et al., 2001), rather than uncoupled eNOS activity. Another group also showed 
that experimental hyperglycaemia induced mitochondrial superoxide production 
(Nishikawa et al., 2000). 
Experimental hyperglycaemia may also increase oxidative stress by modulating the levels 
of other reactive oxygen species, such as hydrogen peroxide, which was increased in 
HUVEC after 48h with 33 mM glucose (Ho  et al., 1999). A correlation between decreased 
eNOS expression, reduced nitrite levels and increased mitochondrial ROS production in Christine F. Kohlhaas    Chapter 4, 174 
 
hyperglycaemic HAEC after 7 days was postulated by another group (Srinivasan et al., 
2004). Decreased eNOS promoter activity in HAEC was ameliorated by quenching of 
ROS. In addition, inhibition of mitochondrial ROS production normalised eNOS mRNA 
levels in diabetic mice (Srinivasan et al., 2004). By contrast, it has also been suggested that 
ROS can increase eNOS mRNA expression via NF?B (Zhen  et al., 2008).  
The reaction product of NO and O2
-, peroxynitrite, has been suggested to suppress PKB 
activity and induce apoptosis during experimental hyperglycaemia by upregulation of 
PTEN (Song et al., 2007). Although this and other findings described above stand in 
contrast to the present results of unchanged O2
- , eNOS, PKBT308, PKBS473 and PTEN 
levels, the experimental evidence from the single superoxide assay shown in the present 
study is not sufficient to draw definitive conclusions about superoxide generation under 
experimental hyperglycaemia in HUVEC. Therefore, further experiments are needed to 
elucidate the situation more fully.  
Although insulin-stimulated NO synthesis has not been investigated in the present study, 
previous results in this laboratory  demonstrated that 48h of experimental hyperglycaemia 
(25 mM) in HAEC decreased insulin-stimulated NO production by 60% (Salt et al., 2003). 
Given the frequently postulated imbalance between NO and O2
-/ROS production 
(Cosentino et al., 1997, Ho et al., 1999, Noyman et al., 2002, Srinivasan et al., 2004, 
Quagliaro et al., 2007), and its potential involvement in causing endothelial dysfunction 
and atherogenesis, measurement of NO synthesis by HUVEC - and its relation to 
superoxide/ROS levels - under the experimental hyperglycaemic conditions employed here 
would be a valuable addition to the present study. Christine F. Kohlhaas     175  
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5.1  Introduction 
5.1.1  Background  
The localisation of a molecule within the cell is important to its function. Initially, eNOS 
was found in the particulate subcellular fraction of bovine aortic endothelial cells 
(Forstermann et al., 1991, Pollock et al., 1991) and eNOS-transfecetd COS-7 cells 
(Busconi & Michel, 1993). Later studies showed that eNOS is targeted to the Golgi body 
of eNOS-transfected HEK cells (Sessa et al., 1995). In the cell line ECV304, exogenous 
eNOS localised to the plasma membrane and the perinuclear/Golgi area (Sowa et al., 
1999), but the endothelial nature of ECV-304 cells is doubtful (Brown et al ., 2000). At the 
plasma membrane, eNOS is thought to localise to caveolae, plasma membrane 
microdomains coated with the protein caveolin (Garcia-Cardena et al., 1996a, Garcia-
Cardena et al., 1996b, Shaul et al., 1996). However, it is unclear whether eNOS also 
localises to other cellular compartments.  
Targeting of eNOS to caveolae is determined by dual acylation with the fatty acids 
myristate and palmitate (Liu & Sessa, 1994, Garcia-Cardena et al., 1996b, Shaul et al., 
1996). Its presence at the plasma membrane is thought to optimise eNOS activation and 
nitric oxide release to the extracellular environment (Garcia-Cardena et al., 1996b, Shaul et 
al., 1996). Based on data from eNOS-transfected COS-7 cells, the plasma membrane- and 
Golgi-associated pools of eNOS are thought to respond differently to activation by PKB 
and calcium-dependent mechanisms (Fulton et al., 2004a). To date, little is known about 
the effect of agonists on the subcellular distribution of eNOS. Furthermore, much of the 
work so far has been carried out in non-endothelial cell lines or cells whose endothelial 
origin is debated. In addition, the subcellular localisation of phospho-eNOS species has not 
been fully investigated.  
 
5.1.2  Aims of the chapter 
So far, it is not known how stimulation with insulin affects the subcellular distribution of 
eNOS within human vascular endothelial cells. Therefore, the aim of this chapter was to 
investigate the effect of acute insulin stimulation on the subcellular localisation of eNOS 
and its distribution within different cellular compartments of human aortic endothelial 
cells.  Christine F. Kohlhaas    Chapter 5, 177 
 
5.2  Results 
5.2.1  Selection of experimental conditions 
Human aortic endothelial cells were used to investigate the subcellular distribution of 
eNOS, since the central macrovascular origin of HAEC makes them a more relevant model 
system than HUVEC for the study of responses to acute insulin stimulation. In addition, no 
previous reports addressing eNOS localisation in HAEC have been published to date.  
HAEC were left untreated or stimulated acutely with 1 µM insulin for 10 minutes prior to 
fixation in 4% (w/v) formaldehyde. An ammonium chloride blocking step was used to 
prevent overfixation of cells. HAEC were permeabilised gently (0.5 -1% (v/v) Triton X-
100, 7 min) to avoid detachment of the plasma membrane. For co-labelling experiments, 
cells were co-incubated with anti-eNOS and anti-caveolin-1 antibodies. After washing, 
cells were co-incubated with both secondary antibodies. DAPI dye was used to stain nuclei 
(see section 2.2.13 for a detailed description). 
For subcellular fractionation experiments, iodixanol was chosen because of its ability to 
form a continuous gradient upon centrifugation, which results in good yields of cellular 
organelles at high purity (Graham et al., 1994).  
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5.2.2  Subcellular localisation of eNOS 
In order to investigate the subcellular localisation of eNOS, HAEC were immunolabelled 
with anti-eNOS antibody and stained with DAPI. Subsets of cells were co -labelled with 
anti-caveolin-1 antibody. Confocal microscopy of immunolabelled HAEC showed that 
eNOS is present throughout the cell, including the nucleus (Figure 5-1, panels A, C-E). 
Frequently, prominent eNOS labelling was observed in the perinuclear area (Figure 5-1, 
panel F). eNOS was also found at the plasma membrane, and also colocalised with the 
membrane marker caveolin-1 (Figure 5-1, panels B and E). 
It was investigated whether acute treatment with insulin affected the subcellular 
localisation of eNOS. Subsets of HAEC were stimulated with insulin for 10 minutes prior 
to fixation and immunolabelling. Confocal analysis and subsequent quantification of 
fluorescence intensity in nucleus, perinuclear area and cytoplasm demonstrated that there 
was no difference between insulin-treated and control HAEC (Figure 5-2). The majority of 
eNOS localised to the perinuclear region, where 1.8-fold greater quantities of eNOS were 
detected than in the nuclei of untreated and insulin-stimulated HAEC. The smallest 
proportion of eNOS was seen in the cytoplasm (34% and 32% compared to 100% nuclear 
eNOS content in untreated and insulin-stimulated cells, respectively). Insulin had no 
discernible effect on the subcellular localisation of eNOS in HAEC. Statistical analysis 
could not be performed on this singlicate experiment, but the ranges of eNOS fluorescence 
are indicated in the graph in Figure 5-2, panel C. 
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Figure 5-1 eNOS localises to the plasma membrane and the perinuclear region. 
HAEC were immunolabelled with anti -eNOS (green, panel A) and anti-caveolin-1 (red, panel B) 
antibodies and stained with DAPI (blue, panel D). Confocal images of fluorescence and brightfield 
channels were taken (see sections 2.2.13 and 2.2.13.1). Representative images from two separate 
fields (Panels A-E, panel F) are shown. Membrane localisation of eNOS and co-localisation with 
the membrane-marker caveolin-1 (panel E) and perinuclear localisation of eNOS (panel F) are 
indicated by arrows. To normalise against background fluorescence, separate controls were 
performed in absence of primary antibody and in presence of irrelevant secondary antibody. Christine F. Kohlhaas    Chapter 5, 180 
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Figure 5-2 Insulin has no effect on eNOS localisation. 
HAEC were stimulated with 1 µM insulin for 10 min or left untreated before fixation in 4% 
formaldehyde and immunolabelling with anti-eNOS antibody as described in section 2.2.13. 
Representative confocal images of untreated (panel A) and insulin-stimulated (panel B) HAEC are 
shown. To normalise against background fluorescence, separate controls were performed in 
absence of primary antibody and in presence of irrelevant secondary antibody. Panel C shows the 
quantification of fluorescence intensity in different cellular regions relative to nuclear fluorescence 
intensity as mean ± range. Per treatment group, 30 individual cells were analysed. For cytoplasmic 
measurements, three separate measurements were taken from the cytoplasm of each cell, covering 
areas of high, medium and low fluorescence intensity, and expressed as a ratio to nuclear 
fluorescence intensity before calculation of the mean.  
 Christine F. Kohlhaas    Chapter 5, 181 
 
5.2.3  Distribution of eNOS within different cellular compartments 
To obtain a more detailed picture of the subcellular distribution of eNOS, iodixanol 
gradient centrifugation was performed to yield purified cellular organelles. Resulting 
fractions of the gradient were TCA-precipitated prior to Western blot analysis. Antibodies 
against marker proteins for different cellular organelles were used to determine which 
organelles were contained in individual fractions. 
Fractions 1 -3 contained the plasma membrane marker Na
+/K
+-ATPase and the caveolae 
marker caveolin-1. Fractions 4-7 contained markers for Golgi body and late endosomes, 
fractions 5-7 the markers for early endosomes and cytoplasm. As expected, eNOS was 
detected mainly in the plasma membrane fractions and in the denser fractions containing 
endosome, Golgi and cytoplasm markers. Probing of Western blots with phospho-specific 
antibodies against eNOST495, eNOSS615 and eNOSS1177 demonstrated that eNOST495 and 
eNOS
S615 localised almost exclusively to the plasma membrane, whereas eNOS
S1177 
localised predominantly to plasma membrane and, to a lesser degree, early endosome-
containing fractions. PKB localised to cytoplasmic and Golgi body-containing fractions, 
but was not found at the plasma membrane (Figure 5-3).  
The distribution of marker proteins within fractions from insulin-treated cells differed 
slightly from that of untreated cells. However, in most cases, there was no marked 
difference in the subcellular distribution of eNOS species between insulin-treated and non-
treated cells as judged by co-fractionation with marker proteins. Interestingly, a higher 
molecular weight species, recognised by the anti-eNOST495 and anti-eNOS antibodies, was 
detected in the endosomal/cytoplasmic fractions of unstimulated HAEC. Abundance of this 
species was lower in insulin-treated cells.Christine F. Kohlhaas    Chapter 5, 182 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 eNOS localises to different cellular compartments. 
HAEC were stimulated acutely with 1 µM insulin or left untreated before preparation of cell 
homogenates and centrifugation on an iodixanol gradient (10-40%) (see section 2.2.4 for details). 
After centrifugation, 500 µl fractions were collected from the top of centrifuge tubes and TCA-
precipitated prior to Western blot analysis with specific antibodies as indicated. Antibodies against 
markers of cellular organelles were used to determine the content of each fraction. Two different 
exposures of total eNOS are shown to illustrate the presence of a higher molecular weight eNOS 
species in fractions 4-7 of unstimulated HAEC lysates (see arrow) . This species is also detectable 
by anti-eNOS
T495. Data are shown are representative blots from 2 separate experiments.               
PM = plasma membrane, EE = early endosome, LE = late endosome 
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5.3  Discussion 
In the present study, confocal microscopy analysis of eNOS-immunolabelled HAEC 
showed that eNOS is detectable at the plasma membrane and in the nuclei, perinuclear 
regions and the cytoplasm of HAEC. Proportionally, the greatest eNOS abundance was 
found in the perinuclear region, which most likely corresponds to the Golgi body. eNOS 
abundance in the cytoplasm was low (Figure 5-1). eNOS abundance at the plasma 
membrane was not quantified from confocal images, as the plasma membrane represents 
too small a proportion of the cell in a given plane of a confocal image. 
Previous studies have shown that eNOS localises to the plasma membrane and 
perinuclear/Golgi area in foetal lamb pulmonary artery endothelial cells (Shaul et al., 
1996) and BAEC (Garcia-Cardena et al., 1996a, Garcia-Cardena et al., 1996b), but this is 
the first report to show that eNOS is also detectable in the nuclei of human aortic 
endothelial cells. In line with the present findings, cytosolic and nuclear localisation of 
eNOS was reported for bone marrow-derived mesenchymal stem cells (Klinz et al., 2005).  
A more detailed picture of the distribution of eNOS within the cell was obtained by 
iodixanol gradient fractionation of HAEC homogenates. As expected, eNOS was detected 
primarily in the plasma membrane fractions and in the denser fractions containing 
endosome, Golgi and cytoplasm markers, confirming microscopy data. In order to obtain 
improved resolution and purity of organelles and molecules, the gradient fraction size 
could be reduced, thus providing greater accuracy in determining localisation of different 
cellular components. The protocol employed for iodixanol gradient centrifugation involves 
pelleting of the nuclei prior to gradient centrifugation; hence, eNOS abundance in nuclei 
could not be quantified by this method.  
To date,  the distribution of different phospho-eNOS species within human vascular 
endothelial cells has not been fully investigated. The present study showed that eNOS
T495 
and eNOS
S615 localised almost exclusively to the plasma membrane, whereas eNOS
S1177 
localised predominantly to the plasma membrane and, to a lesser degree, to early 
endosome-containing fractions (Figure 5-3). In BAEC, eNOS
S1179 was shown to localise to 
caveolae and Golgi domains (Fulton et al., 2002), supporting the present findings. In 
mesenchymal stem cells, eNOSS1177 was found in filamentous perinuclear structures (Klinz 
et al., 2005). eNOSS1177 was also detected in the perinuclear region and, interestingly, the 
nucleoli of rat glioma cells (Klinz et al., 2007). Together, these data suggest that eNOS
S1177 
localises to the plasma membrane and the Golgi body in several different cell types. Christine F. Kohlhaas    Chapter 5, 184 
 
Furthermore, eNOSS114 was heavily enriched in the nucleus of mesenchymal stem cells 
(Klinz et al., 2005). 
As each eNOS phospho-species was detected only once in two separate experiments, it 
needs to be clarified whether these and other phospho-eNOS species are also present in 
other cellular compartments of human vascular endothelial cells. The above data indicate 
that the distribution of eNOS can vary according to its phosphorylation status. While it is 
thought that the phosphorylation status influences the activity and function of eNOS, the 
localisation of eNOS and its phospho-species may play an equally important role in 
regulating its activity. For example, previous experiments with eNOS-targeting mutants in 
BAEC have shown that eNOS-mediated NO production is more effective and more 
responsive to calcium-dependent agonists and the PKB activator angiopoietin when eNOS 
is located at the plasma membrane, rather than the Golgi body, whereas the response of 
both pools of eNOS to insulin was comparable (Zhang et al., 2006). Therefore, it is 
speculative that agonists will promote the presence of active eNOS species (such as 
eNOS
S1177) at the plasma membrane.  
Interestingly, a higher molecular weight species was detected with the anti-eNOS
T495 and 
anti-eNOS antibodies in the endosomal/cytoplasmic fractions of unstimulated HAEC. 
Abundance of this species was lower in insulin-treated cells. If this higher molecular 
weight species is a modified form of eNOST495, this may indicate that i) acute stimulation 
with insulin likely reduces the amount of eNOS
T495 and/or the higher molecular weight 
species in the cell and ii) eNOS
T495 may be labelled for degradation, for example by 
ubiquitin-conjugation, and trafficked in endosomes. This lends support to the idea that 
trafficking and cellular localisation of eNOS and its phospho-species may influence its 
activity.  
Other than eNOS
T495, acute treatment with insulin did not modify the distribution of eNOS 
or phospho-eNOS species, as determined by confocal microscopy and subcellular 
fractionation. In a previous study, stimulation of BAEC with the eNOS-agonist vascular 
endothelial growth factor (VEGF) was found not to affect eNOSS1179 localisation (Fulton et 
al., 2002). As the present subcellular fractionation data were derived from a single 
experiment, these studies need to be repeated in order to clarify the distribution of eNOS 
and its phospho-species within different cellular compartments. It would be interesting to 
map the trafficking of eNOS and its phospho-species within endothelial cells, and to 
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Co-localisation of eNOS with caveolin-1, a marker of caveolae in the plasma membrane, 
was demonstrated in the present study. Interaction between eNOS and caveolin-1 has 
previously been reported in bovine aortic endothelial cells (Feron et al., 1996, Garcia -
Cardena et al., 1996a, Garcia-Cardena et al., 1997, Feron et al., 1998, Ghosh et al., 1998). 
Tyrosine phosphorylation of eNOS has been suggested to influence its activity, trafficking 
and localisation, as well as its interaction with caveolin-1 in bovine aortic endothelial cells 
(Garcia-Cardena et al., 1996a). Interaction with caveolin-1 is thought to inactivate eNOS, 
blocking NO synthesis (Garcia-Cardena et al., 1997). Disruption of this association by 
binding of Ca
2+-calmodulin to eNOS is postulated to lead to eNOS activation (Michel  et 
al., 1997, Feron et al., 1998, Ghosh et al., 1998). Furthermore, Ca
2+-mobilising agonists 
regulate the cycle of dissociation and re-association between eNOS and caveolin, which is 
thought to influence NO-dependent signalling in the vascular wall (Feron et al., 1998). 
Thus, the localisation of eNOS and its molecular interactions play important roles in 
regulating eNOS activity.  
Other studies also support the idea that the localisation of a molecule within the cell has 
crucial implications for its activity and downstream effects. In pancreatic beta-cells, the 
effect of insulin signalling through its two receptor isoforms is thought to be determined by 
specific localisation of the receptor subtypes within the plasma membrane (Uhles et al., 
2003). Importantly, in 3T3L1 adipocytes, the insulin receptor colocalises and directly 
interacts with caveolin (Kimura et al., 2002). If this association of the insulin receptor and 
caveolin also occurs in vascular endothelial cells, this would bring the receptor close to its 
downstream targets such as eNOS. Rapid recruitment of downstream signalling molecules 
and enzymes is vital for effective signal transduction and appropriate cellular response to a 
stimulus. 
In the present study, the eNOS-activating kinase PKB localised to cytoplasmic and Golgi 
body-containing fractions, but was not found at the plasma membrane, suggesting that it 
was not associated with eNOS at the pla sma membrane. Previous studies have shown that 
eNOS forms a complex with PKB and the molecular chaperone hsp90 (Garcia-Cardena et 
al., 1998, Fontana et al., 2002, Takahashi & Mendelsohn, 2003), enabling rapid activation 
of eNOS. However, the precise location of this complex has not been determined, and thus 
needs to be investigated further. It has also been suggested that association of eNOS with 
different polymerisation states of actin modulates eNOS activity in porcine pulmonary 
artery endothelial cells (Su et al., 2003). To clarify interactions between eNOS and other Christine F. Kohlhaas    Chapter 5, 186 
 
cellular molecules, including cytoskeletal components, co-immunoprecipitation 
experiments and co-labelling confocal microscopy could be used.  
The cellular localisation and association of eNOS with its interaction partners represents a 
sophisticated mechanism for regulation of eNOS activity. More extensive investigations of 
the effect of insulin and other agonists on the localisation and association of eNOS and its 
interaction partners are necessary to clarify the precise nature of these regulatory 
mechanisms. Christine F. Kohlhaas     187  
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6.1  Introduction 
6.1.1  Background 
It has been suggested that patients with diabetes are in a state of chronic low level 
inflammation  (Fernandez-Real & Ricart, 2003, Wellen & Hotamisligil, 2005), which 
promotes atherogenesis. In this study, low-level inflammation was mimicked by treatment 
of HAEC with TNFa. During atherogenesis, monocytes attach to vascular endothelial cells 
and eventually migrate through the endothelium in a process called transendothelial 
migration (transmigration) or diapedesis. This process involves the expression of 
chemokines, which attract leukocytes/monocytes to the vascular endothelium.  
The AMP-dependent protein kinase (AMPK) is an energy-sensor which regulates energy 
metabolism. It is a target for the hypoglycaemic drug metformin, which is thought to lower 
blood glucose levels by inhibiting gluconeogenesis (Zhou et al., 2001, Shaw et al., 2005). 
Importantly, in the context of the present study, AMPK can activate eNOS by 
phosphorylating Ser1177, thus increasing NO production in bovine and human aortic 
endothelial cells (Chen  et al., 1999, Morrow et al., 2003). Given the potential 
antiatherogenic properties of NO (Li et al., 2002, Dickhout et al., 2005, Rask-Madsen & 
King, 2005, Tesauro  et al., 2005, Rask -Madsen & King, 2007), this evidence suggests that 
AMPK is involved not only in glucose homeostasis, but also promotes an antiatherogenic 
phenotype by increasing NO synthesis, which is likely to increase vasodilation and reduce 
the potential of leukocyte-endothelium interactions. 
Previous work carried out by Dr Marie-Ann Ewart in the laboratory has demonstrated that 
AMPK attenuates the TNFa-induced expression of cell surface adhesion molecules in 
human aortic endothelial cells after 4h of stimulation with the AMPK agonist AICAR, but 
this effect was not observed after short-term (45 min) stimulation of AMPK (see Figure 
6-1). Furthermore, monocyte adhesion to HAEC was downregulated by acute (45 min) 
stimulation of AMPK activity in a nitric oxide-dependent fashion. Prolonged (4h) 
stimulation of AMPK activity was more effective at decreasing monocyte adhesion, but 
this effect was not NO-dependent (see Figure 6-2) (unpublished observations). 
Since these phenomena could not be explained by the effect of AMPK on adhesion 
molecule expression, it was decided to investigate endothelial chemokine production, 
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that acutely, AMPK activity negatively regulates chemokine production, while longer-term 
AMPK activity downregulates adhesion molecule expression in vascular endothelial cells.  
In addition, the impact of AMPK activity and NO bioavailability on monocyte migration 
was investigated, since work by other groups has suggested that AMPK activity can reduce 
migration of monocytic and hepatic stellar cells (Kanellis et al., 2006, Caligiuri et al., 
2008). 
 
6.1.2  Aims of the chapter 
The aim of this chapter was to look at the potential antiatherogenic properties of AMPK 
activity and NO bioavailability. Specifically, the effect of short-term and prolonged  AMPK 
activity on NO-mediated regulation of chemokine production in human aortic endothelial 
cells was investigated. Furthermore, the effect of AMPK activity and NO bioavailability on 
monocyte migration was assessed. 
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Figure 6-1 Prolonged but not rapid AMPK activation inhibits TNFa-stimulated cell 
surface expression of adhesion molecules. 
HAEC were infected with adenovirus encoding constitutively active AMPK (AMPK-CA) for 24h 
prior to incubation in the presence or absence of TNFa (10 ng/ml, 6h) and in the presence or 
absence of 2 mM AICAR for the final 45 or 240 min. Cell surface expression of ICAM-1, VCAM-
1 and E-selectin was assessed by flow cytometry. The results shown are from six independent 
experiments performed in triplicate. *p<0.01 relative to TNFa-stimulated value in absence of 
AICAR or AMPK-CA                                                                                                                      
This work was carried out by Dr Marie-Ann Ewart in the laboratory. 
 
 
          
Figure 6-2 The effects of rapid, but not prolonged stimulation of AMPK on U937 cell 
adhesion are sensitive to L-NAME. 
HAEC were infected with control adenoviruses or AMPK-CA-encoding virus 24h prior to 
incubation in the presence or absence of TNFa (10 ng/ml, 6h) after preincubation (30 min) in the 
presence or absence of 1 mM L-NAME.  For the final 45 or 240 min subsets of cells were also 
incubated with 2 mM AICAR. The results of seven independent U-937 cell adhesion assays are 
shown. # p<0.05 relative to value in the absence of L-NAME                                                             
This work was carried out by Dr Marie-Ann Ewart in the laboratory. Christine F. Kohlhaas    Chapter 6, 191 
 
6.2  Results 
6.2.1  Experimental conditions 
A literature search was performed to determine which chemokines were produced by 
vascular endothelial cells. The range of chemokines secreted by vascular endothelial cells 
included MCP-1, -2 and -3, MIP-1a and -1ß, MIG, Eotaxin, RANTES, GRO and IP-10. 
Therefore, secretion of each of these proteins from stimulated HAEC was assessed using 
an antibody-based chemokine assay.  
HAEC were first stimulated with the AMPK activator, AICAR, for 45 min or 4h with or 
without co -incubation with 10 ng/ml TNFa for 4h and/or the eNOS inhibitor L-NAME. In 
a parallel set of experiments, HAEC were infected with adenovirus encoding for 
constitutively active AMPK (AMPK-CA), dominant-negative AMPK (AMPK-DN), or an 
empty expression cassette. HAEC were then treated with AICAR and/or TNFa and/or the 
eNOS inhibitor L-NAME (see section 2.2.11 for a detailed description). In each case,  the 
cell culture medium was aspirated at the end of the treatment period, and replaced with 
fresh, serum-free RPMI (SF-RPMI) after thorough washing, to obtain conditioned medium 
containing secreted chemokines.  It should be noted that under these conditions, both 
TNFa and AICAR had been washed away prior to collection of conditioned medium. This 
conditioned medium was used for chemokine analysis (section 6.2.2) and monocyte 
migration assays (section 0).
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6.2.2  Chemokine production by HAEC 
Previous work in the laboratory has shown that monocyte adhesion to HAEC is decreased 
by acute (45min) AMPK activation, but this was not dependent on cell surface adhesion 
molecule expression (see Figure 6-1and Figure 6-2). Therefore, it was speculated that 
AMPK acutely regulates the secretion of endothelial cell chemokines, thereby influencing 
the attraction of monocytes to endothelial cells. Hence, production of the ch emokines 
MCP-1, -2 and -3, MIP-1a and  -1ß, MIG, Eotaxin, RANTES, GRO and IP-10 by HAEC 
was assessed using a Human Chemokine Multiplex Bead Immunoassay and a Luminex 
100TM-based detection system (see section 2.2.12 for details). 
Analysis of chemokine secretion showed that treated and untreated HAEC secrete 
measurable levels of MCP-1, MCP-2, Eotaxin, RANTES and IP-10; however, only MCP-1 
secretion was stimulated by TNFa; hence, only MCP-1 data are illustrated in Figure 6-3. 
Secretion levels of MCP-3, MIP -1a and -1ß, MIG, and GRO were below the detection 
limits of the assay.  
As expected, treatment of HAEC with TNFa for 4h strongly induced production of MCP-1 
to 47.7±5.3-fold above basal (p<0.001; Figure 6-3). Treatment with AICAR alone for 45 
minutes or 4h had no effect on chemokine production. Prolonged stimulation of AMPK 
activity by AICAR (4h) significantly reduced TNFa-induced MCP-1 secretion, both in the 
absence (2.0±0.3-fold, p<0.005) and presence of L-NAME (1.8±0.2, p<0.05; paired t-
tests).  
Incubation of TNFa -treated cells with AICAR for 45 minutes also reduced TNFa-induced 
MCP-1 secretion in the absence of L-NAME (1.9±0.5-fold, p = 0.0653; paired t-test), but 
not in the presence of L-NAME. For all treatments, addition of L-NAME slightly increased 
the secretion of MCP-1, resulting in a 2.6±1.5-fold increase in chemokine production 
under control conditions (p = 0.393). 
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Figure 6-3 MCP-1 production in HAEC is downregulated by AMPK activity. 
Chemokine production by HAEC was assessed using antibody-based technology. HAEC were 
treated with 2 mM AICAR for 45 min (A45) or 4h (A4) in the presence (AT45; AT4) and absence 
of 10 ng/ml TNFa (T, 4h) and/or 200 µM L-NAME (4h) as indicated. Thereafter, cells were 
washed thoroughly and incubated with fresh SF-RPMI for 1h at 37°C. This conditioned medium 
was collected and used for chemokine analysis using BioSource
TM technology. The graph shows 
MCP-1 secretion data from 5 (vehicle) or 4 (+ L-NAME) independent experiments as mean ± 
SEM. TNFa strongly induced MCP-1 secretion ($p<0.001, paired t-test). Treatment with AICAR 
for 4h significantly reduced TNFa-induced MCP-1 secretion (**p<0.005 for AT4 compared to T 
without L-NAME; *p<0.05 for AT4 compared to T with L-NAME; paired t-tests). C = untreated 
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6.3  Discussion 
In the present study, HAEC were found to secrete low levels of the chemokines MCP-1, 
MCP-2, Eotaxin, RANTES and IP-10. Basal MCP-1 secretion was about 5 times higher 
compared to all other chemokines measured. TNFa markedly  stimulated the secretion of 
MCP-1 only; hence, only MCP-1 data are included in this thesis. In line with the 
hypothesis, treatment with AICAR for 4h or 45 minutes slightly reduced TNFa -induced 
secretion of MCP-1; this was statistically significant for 4h of AICAR treatment (see 
Figure 6-3). 
As predicted by the hypothesis, inhibition of NO synthesis through L-NAME increased 
TNFa-stimulated secretion of MCP-1 under all conditions (Figure 6-3), indicating that 
negative regulation of MCP-1 production in HAEC is (partially) NO-dependent or at least 
enhanced by NO bioavailability. These data suggest that decreased NO bioavailability 
promotes a proatherogenic endothelial profile. The present findings are corroborated by 
clinical evidence which suggests that patients with hyperinsulinaemia and diabetes, which 
have decreased NO bioavailability, show an increased risk for atherosclerosis (Li et al., 
2002, Dickhout et al., 2005, Rask -Madsen & King, 2005, Tesauro  et al., 2005, Rask-
Madsen & King, 2007).  
The present data suggest that the attenuating effect of AMPK activity on TNFa-stimulated 
MCP-1 production was NO-dependent in the short-term, but not during prolonged AMPK 
activation (Figure 6-3). Acute (45 min) stimulation of AMPK reduced TNFa-stimulated 
MCP-1 secretion in the absence, but not in the presence of L-NAME (results not 
statistically significant due to spread of data points). Prolonged AMPK stimulation (4h) 
significantly decreased TNFa -stimulated MCP-1 secretion in HAEC independently of NO 
synthesis. These findings suggest that acutely, AMPK stimulates eNOS-mediated NO 
production, whereas prolonged AMPK activity reduces chemokine secretion via (an) 
eNOS- and NO-independent pathway(s). The precise nature of this/these pathway(s) 
remains to be investigated. 
Furthermore, the present data indicate that AMPK-mediated downregulation of MCP-1 
secretion occurs before downregulation of cell surface adhesion molecule expression in 
HAEC (see Figure 6-1), but also persists over longer periods of time. These studies need to 
be extended to confirm the time course of events in the regulation of endothelial 
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study the effect of AMPK activity and NO bioavailability on the secretion of other 
chemokines which have not been measured in the present study.  
Based on the higher levels of secreted MCP-1 and its monocyte chemotactic role, 
conditioned medium from HAEC treated with TNFa should be able to stimulate monocyte 
migration. This speculation will have to be validated by monocyte migration assays using 
conditioned medium from HAEC. 
Previous studies have shown that AMPK activation through AICAR reduces chemokinesis 
and chemotaxis of U937 pre-monocytic cells by ~50% (Kanellis et al., 2006). Work on 
hepatic stellar cells showed that activation of AMPK reduced proliferation, migration and 
MCP-1 secretion, thus reducing the activated phenotype of these cells (Caligiuri et al., 
2008). While these studies were carried out in different cell types, the findings correlate 
with the present study in that AMPK activation through AICAR reduced MCP-1 secretion, 
which would be expected to attenuate monocyte migration.   
Overall, the present findings support an antiatherogenic role for AMPK, as AMPK activity 
can compensate for reduced NO bioavailability and decrease the atherogenic profile of 
HAEC cultured with proinflammatory stimuli. This has already been proposed by other 
groups who found that AMPK may have an anti-inflammatory role in vitro and in vivo. It 
was postulated that AMPK plays an important role in decreasing inflammation via 
inhibition of NF?B signalling in animal models of experimental autoimmune encephalitis 
(EAE) (Nath et al., 2005, Prasad et al., 2006). In addition, AICAR-stimulated AMPK 
activity prevented lipopolysaccharide-induced cytokine and iNOS expression in cultured 
rat astrocytes, microglia and macrophages, and in rats in vivo, by prevention of NF?B 
activation (Giri et al., 2004). Further studies are required to define the molecular 
mechanism underlying the potential AMPK-mediated antiatherogenic effects in the present 
study. Christine F. Kohlhaas     196  
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The vascular endothelium plays a crucial role in the maintenance of vascular health by 
regulating vascular tone, platelet aggregation, coagulation, fibrinolysis and monocyte 
adhesion, amongst others. Endothelial regulation of vascular tone occurs through the 
coordinated secretion of endothelial vasodilators and vasoconstrictors. The principal 
endothelial vasodilator is NO, which is produced by endothelial nitric oxide synthase. NO 
mediates vasodilation in vivo and ex vivo, and is thought to have vasoprotective properties 
(Gewaltig & Kojda, 2002, Hsueh & Quinones, 2003, Wheatcroft et al., 2003). In several 
disorders, including insulin resistance, diabetes and atherosclerosis, endothelial function 
can be impaired, which promotes adverse cardiovascular effects such as hypertension, 
cardiac infarction and strokes, as well as microvascular disease. NO bioavailability has 
been shown to be reduced in patients with hyperinsulinaemia and diabetes (reviewed in 
(Rask-Madsen & King, 2007)). However, the causal relationship between impaired NO 
bioavailability, endothelial dysfunction and disease is still under debate. 
Insulin is a vasoactive hormone that stimulates vasodilation by activating eNOS through 
the insulin signalling pathway (Scherrer et al., 1993, Scherrer et al., 1994, Zeng & Quon, 
1996, Zeng et al., 2000). Hyperinsulinaemia/insulin resistance is closely linked to 
endothelial dysfunction, which in turn is frequently associated with decreased NO 
bioavailability and proatherogenic processes in patients (Li et al., 2002, Dickhout et al., 
2005, Rask -Madsen & King, 2005, Tesauro et al., 2005). Current evidence suggests that 
hyperinsulinaemia impairs eNOS-mediated NO synthesis in vitro and in vivo (Steinberg  et 
al., 1996, Hogikyan et al., 1998, O'Driscoll et al., 1999, Balletshofer et al., 2000, 
Cheetham et al., 2000, Cleland et al., 2000, Ding et al., 2000, Arcaro et al., 2002, Fulton et 
al., 2004b, Katakam et al., 2005, Pandolfi et al., 2005, Potenza et al., 2005). However, the 
contribution of hyperinsulinaemia per se to these disorders, and the molecular mechanisms 
responsible, are poorly characterised. To date, the effect of hyperinsulinaemia on insulin-
stimulated endothelial NO production has not been investigated in endothelial cells or the 
vasculature.  
In chapter 3, the present study therefore addressed how experimental hyperinsulinaemia 
affects eNOS-mediated NO production and the insulin signalling pathway in human aortic 
endothelial cells. Experimental hyperinsulinaemia (100 nM, 48h) in this study was 
designed to model high pathological hyperinsulinaemia in patients with insulin resistance. 
While insulin stimulated NO synthesis to a lesser degree than expected, this increase was 
statistically significant under control but not under experimental hyperinsulinaemic 
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groups. These findings can be explained by increased basal NO synthesis in 
hyperinsulinaemic cells and interexperimental variation in the insulin-sensitivity of HAEC. 
Ionomycin-responsive NO synthesis was blunted in hyperinsulinaemic HAEC, indicating 
that hyperinsulinaemia may have a negative effect on Ca2+-dependent NO synthesis. At the 
molecular level, eNOS protein expression in hyperinsulinaemic HAEC remained 
unchanged . Basal and insulin-stimulated  eNOS
S1177 phosphorylation compared to total 
eNOS tended to  increase slightly over time, while eNOST495 phosphorylation in 
hyperinsulinaemic cells showed a tendency toward increased phosphorylation levels 
following acute stimulation with insulin.  
The protein expression levels of insulin signalling pathway components and the eNOS-
activating kinase AMPK were assessed. No changes were found in the expression of PKB, 
PI3K, PDK-1, PTEN or AMPK. PKB
S473 phosphorylation remained insulin-sensitive under 
experimental hyperinsulinaemia, but the fold-stimulation elicited by insulin was decreased 
by 50% in hyperinsulinaemi c cells after 48h (data not statistically significant). Stimulated 
AMPK
T172 phosphorylation was decreased and basal phosphorylation was increased after 
48h of experimental hyperinsulinaemia (data not statistically significant). 
Interestingly, acute treatment with insulin markedly increased the phosphorylation of 
AMPKT172, which is a novel and somewhat unexpected finding, given AMPK’s role in 
shutting down energy-consuming pathways. Under physiological conditions, insulin is 
released when glucose levels are high and therefore, energy is readily available. Activation 
of AMPK by phosphorylation would therefore make little sense in the context of energy 
conservation. However, in the context of vasodilation, the metabolic insulin signalling 
pathway and AMPK both act on eNOS to increase NO production, and it would therefore 
make perfect sense for these two components to act in synergy to promote increased 
vasodilation and blood flow in response to nutrient intake. Increased blood flow would 
result in glucose uptake into peripheral target tissues and thus, overall energy conservation. 
Insulin may therefore selectively upregulate the eNOS-activating kinase activity of AMPK, 
without affecting other AMPK-mediated events. Further investigation of this theory would 
be an interesting endeavour.  
Since insulin-stimulated eNOS
S1177 and PKB
S473 phosphorylation and NO production were 
not significantly  impaired in hyperinsulinaemic HAEC, this suggests that the insulin 
signalling pathway is functional after 48h of experimental hyperinsulinaemia. In 
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production is mediated via the PI3K-PKB pathway, rather than the AMPK pathway, which 
was slightly impaired after 48h of experimental hyperinsulinaemia , but did not show a 
negative effect on NO synthesis. Basal eNOS
S1177 phosphorylation may be increased by 
enhanced AMPK activity. These hypotheses need to be confirmed using kinase inhibitors 
and kinase activity assays to study the impact of individual pathway components (in 
particular, PI3K, PKB and AMPK) and their activity levels on eNOS-mediated NO 
production.  
The present study also briefly investigated whether experimental hyperinsulinaemia 
differentially affected the metabolic and mitogenic branches of the insulin signalling 
pathway. Quantification of p44/42 MAPK levels indicated that MAPK levels were 
unchanged  under experimental hyperinsulinaemia.  
While these data require further confirmation, it is becoming clear that experimental 
hyperinsulinaemia in HAEC has distinct effects on different components of signalling 
pathways. Experimental hyperinsulinaemia for 48h had no marked effects on endothelial 
NO production in the present study. The present results stand in contrast to several studies 
using different types of tissues, which reported that NO production was impaired  in 
hyperinsulinaemic states (Steinberg  et al., 1996, Balletshofer et al., 2000, Cleland et al., 
2000). Therefore, the impact of the present results on endothelial function has to be 
clarified. In addition, extended periods of experimental hyperinsulinaemia along with 
investigation of other areas of endothelial function, such as angiogenesis, may yield 
valuable clues to the biological impact of hyperinsulinaemia. The small changes observed 
in HAEC under experimental hyperinsulinaemia are illustrated in Figure 7-1. 
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Figure 7-1 The effects of experimental hyperinsulinaemia in HAEC 
Schematic diagram summarising the changes observed under experimental hyperinsulinaemia in 
HAEC. Note that none of the indicated changes were statistically significant. 
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Hyperinsulinaemia is a disease state that precedes hyperglycaemia and overt diabetes. 
Endothelial dysfunction and impairment of the underlying molecular mechanisms is likely 
to progress over time, and may therefore be exacerbated in hyperglycaemia. As with 
hyperinsulinaemia, endothelial function and NO bioavailability can be impaired by 
hyperglycaemia (Calver et al., 1992, McVeigh et al., 1992, Hogikyan et al., 1998, De 
Vriese et al., 2000, Rask-Madsen & King, 2007). In vitro and in vivo evidence suggests 
that hyperglycaemia dysregulates insulin signalling (Sobrevia  et al., 1998, Federici  et al., 
2002, Salt et al., 2003) and NO-mediated vasodilation (Tesfamariam et al., 1990) and 
increases production of reactive oxygen species (Cosentino et al., 1997, De Vriese et al., 
2000, Hink et al., 2001, Srinivasan et al., 2004). Previous studies on the effect of 
hyperglycaemia on eNOS phosphorylation have yielded conflicting results, and the 
underlying mechanisms regulating eNOS phosphorylation are poorly characterised. In 
addition, the role of the individual eNOS phosphorylation sites is not clear. 
Therefore, chapter 4 presents work on the effect of experimental hyperglycaemia on the 
regulation of eNOS phosphorylation and superoxide production in human umbilical vein 
endothelial cells. Furthermore, the effect of acute insulin treatment on eNOS 
phosphorylation at Ser114, Thr495, Ser615, Ser633 and Ser1177 was investigated in 
HUVEC. Acute insulin moderately stimulated the phosphorylation of eNOS
S615 and 
eNOS
S1177, and decreased the phosphorylation of eNOS
S114, eNOS
T495 and eNOS
S633 (data 
not statistically significant). Given insulin’s role as an activator of eNOS-mediated NO 
synthesis, these results suggest that Ser114, Thr495 and Ser633 are inhibitory sites, while 
Ser615 and Ser1177 are activating sites of eNOS in insulin-stimulated HUVEC.  
The nature of the stimulus and the tissue type studied may affect the interpretation of the 
roles of eNOS phosphorylation sites. The present findings are in agreement with 
previously published data on Thr495, Ser615 and Ser1177  (Chen et al., 1999, Fleming et 
al., 2001, Michell et al., 2001, Montagnani et al., 2001, Greif et al., 2002, Michell et al., 
2002, Fleming & Busse, 2003, Matsubara et al., 2003, Salt et al., 2003, Ritchie et al., 
2007). The role of Ser114 is less clear, but it is dephosphorylated in response to the eNOS 
stimulator VEGF (Kou et al., 2002). Ser633 has been shown to increase eNOS activity and 
was proposed to maintain prolonged activity of eNOS (Boo et al., 2002, Michell et al., 
2002, Bauer et al., 2003), which stands in contrast to the present findings. Further studies 
are needed to clarify the individual contributions of eNOS phosphorylation sites to eNOS 
activity and the effect of various stimuli on eNOS phosphorylation in a variety of vascular 
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To date the effect of hyperglycaemia on eNOS expression and phosphorylation is debated. 
In the present study, total eNOS expression was unaffected by experimental 
hyperglycaemia (25 mM, 48h). Basal phosphorylation of eNOS
S633 was reduced (non-
significantly) and insulin-stimulated phosphorylation of eNOSS114 was significantly 
reduced, whereas basal eNOS
S615 phosphorylation was increased (non-significantly) 
compared to control cells cultured with 4 mM glucose. Based on the roles of eNOS 
phosphorylation sites proposed above, these data indicate that experimental 
hyperglycaemia may promote eNOS activity. However, given the lack of effect on Ser 
1177 and Thr495, it is unlikely that NO production would be enhanced under these 
conditions. More likely, these changes in phosphorylation modify the interaction of eNOS 
with other molecules such as PKB and hsp90 and the subcellular localisation of eNOS. 
Figure 7-2 summarises the present findings on eNOS phosphorylation.   
The present study also addressed which regulatory pathways may be involved in mediating 
altered eNOS phosphorylation under experimental hyperglycaemia in HUVEC. Published 
evidence on eNOS regulatory pathways is controversial. The present findings showed that 
the metabolic insulin signalling pathway is not impaired by experimental hyperglycaemia 
in HUVEC. Preliminary experiments in the present study suggest that the stress-activated 
JNK pathway and the NF?B pathway were mildly (non-significantly) impaired by 
experimental hyperglycaemia, while the CAP-Cbl pathway was unaffected. The NF?B and 
JNK pathways have been implicated in promoting a proatherogenic profile through their 
involvement in adhesion molecule expression (Gilmore, 2006). Based on the limited effect 
on the NF?B and JNK pathways, the present study  gives insufficient evidence to support a 
proatherogenic role for experimental hyperglycaemia in HUVEC. The molecular cause for 
altered eNOS phosphorylation will have to be further assessed, and the biological 
significance investigated. 
Interestingly, the present data also demonstrated that high mannitol (20 mM + 5 mM 
glucose) in HUVEC affects the phosphorylation of eNOS
S633, eNOS
S1177, PKB
S473 and 
I?Ba
S32 and the expression of IKKß when compared to cells cultured with 4 mM glucose 
alone. This effect has not been previously reported, and suggests that the use of equimolar 
mannitol as an osmotic control for hyperglycaemia is questionable. This should be kept in 
mind when interpreting data from studies using high mannitol as a control. Further 
investigations are needed to identify the mechanism(s) by which mannitol mediates its 
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Figure 7-2 eNOS phosphorylation in HUVEC 
The diagram summarises the changes in eNOS phosphorylation in HUVEC after acute treatment 
with insulin (top panel) and the changes compared to control after 48h of experimental 
hyperglycaemia (bottom panel). Note that only the effect on eNOS
S114 was statistically significant 
under experimental hyperglycaemia (p<0.05). Christine F. Kohlhaas    Chapter 7, 204 
 
Previous results from our laboratory indicated that endothelial NO pr oduction was 
inhibited during experimental hyperglycaemia in HAEC (Salt et al., 2003). Given the 
potential for eNOS-mediated ROS production, it was investigated whether experimental 
hyperglycaemia increased eNOS-mediated superoxide generation. In the present study, 
endothelial cell superoxide generation was unaffected by experimental hyperglycaemia, 
which contrasts previous findings (Cosentino et al., 1997, De Vriese et al., 2000, Hink et 
al., 2001, Srinivasan  et al., 2004). As the present results are preliminary, these studies will 
have to be repeated. In the light of the above findings, the effect of hyperglycaemia on 
superoxide production in vascular endothelial cells ought to be compared to untreated 
control cells and osmotic controls to determine whether mannitol influences superoxide 
generation, perhaps through increased osmotic stress. 
Chapter 5 addressed the question of how acute insulin stimulation affects the subcellular 
distribution of eNOS in HAEC. eNOS has been demonstrated to localise to the plasma 
membrane, caveolae, the Golgi body and nucleoli in various cell types (Garcia-Cardena et 
al., 1996a, Garcia-Cardena et al., 1996b, Shaul et al., 1996, Klinz et al., 2005), but the 
localisation of endogenous eNOS has not been characterised in human vascular endothelial 
cells. Since the localisation of eNOS within the cell is thought to have implications for its 
activity and function (Fulton et al., 2004b), insulin may modify the subcellular distribution 
of eNOS. The subcellular distribution of eNOS
T495, eNOS
S615 and eNOS
S1177 was also 
investigated in the present study. 
Confocal microscopy data shown in chapter 5 demonstrated that eNOS localised to the 
plasma membrane, the nucleus and perinuclear region and the cytoplasm. The greatest 
abundance of eNOS was found in the perinuclear region. At the plasma membrane, eNOS 
colocalised with caveolin-1, a marker of caveolae, confirming the previously reported 
interaction between eNOS and caveolin-1 (Feron et al., 1996, Garcia-Cardena et al., 
1996a, Garcia-Cardena et al., 1997, Feron et al., 1998, Ghosh et al., 1998). In agreement 
with these microscopy data, iodixanol gradient fractionation studies showed that eNOS 
was located principally in the plasma membrane fractions and in the denser fractions 
containing endosome, Golgi and cytoplasm markers. eNOST495 and eNOSS615 localised 
almost exclusively to the plasma membrane, whereas eNOSS1177 localised predominantly 
to the plasma membrane and, to a lesser degree, to early endosome-containing fractions of 
HAEC. These data are in agreement with previous findings by other groups (Fulton et al., 
2002, Klinz et al., 2005, Klinz et al., 2007).  Christine F. Kohlhaas    Chapter 7, 205 
 
Acute (10 min) insulin stimulation did not affect the distribution of eNOS, eNOSS615 or 
eNOS
S1177, but reduced the levels of a higher molecular weight species detected with anti-
eNOS
T495 and anti-eNOS antibodies. Given its detection in endosomal marker-containing 
fractions, this species may represent an ubiquitinated form of eNOST495 destined for 
degradation. Its levels may be reduced by insulin-stimulated reduction of eNOS
T495 
phosphorylation. This lends support to the theory that extracellular agonists can modulate 
the distribution of molecules within the cell to coordinate their localisation with their 
effectors and targets, thus maximising their effectiveness. The relationship between eNOS 
subcellular localisation and function will have to be investigated further in human vascular 
endothelial cells. 
The proposed antiatherogenic properties of NO bioavailability were investigated  in chapter 
6 by assessing the potential of AMPK- and NO mediated inhibition of chemokine 
production in HAEC. AMPK can directly phosphorylate eNOSS1177 and thus stimulate NO 
synthesis in HAEC (Morrow et al., 2003). While AMPK is thought to be involved 
principally in the regulation of energy homeostasis, it may also promote an antiatherogenic 
phenotype by increasing NO synthesis, which is likely to increase vasodilation and reduce 
the potential of leukocyte-endothelium interactions. Previous work in our laboratory has 
indicated that prolonged, but not short-term activation of AMPK attenuates TNFa -induced 
expression of cell surface adhesion molecules in HAEC. However, short-term activation of 
AMPK reduced monocyte adhesion to HAEC in a NO-dependent fashion, whereas this 
same effect was enhanced by prolonged activation of AMPK in a NO-independent manner 
(unpublished observations). Therefore, it was speculated that early AMPK-mediated 
inhibition of monocyte adhesion was mediated through negative regulation of chemokine 
production. 
In the present study, HAEC were found to secrete low concentrations of MCP-2, Eotaxin, 
RANTES and IP-10, and higher concentrations of MCP-1. In line with the hypothesis, 
treatment with AICAR for 4h or 45 minutes slightly reduced TNFa -induced secretion of 
MCP-1. As predicted, inhibition of NO synthesis through the eNOS inhibitor L-NAME 
increased TNFa-stimulated secretion of MCP-1. Decreased NO bioavailability therefore 
promotes a proatherogenic endothelial profile in HAEC. These data are in agreement with 
clinical data that decreased NO bioavailability in patients with hyperinsulinaemia and 
diabetes have an increased risk for atherosclerosis (Li et al., 2002, Dickhout et al., 2005, 
Rask-Madsen & King, 2005, Tesauro et al., 2005, Rask -Madsen & King, 2007).  Christine F. Kohlhaas    Chapter 7, 206 
 
Furthermore, the present data suggest that the attenuating effect of AMPK activity on 
TNFa-stimulated MCP-1 production was at least partly NO-dependent in the short-term, 
but may beNO-independent during prolonged AMPK activation. It is therefore tentative to 
speculate that acutely, AMPK stimulates eNOS-mediated NO production, whereas 
prolonged AMPK activity reduces chemokine secretion in an eNOS- and NO-independent 
way. In addition, the present data indicate that negative regulation of HAEC chemokine 
production by AMPK occurs before downregulation of adhesion molecule expression, and 
this may contribute to the previously observed AMPK-mediated inhibition of monocyte 
adhesion. These findings, summarised in Figure 7-3, support an antiatherogenic role for 
AMPK, as AMPK activity can compensate for reduced NO bioavailability and decrease 
the atherogenic profile of HAEC cultured with proinflammatory stimuli. This is in 
agreement with results presented in chapter 3, which showed that insulin stimulates 
AMPK
T172 phosphorylation and may thus promote an antiatherogenic phenotype in HAEC. 
Further studies are required to define the antiatherogenic potential of AMPK activity and 
its impact on endothelial function in vivo. 
 
 
 
Figure 7-3 The antiatherogenic actions of AMPK  
The diagram summarises present and previous findings from our laboratory regarding the 
antiatherogenic effects of AMPK activity and NO bioavailability.  Christine F. Kohlhaas    Chapter 7, 207 
 
7.1  Conclusions 
The vascular endothelium is a key player in the maintenance of vascular tone and the 
prevention of atherosclerosis. Endothelial dysfunction is characteristic of dis orders 
involving hyperinsulinaemia and/or hyperglycaemia. The present study demonstrated that 
neither experimental hyperinsulinaemia nor experimental hyperglycaemia significantly 
impaired the metabolic branch of the insulin signalling pathway in human vascular 
endothelial cells, although it provided evidence for mildly dysregulated eNOS 
phosphorylation under experimental hyperglycaemia in HUVEC. Other regulatory 
pathways were also predominantly unaltered. Superoxide production by HUVEC was not 
affected by experimental hyperglycaemia, but the significance of insulin-stimulated NO 
release by HAEC was lost during experimental hyperinsulinaemia. 
eNOS was shown to localise to the plasma membrane, the nucleus, the perinuclear region 
and the cytoplasm of HAEC. Acute treatment with insulin did not change this distribution 
or that of eNOS
S615 and eNOS
S1177, but did alter the levels of a higher molecular weight 
species of eNOS
T495. 
In HAEC, experimental hyperinsulinaemia had no effect on monocyte adhesion. AMPK 
and NO negatively regulated the secretion of MCP-1 in the present study, promoting an 
antiatherogenic profile.   
In summary, this study has shown that 48h of experimental hyperinsulinaemia or 
experimental hyperglycaemia do not markedly alter cellular signalling pathways in human 
vascular endothelial cells and do not predispose to a proatherogenic cellular phenotype. By 
contrast, AMPK activity and NO bioavailability have been implicated in the regulation of 
endothelial chemokine production and mediation of an antiatherogenic profile. This study 
has therefore gone some way to elucidate potential molecular mechanisms underlying 
vascular endothelial dysfunction, but further investigations using more robustly insulin-
sensitive cell models are required to gain a clearer understanding of the regulation of 
endothelial function in health and disease.Christine F. Kohlhaas     208  
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